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Summary 
 
Inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, are chronic 
inflammatory disorders of the gastro-intestinal tract. Both diseases are characterized by 
intestinal epithelial barrier disruption and are driven by an exaggerated immune response to 
luminal antigens in genetically susceptible individuals. During intestinal inflammation, 
oxygen supply towards the epithelium is insufficient and adaptive mechanisms are activated. 
This involves the induction of hypoxia-inducible factor 1 (HIF-1) which trans-activates neo-
angiogenic genes such as vascular endothelial growth factor (VEGF). Parts of the epithelium 
get however severely compromised and these cells will release ‘damage-associated 
molecular patterns’ (DAMPs or danger signals) to attract, alarm or activate immune cells in 
order to inform the immune system of the damage. The attraction and activation of immune 
cells during intestinal inflammation includes the recruitment and polarization of 
macrophages towards efficient pro-inflammatory M1 cells. The M1 macrophages are 
essential for proper clearance of tissue debris and foreign material and further drive 
inflammation by the production of pro-inflammatory cytokines. However, they may cause 
substantial bystander damage and are therefore controlled by regulatory M2 macrophages 
which dampen M1 signals and initiate recovery by promoting wound healing.  
Metallothioneins (MTs) are 6-7 kDa, cysteine rich proteins with cellular and immune-related 
functions. The MT1 and MT2 isoforms serve as zinc chaperones within the cell and through 
the body, protect against heavy metal toxicity and are able to capture free radicals through 
zinc exchange. Metallothionein 1/2 are rapidly up-regulated during stress, including 
inflammation, and are therefore denoted as acute stress or phase proteins. They are able to 
alter immune responses through the modulation of humoral and cellular immune processes 
and are involved in a number of inflammatory conditions. However, their role in IBD was 
formerly unclear. Reports in literature describing MT1/2 expression in human IBD patients 
are inconsistent and groups investigating the contribution of MT1/2 to intestinal 
inflammation did not produce conclusive results.  
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The general aim of this thesis was to unravel the role of MT1/2 in experimental colitis. This 
work consists of three chapters, each describing a specific aspect of how MT1/2 might be 
involved in the pathogenesis of intestinal inflammation. 
 
In chapter 1 we describe the relation between MT1/2 and HIF-1α, the key player in the 
hypoxic adaptive response. HIF-1α is stabilized during hypoxia, translocated to the nucleus 
to form a functional HIF-1 transcription factor which induces the transcription of pro-
angiogenic genes such as VEGF. HIF-1 is protective in murine IBD models and a positive 
correlation between HIF-1 and MT expression has been described in other inflammatory 
conditions. Surprisingly, we found a down-regulation of MT1/2 expression following HIF-1α 
stabilization in vitro in HT29 cells, ex vivo in isolated epithelial cells from human intestinal 
biopsies and in vivo in mouse colonocytes. This MT1/2 down-regulation was HIF-1 regulated, 
as demonstrated by siRNA targeting HIF, and was mediated through zinc. Conversely, the up-
regulation of MT1/2 suppressed and MT1/2 silencing enhanced HIF-1α stabilization 
following prolyl hydroxylase domain inhibition. The inverse relation between MTs and HIF-1 
was confirmed in dextran sulphate sodium (DSS)-induced colitis. The mRNA expression of 
Mt1 was significantly induced and VEGF expression reduced during the peak of 
inflammation.  
 
In chapter 2, we investigated the role of MT1/2 in experimental colitis by genetic deletion of 
Mt1 and Mt2 and by anti-MT1/2 antibodies. We showed that lacking MT1/2 significantly 
favours the outcome of DSS-induced colitis. Anti-MT1/2 antibody treatment partly reduced 
the signs of colitis and resulted in less macrophage infiltration in DSS- and trinitrobenzene 
sulfonic acid (TNBS)-induced colitis. We demonstrated that the applied anti-MT1/2 
antibodies targeted the colon during colitis by subjecting mice, injected with radioactive 
antibody, to micro-single-photon emission computed tomography (µSPECT/CT). Radio-
activity of the colon was significantly increased during acute inflammation and decreased 
during recovery. Since antibodies act outside the cell, we needed to confirm the cellular 
release of MT1/2. We demonstrated that MT1/2 are released upon necrotic cell death and 
that they are able to attract leukocytes upon release. These results indicate that MT1/2 act 
as danger signals, propagating intestinal inflammation.  
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In chapter 3, we explored the effect of MT1/2 on macrophage phenotype and polarization 
using bone-marrow derived macrophages from MT1/2 knockout (MT-KO) and wild type (WT) 
mice. The absence of MT1/2 decreased the levels of M1- and enhanced the levels of M2-
associated signal transducers and transcription factors in macrophages. Subsequently, the 
M2 phenotype of MT-KO macrophages  resulted in an enhanced response towards M2 
stimulation and a lower induction of pro-inflammatory cytokines following M1 stimulation 
compared to WT macrophages. These results show that MT1/2 deletion shifts macrophages 
towards the regulatory M2 phenotype which may additionally have contributed to the 
observed reduced susceptibility to colitis of MT-KO mice. 
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Samenvatting 
 
Inflammatoire darmziekten (IBD), de ziekte van Crohn en ulceratieve colitis, zijn chronisch 
aandoeningen van het gastro-intestinaal kanaal. Beide ziekten worden gekenmerkt door een 
beschadigde darmbarrière en een overdreven reactie van het immuun systeem tegen 
luminale antigenen in genetisch belaste personen. Tijdens inflammatie is de mucosale 
zuurstofvoorziening onvoldoende en adaptieve mechanismen  worden aangesproken. Deze 
omvatten de inductie van hypoxie-induceerbare factor 1 (HIF-1), wat resulteert in de 
transactivatie van pro-angiogene genen zoals vascular endothelial growth factor (VEGF). 
Echter, een deel van het epitheel is zodanig beschadigd en zal door de vrijstelling van  
‘damage-associated molecular patterns’ (DAMPs of ‘danger signalen’), welke immuuncellen 
alarmeren, aantrekken en/of activeren, zelf de immuunrespons onderhouden. De 
aantrekking en activatie van inflammatoire cellen omvat de infiltratie van macrofagen en 
hun polarisatie naar inflammatoire M1 cellen. Deze M1 macrofagen zijn essentieel voor het 
fagocyteren van weefselresten en vreemd materiaal. Echter, door de productie van pro-
inflammatoire cytokines onderhouden zij verder de ontstekingsreactie en kunnen zij zelf 
verantwoordelijk zijn voor verdere schade aan het darmweefsel. Daarom worden ze onder 
controle gehouden door regulatoire M2 macrofagen, welke herstel bevorderen.  
Metallothioneines (MTs) zijn 6-7 kDa, cysteine-rijke eiwitten. De isovormen MT1 en MT2 
fungeren als zink chaperones, beschermen tegen zware metalen en kunnen zuurstof 
radicalen capteren. Doordat MT1/2 snel worden op-gereguleerd bij stress en inflammatie, 
worden zij beschouwd als acute stress of fase eiwitten. Deze eiwitten zijn verder in staat de 
humorale en cellulaire immuunrespons te beïnvloeden en hun functies worden in verband 
gebracht met verschillende inflammatoire aandoeningen. Echter, de rol van MT1/2 in IBD 
was tot voordien onduidelijk. Er werden tegenstrijdige gegevens gepubliceerd omtrent de 
expressie van MT1/2 in IBD patiënten en hun effect op intestinale inflammatie. 
 
Het hoofddoel van dit werk was het bestuderen van de rol van MT1/2 in experimentele 
darminflammatie. Deze thesis bestaat uit drie delen. Elk deel behandelt specifieke 
mechanismen betrokken in de pathogenese van darminflammatie en hoe MT1/2 hierin 
betrokken zijn. 
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In hoofdstuk 1 van de thesis werd de relatie tussen MT1/2 en HIF-1α onderzocht. HIF-1α 
wordt gestabiliseerd tijdens hypoxie wat resulteert in de inductie van HIF-1. HIF-1 is 
protectief in  muismodellen voor IBD en in andere inflammatoire aandoeningen werd een 
positief verband aangetoond tussen HIF-1 en MTs. Wij vonden echter dat MTs worden neer-
gereguleerd bij HIF-1α stabilisatie in vitro in HT29 cellen, ex vivo in geïsoleerde epitheelcellen 
van colon biopten en in vivo in primaire muis colonocyten. Deze MT1/2 neer-regulatie was 
HIF-1α gemedieerd en afhankelijk van zink. Omgekeerd, de inductie van MT1/2 resulteerde 
in een verminderde stabilisatie van HIF-1α. De omgekeerde verhouding tussen HIF-1α en 
MTs werd bevestigd in dextraan sulfaat sodium (DSS)-geïnduceerde colitis waarbij Mt1 
expressie werd geïnduceerd en VEGF expressie onderdrukt tijdens actieve inflammatie.  
 
In hoofdstuk 2 onderzochten we de rol van MT1/2 in darminflammatie door gebruik te 
maken van muizen met een genetische Mt1 en Mt2 deletie (MT-KO) en wild type (WT) 
muizen. We toonden aan dat MT1/2 deletie de symptomen van DSS-geïnduceerde colitis 
vermindert. De behandeling van anti-MT1/2 antilichamen reduceerde deels de 
ziekteactiviteit in acute DSS- en trinitrobenzene sulfonic acid (TNBS)-geïnduceerde colitis 
met een duidelijk verminderde macrofaaginfiltratie. We toonden aan dat anti-MT1/2 
antilichamen effectief ter hoogte van de darm terechtkomen tijdens colitis door muizen te 
injecteren met radioactieve anti-MT1/2 antilichamen en deze te onderwerpen aan micro-
single-photon emission computed tomography (µSPECT/CT). Er werd een duidelijk 
verhoogde radioactiviteit waargenomen tijdens actieve colitis welke terug daalde tijdens 
herstel. Aangezien antilichamen extracellulair werken, onderzochten we de vrijstelling  van 
MT1/2 uit HT29 cellen. Extracellulaire MT1/2 konden enkel aangetoond worden na necrose 
en waren bovendien in staat leukocyten aan te trekken. Deze resultaten wijzen erop dat 
MT1/2 fungeren als DAMPs in de pathogenese van colitis. 
 
In het laatste hoofdstuk werd het effect van MT1/2 op macrofaag fenotype en polarisatie 
nagegaan adhv. beenmerg-gederiveerde macrofagen van MT-KO en WT muizen. We 
toonden aan dat MT-KO macrofagen verlaagde levels van M1 en verhoogde levels van M2-
geassocieerde receptoren en transcriptiefactoren bevatten. Dit M2 fenotype in MT-KO 
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macrofagen ging gepaard met een verhoogde functionele M2 polarisatie en een verlaagde 
productie van pro-inflammatoire cytokines na M1 stimulatie in vergelijking met WT 
macrofagen. Deze resultaten wijzen erop dat MT1/2 deletie geassocieerd is met een 
regulatoir M2 type macrofagen, wat mogelijks kan hebben bijgedragen tot de verlaagde 
gevoeligheid voor DSS-colitis van MT-KO muizen. 
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Introduction 
 
I. The immunogenicity of the mucosal barrier in inflammatory 
bowel diseases 
 
Inflammatory bowel diseases (IBD) comprise two chronic inflammatory diseases, Crohn’s 
disease (CD) which can affect the whole gastrointestinal tract and ulcerative colitis (UC) 
which merely affects the colon and rectum 1. Patients with IBD often present with abdominal 
pain, bloody diarrhoea, weight loss and fever. Diagnosis is based on endoscopic evaluation: 
patchy inflamed regions interspersed with normal mucosa, often with fistulas or stenosis, 
are frequently observed in case of CD whereas a continuous confluent colorectal 
inflammation with erosions and ulcerations is characteristic for UC. Histopathology is needed 
to confirm the diagnosis: inflammatory cell infiltration, loss of goblet cells, erosions and 
ulcerations are common for both diseases while a segmental or patchy transmural 
inflammation with granulomas is specific for CD and a superficial infiltrate with ulcerations, 
crypt distortion and abscesses are characteristic for UC 2–6. Both diseases, CD and UC, show 
distinct differences in aetiology and pathogenesis but share a dysregulated immune 
response to the intestinal microflora in genetically susceptible individuals. Over the past 
years, studies have tried to elucidate the underlying immunopathological mechanisms of the 
impaired intestinal epithelial barrier and aberrant immune activation 7–9.  
Intestinal homeostasis is basically depending on a proper intestinal barrier function and an 
adequate cross-talk between intestinal epithelial cells (IECs), the luminal microflora and 
lamina propria immune cells 8. Intestinal barrier function is achieved by a continuous 
monolayer of IECs and is maintained by controlled IEC turn-over, by the formation of 
epithelial junctions and by the production of antimicrobial peptides and mucus by IECs, 
protecting the gut from luminal stressors. In addition, IECs are responsible for proper 
communication between the luminal microflora and lamina propria immune cells and 
thereby preserve, together with resident immune cells, a controlled immune status of 
commensal ignorance and foreign recognition 10. Thus, IECs are topographically and 
functionally centralized within gut mucosal immunity. A disturbance in one of the tightly 
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regulated signalling pathways protecting this homeostatic equilibrium can initiate a cascade 
of immune responses, and thereby drive chronic inflammatory diseases such as IBD. Hence, 
the intestinal epithelium has evolved adaptive mechanisms which enable IECs to respond to 
(environmental) stressors and yet maintain the controlled communication with microflora 
and immune cells. However, these mechanisms may aid in perpetuating the inflammatory 
response if not efficiently turned off. Consequently, these mechanisms have been linked as 
contributors to the defective barrier function and/or dysregulated immune status in IBD. In 
this thesis, we discuss some of these aspects and investigated how metallothioneins (MTs), 
acute stress proteins, are integrated in these mechanisms.  
 
1. The IEC as innate immune cell 
 
1.1. Intestinal epithelial cells  are homeostatic guardians 
The intestinal epithelium is composed of specialized IECs, each conferring a different aspect 
of barrier protection and gut homeostasis. Firstly, enterocytes maintain the absorptive 
function by selective uptake of nutrients and fluids and exclude entrance of undesired 
compounds. Secondly, neuroendocrine cells are scattered as single cells deep in the crypts of 
the entire intestine and produce hormones and peptides. Thirdly, the secretory cells 
comprising goblet and Paneth cells are in charge of mucosal mucus secretion. Goblet cells 
produce the mucus, responsible for a bacterial gradient from outer to inner mucus layer, 
which is essential for epithelial cell sensing of commensals and protection against 
pathogens. Paneth cells are mainly located deep in the crypts of the ileum and produce 
antimicrobial peptides. Finally, specialized antigen sampling cells, M cells, are interspersed in 
the epithelium covering isolated lymphoid follicles and Peyer’s patches and present sampled 
antigens to antigen presenting cells (APCs). Antigen presenting cells prime naïve T and B cells 
which become memory and effector cells and migrate via lymph vessels to finally home the 
intestinal mucosae and control oral tolerance 11.  
Consecutive IECs are connected by epithelial junctions, adherens and tight junctions and 
desmosomes, and form a continuous monolayer which is the interface between the gut 
lumen containing foreign potential pathogens and the underlying mucosal layers. The 
intestinal epithelium is renewed every 2-3 days in the small intestine and every 6-7 days in 
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the colon by controlled IEC proliferation and cell shedding at the top of the villi and surface 
epithelium respectively. Any disturbance in epithelial turn-over or enterocyte function can 
cause a disruption of the epithelium and an uncontrolled influx of antigens into the lamina 
propria, resulting in immune cell activation and inflammation, a situation contributing to IBD 
pathogenesis 9,12. 
 
1.2. Intestinal epithelial cell-interaction with microflora 
Immune tolerance is accomplished by the adequate recognition of foreign pathogens and 
the ignorance of non-pathogenic compounds, among them the commensal gut-specific 
microflora. The IECs vouch, together with resident phagocytes (dendritic cells (DCs) and 
macrophages), for this proper recognition and are therefore  provided by a set of pattern 
recognition receptors (PRRs) 10,13. The PRRs recognize microbial components, known as 
pathogen-associated molecular patterns (PAMPs) or better microbe-associated molecular 
patterns (MAMPs), and control the basal immune status of gut’s mucosa 13,14. Microbe–
sensing PRRs include Toll-like receptors (TLRs), intracellular nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs), leucine-rich repeat receptors (C-type 
leptin receptors) and retinoid acid (RA)-inducible gene 1-like receptors and have genetically 
been linked to IBD pathogenesis 15. Genetic deletion of different TLRs and NLRs increases 
susceptibility to experimental colitis whereas sustained PRR signalling maintains chronic 
colitis in mice. A basal PRR activity on IECs is essential for maintenance of the epithelial 
barrier function by induction of effector responses involved in cell survival, maintenance of 
IEC interconnections and production of antimicrobial peptides 10,13. They furthermore enable 
a constant surveillance of the gut microbiota. However, binding of the ligand to its IEC-PRR 
triggers downstream signalling events resulting in the expression of chemokines and 
cytokines involved in innate immune activation. This activation is believed to be controlled 
by the polarized character of IECs conferring a homeostatic or activation response 
accomplished by as yet undefined mechanisms.  Given their ‘homeostatic’ barrier function 
and their role as innate immune activators, it is presumable that a disturbance in PRR 
effector signalling, due to microbial misbalance, pathogen invasion or danger motifs 
recognition, may evoke inflammation and immune activation.  
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1.3. Intestinal epithelial cell-interaction with resident mucosal immune cells 
Resident immune cells comprise specialized APCs, including DCs and macrophages, innate 
lymphoid cells and natural killer cells. Innate lymphoid cells are positioned within the 
epithelial layer and in the lamina propria. Intra-epithelial lymphocytes specifically respond to 
ligands expressed on IECs and although their precise role is not fully understood, these cells 
promote important barrier functions 16. The APCs are, together with IECs, responsible for the 
oral tolerance which is achieved by luminal sampling in case of DCs or by phagocytosis in 
case of macrophages. Recent advantage using in vivo imaging revealed that, besides M cells, 
other specialized IECs, small intestinal goblet cells, function as transporters of luminal 
antigens to DCs 17. These antigens are subsequently presented to prime T-cells. The APCs 
possess, as IECs, PRRs controlling the microbial-derived response. In addition to PAMP-
mediated PRR signalling, PRRs are also triggered by signals released from stressed or 
damaged (intestinal epithelial) cells and are as such part of the IEC-innate immune cell 
intercommunication 18.  
Conventional inflammatory signalling runs through cytokines, up-regulated and produced by 
inflammatory cells and IECs in response to a foreign pathogen. However in 1994, Matzinger 
proposed the ‘danger hypothesis’ implementing an innate immune response against 
‘danger’ and not merely towards ‘foreign’. Damaged cells express or release molecules that 
are normally hidden from the immune system, which alarm and/or activate surrounding 
cells. These signals are therefore called ‘alarmins’, ‘danger signals’ or damage-associated 
molecular patterns (DAMPs) 19. These DAMPs activate immune cells by triggering cytokine 
release after receptor binding or they are involved in immune cell attraction. Inflammatory 
bowel diseases are characterized by a compromised intestinal epithelium and DAMPs which 
are released from IECs may alert/activate resident immune cells of the lamina propria. In 
addition, DAMPs are also released or secreted from activated immune cells and in turn 
activate IECs and other immune cells to cytokine release and further attraction of immune 
cells. The different PAMPs, DAMPs and their receptors that have been linked to IBD 
pathogenesis are further discussed below. 
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2. The cellular response of compromised IECs 
 
2.1. The hypoxic adaptive response 
The intestinal epithelium forms the interface between the richly perfused sub-epithelial 
mucosae and the anoxic gut lumen 20. As such, IECs are subjected to a unique oxygen 
gradient and this ‘physiologic hypoxia’ renders them highly susceptible to any further 
decrease in oxygen supply, which occurs during inflammation. The mechanism anticipating 
to this internal hypoxia is called the ‘hypoxic adaptive response’ 20,21. Prolyl hydroxylases 
(PHDs, PHD1, 2 and 3) degrade hypoxia inducible factor 1 alpha (HIF-1α), however, PHDs are 
inhibited during low oxygen tension leading to an increased stabilization of HIF-1α. After HIF-
1α translocation to the nucleus and heterodimer formation with HIF-1β, HIF-1 
transcriptionally induces different adaptive target genes, such as vascular endothelial growth 
factor (VEGF), glucose transport protein GLUT-1 and erythropoietin, which are responsible 
for re-establishment of epithelial vascularization 22.  
In intestinal inflammation, and in IBD, oxygen supply towards the epithelium is insufficient 
partly due to vasculitis and increased oxygen consumption by the inflammatory infiltrate 
20,22. This results in a further increase of mucosal hypoxia with the net result of epithelial 
dysfunction, compromised barrier integrity and inflammation. The intestinal epithelium of 
IBD patients displays increased levels of HIF-1α and data from mouse models associate an 
increased HIF-1α stabilization with an enhanced outcome 23–27. The latter warrants for future 
therapeutics able to activate this transcriptional machinery. Dimethyloxalylglycine (DMOG), 
a pan-PHD inhibitor designed for experimental approach, induces hydroxylase inhibition, 
HIF-1α stabilization and disease amelioration in murine IBD models 25,26. The potential of 
more specific PHD inhibitors as treatment strategy for IBD is currently being explored and 
points in the direction of selective PHD1 inhibition since PHD1 is significantly over-expressed 
in IBD patients and PHD1 knockout mice are protected against experimental colitis 27,28.   
 
2.2. Endoplasmatic reticulum stress 
Protein synthesis is accomplished by chaperones of the endoplasmatic reticulum (ER) which 
stimulate protein folding, prevent protein aggregation and ensure correct transfer of folded 
proteins to cellular and extracellular compartments. A range of environmental and host-
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related factors can activate the ‘unfolded protein response’ (UPR) and trigger proteostasis. 
The chaperone glucose-related protein (GRP) 78, known as binding immunoglobulin protein 
(BIP), is associated with the transmembrane sensor proteins inositol requiring enzyme 1 
(IRE1), activation transcription factor 6 (ATF6) and PKR-like ER kinase (PERK) which are in 
quiescent state of activation. Upon mis- or unfolded protein sensing, BIP is dissociated from 
its sensors and liberates IRE1, ATF6 and PERK which initiates three branch-signalling and 
aims to resolve the ER stress 29. The IECs have a high turn-over, specific roles in preserving 
immune homeostasis and are constantly exposed to microbes and toxins. It is thus not 
surprising that specialized IECs, Paneth cells and goblet cells, are most sensitive to ER stress 
and highly challenged in resolving ER stress 30,31. Indeed, mice deficient for IRE1β, which is a 
unique IRE1 isoform of the digestive and respiratory tract, showed an increased 
susceptibility towards dextran sulphate sodium (DSS)-induced colitis 32. Intestinal epithelial 
deletion of a key transcription factor in ER stress, X-box-binding protein 1 (XBP1), resulted in 
spontaneous ileitis with absence of Paneth cells, reduced goblet cells and marked ER stress 
in mice 33. In accordance, deletion of other ER stress markers also resulted in spontaneous 
and/or increased susceptibility towards intestinal inflammation in mice and this has been 
linked to perturbations in the mucus production system. Anterior gradient homolog 2 (AGR2) 
protein is present in the ER of secretory IECs and is essential for intestinal mucus production 
by its association with MUC2, the main component of the mucus produced by goblet cells. 
Park et al. described the absence of MUC2 protein and intestinal mucus in AGR2-/- mice 
which resulted in increased susceptibility to DSS-colitis 34. The AGR2-/- mice produced by 
Zhao showed abnormal goblet and Paneth cells, decreased MUC2 levels and developed 
spontaneous ileitis and colitis 35. In accordance, MUC2-/- mice were also predisposed to DSS-
induced colitis 36. As for the ATF6 and PERK branch, ATF6α-/- mice reconstituted with wild 
type bone marrow show an impaired  ER stress response and  are highly sensitive to DSS 
colitis whereas the deletion of CCAAT/enhancer-binding protein (C/EBP) homologous protein 
(CHOP) protects mice from colitis 37,38. The up-regulation of CHOP indicates PERK activation 
and induces apoptosis to eliminate cells that are unable to resolve ER stress.  
Besides the number of mouse models linking ER stress to intestinal inflammation, activation 
of the UPR and impairment to cope with ER stress have been reported in IBD patients 31,33,39–
41. Furthermore,  the UPR markers XBP1, AGR2 and Orosomucoid-like 3 (ORMDL3, which is 
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an ER transmembrane molecule) are genetically associated with human IBD underlining their 
role in human intestinal inflammation 33,42–44.  
 
2.3. Mitochondrial stress 
Mitochondria are physically and functionally in close relationship with the ER. While ER 
stress results in activation of the UPR, mitochondrial stress activates the mitochondrial UPR 
(mtUPR). The mtUPR also senses disturbance in protein homeostasis and aims at restoring 
this by inducing protein folding and degradation. mtUPR signalling involves the activation of 
CHOP and activator protein-1 (AP-1); however CHOP activation by ER- and mtUPR runs 
through different elements 45. Recently, mitochondria have been implemented in the cellular 
danger response and associated immune activation in IBD 46,47. Dysfunctional mitochondria 
induce a TLR4-mediated inflammatory response and mitochondrial reactive oxygen species 
(ROS) are able to activate NLRP3 48,49; two signalling cascades which have been shown to 
contribute to IBD pathogenesis. Furthermore, IECs of IBD patients show abnormal 
mitochondria and mtUPR is activated in mouse models for IBD 46,50,51. Thus, future studies 
using mice deficient in mtUPR players will highlight the specific mechanisms underlying the 
role of mitochondrial stress in IBD.  
 
2.4. The release of DAMPs  
The intestinal epithelial monolayer is physically maintained by the adequate renewal of the 
IECs. This process is controlled by proliferation, differentiation and migration of IECs along 
the crypt and villus axis. Any process interfering with this fine-tuned machinery may evoke 
stress to the epithelium, forcing IECs to respond in a self-defensive or –destructive manner. 
In patients with IBD, epithelial barrier continuity is affected and different forms of 
(excessive) cell death have been implemented in this process. Apoptosis, or controlled cell 
death, is physiologically responsible for IEC shedding (anoikis) at the top of the villus and 
surface epithelium, which is initiated by the loss of cell-cell contact, and excessive rates of 
apoptosis have been observed in patients with IBD and IBD mouse models 52–57. Apoptotic 
cells normally transmit ‘find-me’ signals towards phagocytes, resulting in the silent removal 
of apoptotic bodies without evoking an inflammatory response. However, one can assume 
that when the apoptotic rate exceeds phagocyte capacity, these cells end up as secondary 
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necrotic cells eventually bursting and spilling their intracellular content just like primary 
necrotic cells 58. Necrosis refers to uncontrolled cell death characterized by plasma 
membrane damage. However recently, a specific form of controlled necrotic cell death 
‘necroptosis’ has been introduced. Necrosis is inherent to any inflammatory process and 
necroptosis has been implemented in the pathogenesis of IBD 9,59–62. While different 
regulatory pathways controlling all forms of cell death are being unravelled, its decisive 
result eventually defines the outcome, namely, if the cell leaks its intracellular content or not 
(Figure 1). Necrotic as well as necroptotic cells herein hold the same fate, the intracellular 
content will be spilled out and this contains danger signals. The release of DAMPs is most 
likely a natural occurring event to activate local immune cells and initiate an adequate 
immune response. However, during excessive cell death and signal release, DAMPs may 
prolong the initial inflammatory response resulting in chronic immune activation and 
inflammation, a situation that is actively present in IBD patients (Figure 2: pp. 28) 19,58,63. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effect of apoptotic and necrotic cell death on immune activation. During apoptosis, 
the intracellular content remains hidden from the immune system and cells are removed by 
phagocytosis. During necrotic cell death the integrity of the plasma membrane is 
compromised and intracellular DAMPs now leak outside the cell. These extracellular signals 
communicate with local immune cells and activate the immune system. The same occurs 
when apoptotic bodies are inefficiently removed, adapted from Kono and Rock, 2008  58. 
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3. Pathogen- and damage-associated molecular patterns in IBD 
 
Gut homeostasis covers a situation of ‘controlled inflammation’ where the host can co-exist 
with the multitude of microbes in the luminal gut. Current hypotheses in IBD pathogenesis 
are (1) a loss of tolerance against the luminal microflora, sensed as ‘foreign MAMPs’ and/or 
(2) a massive infiltration of exogenous environmental antigens due to barrier disruption 
which are sensed as PAMPs. Normally, the immune response following MAMP or PAMP 
recognition is quickly and efficiently turned off once the stimulus is removed. Patients with 
IBD lack the potential to switch off the initial response, resulting in chronic immune 
activation and inflammation. In addition, Matzinger postulated that the immune system also 
responds in absence of an exogenous signal but is simply turned on in case of stress and 
tissue damage which is mediated by endogenous activators, DAMPs 19. Typically, DAMPs are 
passively released following plasma membrane leakage or are actively secreted from 
activated immune cells. Conventionally, PAMPs and DAMPs are sensed by PRRs. The PRRs 
recognizing microbial parts are well described and some of them also sense danger signals. 
Two specific DAMP-sensing PRRs, receptor for advanced glycation end-products (RAGE) and 
triggering receptor expressed on myeloid cells (TREM-1), have been identified and linked to 
IBD. However, for different signals functioning as alarmins, the concomitant PRR has not 
been identified. We discuss two families of well described PAMP- and DAMP-sensing PRRs 
and the best described alarmins recently discovered to function as danger signals in IBD. 
 
3.1. Pattern recognition receptors involved in intestinal inflammation 
Of the 4 PRR families, TLRs and NLRs are the best characterized and have extensively been 
investigated in the IBD research field. Toll-like receptors are located at the cellular and/or 
endosomal surface and conventionally recognize extracellular and/or engulfed MAMPs and 
PAMPs 14. All TLRs signal through the adaptor molecule Myeloid Differentiation Primary 
Response gene (MyD88), with exception of TLR3 which signals through Toll-interleukin-1 
receptor domain-containing adaptor inducing IFN-β (TRIF). Toll-like receptor signalling 
results in the activation of the nuclear factor-κB (NF-κB) and the mitogen-activated protein 
kinase (MAPK) pathway which induce the expression and release of pro-inflammatory 
cytokines and chemokines 64,65. The group NOD-like receptors encompasses 4 cytoplasmatic 
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receptors of which NOD1 and NOD2 are best characterized. Upon ligand recognition, the NF-
κB and MAPK pathway are activated leading to the induction of cytokines and chemokines. 
Typically, NLR activation results in the formation of inflammasomes, large multiprotein 
complexes, which induce the active release of interleukin (IL)-1β and IL-18. Interestingly, 
inflammasome cytokine release depends on TLR signalling whereas NLRs in turn dampen 
activated TLR cascades 66–68. Both TLR4 and NOD2 polymorphisms have been linked to IBD, 
bridging the results from mouse models to human disease 69–71 (see Table 1). 
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Table 1. Pattern recognition receptors involved in intestinal inflammation 14,72,73 
 
Receptor Epithelial localization Typical ligand Role in the gut Effect of receptor modulation in mice 
TLR2 53,74,75 Cell surface (mainly crypt IECs) 
Gram+ and Gram- 
compounds 
Epithelial integrity (tight junctions) Deletion: ↑ susceptibility to colitis 
TLR4 52,76–78 Cell surface (mainly crypt IECs) Lipopoly-saccharide 
Essential for oral tolerance, 
colonocyte proliferation and 
protects against apoptosis 
Deletion: ↑ susceptibility to colitis 
TLR5 79,80 
Basolateral celmembrane 
(mainly colonocytes) 
Flagellin Microbial recognition Deletion: spontaneous colitis, ↑susceptibility 
TLR9 81–84 
Apical+basolateral 
celmembrane and endosomal 
Unmethylated CpG 
Apical: tolerance to TLR 
stimulation; Basolateral: NF-ϗB 
activation 
Preventive activation: ↓ susceptibility to colitis; 
Therapeutic activation: ↑ susceptibility to colitis; 
Deletion: ↑ susceptibility to acute colitis and ↓ 
disease activity during chronic colitis 
NOD1 85,86  Cytoplasm 
Medo-diamino-
pimetic acid 
Normal response to gut 
microbiota 
Deletion: ↑ susceptibility to colitis 
NOD2 66,87–90 
Cytoplasm (mainly Paneth 
cells) 
Muramyl dipeptide Secretion of antimicrobial peptides 
Deletion: ↑ susceptibility to colitis; 
Overexpression: ↓ susceptibility to colitis 
NLRP3 91–93 Cytoplasm Muramyl dipeptide, 
bacterial RNA, 
mitochondrial DNA, 
crystals 
Gut microbioom; Epithelial 
proliferation following injury 
Deletion: ↑ or ↓ susceptibility to colitis 
NLRP6 94,95 Cytoplasm Gut microbioom 
Deletion: spontaneous colitis and ↑ susceptibility 
to colitis 
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3.2. Danger signals as modulators of intestinal inflammation 
Any intracellular compound can be released upon plasma membrane damage and can serve 
as potential endogenous danger signal. However, only for a few molecules that are released 
after cell death, immune modulating properties have been described. They are subdivided 
into constitutive and inducible signals. The constitutive ones are ever present in the cell and 
released upon cellular damage, the inducible signals are newly created, up-regulated or 
modified during cellular stress 63.  
 
3.2.1. High-mobility group box 1  
High-mobility group box 1 (HMGB1) is a nuclear protein that binds and distorts DNA to allow 
transcription factors to bind to chromatin. The protein moves from the nucleus to the 
cytosol through nuclear pores which is essential for its cellular release 96. As prototypical 
DAMP, HMGB1 is passively released from necrotic cells or actively secreted from activated 
immune cells in response to different inflammatory triggers, probably via a non-classical 
pathway 18,97–100. The protein functions as danger signal by binding to TLR2 and TLR4 and to 
RAGE and TREM which all signal through the adaptor MyD88 and activate NF-κB 101–104. High-
mobility group box 1 modulates the production of pro-inflammatory cytokines and DC 
maturation and exerts a direct chemotactic effect on neutrophils 68,101–103,105,106. Protein 
levels are correlated with disease activity in murine colitis and this has recently been 
confirmed in human IBD patients 100,107,108. Increased levels of HMGB1 are found in the stool 
of IBD patients and faecal HMGB1 levels correlated with faecal calprotectin levels, a 
commonly used biomarker of IBD activity 100. In vitro assays revealed that HMGB1 is released 
from human Caco-cells and mucosal biopsies treated with tumour necrosis factor-α (TNF-α) 
and interferon-γ (IFN-γ). Further human trails will have to reveal if blocking HMGB1’s 
function as danger signal is able to reduce disease activity in IBD patients or if HMGB1 
merely could function as novel biomarker. Preventing the release of HMBG1 was at least 
able to reduce the signs of colitis in mouse models for IBD 108. 
 
3.2.2. Heat shock proteins  
Heat shock proteins (HSPs) are highly conserved proteins which function as intracellular 
chaperones in protein processing and are important cytoprotectants. They are defined 
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according to their molecular weight and located in different cellular compartments. Some of 
them are constitutively expressed, others induced upon different stimuli such as heat shock 
and inflammation 109–112. Heat shock proteins are generally referred to as danger signals 
released from necrotic cells 63,113,114. However, stimulation with IFN-γ, an important pro-
inflammatory cytokine, was also able to release the constitutive HSC70 from cancer cells 115. 
As extracellular ‘chaperokines’, they stimulate the production of cytokines from APCs and 
the subsequent activation of T-cells has found its therapeutic application in cancer 
management 116. In contrast, macrophages from HSP70 over-expressing mice showed a 
reduced LPS-triggered activity and less pro-inflammatory cytokine production which was 
translated in a decreased susceptibility to colitis in mice over-expressing HSP70 117,118. Heat 
shock proteins additively exert a cytoprotective effect on IECs through the inhibition of NF-
κB signalling and consecutively reduce pro-inflammatory cytokine transcription in IECs 110. 
Pro-inflammatory cytokines play an important role in the activation and infiltration of 
leukocytes during experimental colitis and IBD. Thus, HSPs seem to exert as mitigating 
mediators of intestinal inflammation through a negative feedback loop on pro-inflammatory 
cytokine-mediated excessive immune activation. The immunogenic adjuvant activity of HSPs 
exploited in cancer therapy and their opposite cytokine reducing function in murine colitis 
might depend on the initial trigger and the context in which these proteins act. Perhaps the 
intracellular protective effect of HSPs on IECs overrules their extracellular immune-
stimulatory role in experimental colitis. 
 
3.2.3. S100 proteins 
The calgranulin family of proteins, S100 proteins, includes small calcium binding proteins 
with different intracellular functions. The proteins S100A8, S100A9 and S100A12 are 
passively released from necrotic cells and actively secreted from activated monocytes and 
they have been designated as danger signals 119,120. They bind to TLR4 and RAGE and are 
involved in chemotaxis of leukocytes and S100A12 also induces pro-inflammatory cytokine 
secretion from macrophages 121–125. The S100A8 and S100A9 proteins primarily form the 
heterodimeer S100A8-A9, which is known as calprotectin and used as biomarker in 
inflammatory diseases. Neutrophils are the main source of S100A8-A9 and plasma S100A8-
A9 correlates well with the number of circulated neutrophils 126. Faecal S100A8-A9 is a 
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valuable non-invasive diagnostic tool to evaluate disease activity and to predict flares in IBD 
patients 127,128. 
 
The list of DAMPs involved in intestinal inflammation is certainly indefinite. Inflammatory 
bowel diseases are characterized by a breakdown of the intestinal epithelium and an 
excessive activation of the immune system. Thus, these ‘innate’ signals could represent 
therapeutic targets under pathologic condition where they are part of modulating the 
cascade of inflammation.  
    
 
4. The duality of macrophages in intestinal inflammation 
 
Macrophages originate from a hematopoietic stem cell in the bone marrow. They are 
released in the blood stream as monocytes and extravasate and differentiate to tissue-
specific macrophages. These resident macrophages function as first responders towards an 
initial stimulus and induce neo-synthesis of bone-marrow derived monocytes and 
recruitment of these inflammatory cells from the blood to the inflammatory region. 
Generally, macrophages are divided into different subset according to their response 
following cytokine stimulation. The classically activated macrophages, called M1 types, are 
responsible for host defence and are activated by PRR ligands such as lipopolysaccharide 
(LPS) and IFN-γ. Upon activation, they typically secrete pro-inflammatory cytokines, 
chemokines and adhesion molecules. The alternatively activated macrophages, M2 types, 
have anti-inflammatory functions and are regulated by IL-4 and IL-13. Inflammatory M1 
macrophages are essential for the antimicrobial defence but can additionally cause 
bystander tissue damage and must therefore be controlled by regulatory and anti-
inflammatory M2 macrophages, which drive wound healing and tissue restoration 129.  
In the gut, resident mucosal macrophages play a central role in detection and digestion of 
pathogens, toxins and cell debris and are, on the other hand, responsible for the ignorance 
of self-antigens and oral tolerance. Disturbance in macrophage subsets may likely challenge 
the controlled status of immune activation in the gut. Colonic resident macrophages house 
in an anti-inflammatory state, which is regulated by IL-10 levels. Different groups have 
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focused on the mechanisms disturbing this balance and the contribution of different 
macrophage subtypes to intestinal inflammation. Kühn et al. showed that interference in IL-
10 signalling results in chronic  gut inflammation as demonstrated in mutant IL-10 knockout 
mice and Li and colleagues recently showed that this can be attributed to a macrophage-
specific effect using macrophages with a selective deletion of IL-10Rα 130,131. Platt et al. 
showed that TLR+ macrophages that produce TNF are recruited in a CCR2 dependent 
manner during colitis and that these macrophages promote inflammation whereas TLR- 
macrophages present a different subset of macrophages, independent of inflammation. The 
CCR2 knockout mice that were unable to recruit these pro-inflammatory macrophages were 
protected from colitis 132. Recently, an M1/M2 imbalance has been linked to experimental 
colitis whereas M2 alternative macrophages conferred protection and substitution of M2 
macrophages reduced colitis in mice 133,134. 
The contribution of different macrophage subsets to IBD is far from being fully unravelled. 
Patients with CD possess a specific subset of CD14+ resident macrophages which have an 
increased production of pro-inflammatory cytokines. However, IBD patients seem to have an 
impaired primary response against locally injected pathogens due to failure of TNF secretion 
from pro-inflammatory macrophages 135,136. Additionally, M2 macrophages are involved in 
the initiation, propagation and resolution of fibrosis. Fibrosis results from tissue repair but 
causes intestinal strictures in CD patients when insufficiently turned off. It is not unlikely that 
in multifactorial diseases such as IBD, specific macrophage subsets may have differential 
roles depending on genetic as well as environmental factors. Furthermore, plasticity among 
macrophage types has been described and a specific phenotype with an associated role at 
onset of inflammation may switch towards an opposite macrophage type at a later stage of 
disease. Therefore, mediators which are able to polarize macrophages into a specific 
subtype may have valuable therapeutic potential at specific time points during disease 
progression. 
 
 
 
 
 
36 
 
 
 
Figure 2: Intestinal mucosal homeostasis and its breakdown during inflammatory bowel 
disease. Intestinal homeostasis is accomplished by an intact monolayer of intestinal epithelial 
cells (IECs) and an adequate crosstalk between IECs, luminal microflora and resident lamina 
propria immune cells. During intestinal inflammation, the intestinal epithelial barrier is 
compromised and IEC-derived cytokines and danger signals are released and activate and 
attract immune cells. In addition, luminal constituents penetrate into the lamina propria and 
further activate immune cells to pro-inflammatory cytokine production. DAMP: damage-
associated molecular pattern; DC: dendritic cell; IFN: interferon; IL: interleukin; MAMP: 
microbe-associated molecular pattern; NLR: NOD-like receptor; PAMP: pathogen-associated 
molecular pattern; TLR: Toll-like receptor; TNF: tumour necrosis factor. Adapted from 
Hindryckx and Laukens 2012 137. 
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II. The use of chemically induced mouse models for IBD 
 
Animal models are essential in the progression towards the understanding of disease 
pathogenesis. While the mechanisms underlying IBD onset and progression are complex, 
animal models are designed to mimic immune-pathological characteristics of these diseases. 
Employed models include  spontaneous, genetically engineered, immune modulating 
(adoptive transfer) and chemically induced colitis models. The latter encompasses dextran 
sulphate sodium (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis; due to 
their simplicity, low cost and reproducibility they are the two most widely used models for 
intestinal injury. If the drawbacks inherent to the models are well considered, these models 
can provide valuable information about the pathogenesis and therapeutic options of IBD 
patients.  
 
1. Dextran sulphate sodium-induced colitis 
Dextran sulphate sodium is a sulphated polysaccharide that induces colonic inflammation 
when administered through drinking water in rodents 138–141. The extend, severity and 
duration of inflammation depend on the dose and molecular weight of DSS, the duration and 
frequency of administration, the mouse strain and the experimental (microbial) environment 
142–146. The administration of 2-5% DSS (MW of 40 kDa), administered for a period of 5-7 
days, is most commonly used and induces acute mid-to-distal colitis. Since this application 
results in colonic erosions and a cytokine profile associated with both a Th1 and Th2 
response, it is often referred to as model for human UC. Indeed, when applied as ‘mucosal 
wound healing’ model, it resembles active flares of UC patients with diarrhoea and rectal 
bleeding, weight loss and severe illness. Histology shows a superficial inflammation with 
epithelial erosions, goblet cell depletion and (sub)mucosal polymorphonuclear and 
mononuclear leukocyte infiltration. This model is thus suitable for studying epithelial 
renewal and innate immunity involved in the onset and progression of acute colitis. The 
cyclic administration of DSS and water is conveniently applied to mimic the relapsing 
character of chronic UC and to assess the involvement of the adaptive immune system. 
Repeated cycles of DSS/water mimic chronic injury-induced inflammation with a 
predominant Th2 cytokine profile. Histology reveals alterations of inflammatory regions and 
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epithelial repair with mononuclear cell infiltration and lymphoid follicles in some cases; 
which is however more characteristic for colonic CD than UC 138,144,147,148. Chronic DSS 
administration can additionally be used to induce dysplasia, a common feature in the course 
of chronic human UC 149. 
A huge gap in the use of DSS is the nescience of the trigger initiating exclusively colonic 
inflammation. The mucus composition substantially differs between the colon and the ileum 
and this may define DSS preference to colonic injury 150. Indeed, during DSS-induced colitis 
bacteria are in close contact with the epithelium which is normally protected by the 
impermeable colonic mucus layer. The same alterations in mucus composition and bacterial 
exposure are present in UC patients compared to controls and patients in remission 151,152. 
Increased mucosal permeability and loss of crypts, followed by epithelial cell death and 
erosions, appear to be the earliest signs post DSS administration. Inflammation is believed to 
be secondary to the epithelial damage 153. Direct damage of DSS to epithelial cells has been 
shown 154. However, DSS can already be found in colonic macrophages one day after DSS 
administration so it is unlikely not to cause any immune cell activation following epithelial 
penetration and macrophage uptake 144. An additional factor anticipating in DSS-induced 
colonic injury is that the bacterial load of the colon surpasses that of the small intestine with 
a factor 104 155. Bacteria determine DSS-induced colitis and intestinal inflammation in 
general and this recently resulted in human treatment in extremis: the transplantation of life 
companions ‘healthy microflora’ to patients presenting with signs of dysbiosis! A final 
consideration when using the acute DSS-model for IBD, a disease characterized by a 
dysregulated immune-response, is that adaptive immunity is not required to induce colitis. 
Mice lacking functional immune cells of the adaptive immune system, for example SCID and 
Rag mice, readily develop colonic inflammation following DSS so T and B cells are not 
required for colitis induction. Nonetheless, lymphocytes are essential to recover so these 
mice are unlikely suitable to study epithelial repair 156. When focusing on adaptive immune 
processes involved in the chronicity of disease, repeated cycles of DSS can be applied; 
however, other immune-modulating models such as the adoptive transfer model might be 
more suitable.  
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2. Trinitrobenzene sulfonic acid-induced colitis 
Trinitrobenzene sulfonic acid is a hapten that is applied intra-rectally (IR) in combination 
with ethanol to induce distal colitis in rats and mice. Ethanol is required to break the 
mucosal barrier whereas TNBS is believed to haptenize (colonic or microbial) proteins and 
induce a delayed-type hypersensitivity (DTH). This DTH requires TNBS pre-sensitization 
which is often not implemented in the protocol. Basically, the TNBS model can be applied in 
three different ways, depending on the objective of the study: (1) a single IR bolus of 
TNBS/EtOH results in an acute transmural inflammation with epithelial erosions, leukocyte 
infiltration and granuloma formation which histologically resembles colonic CD, (2) when the 
IR bolus of TNBS/EtOH is preceded by TNBS pre-sensitization (via skin or IR application), a 
specific DTH Th1-driven response is generated which is used to mimic the auto-immune 
character of CD and (3) weekly IR administrations of TNBS/EtOH result in chronic lesions 
associated with repeated DTH reactions and fibrosis, corresponding to the chronic  aspect 
and complications of CD. The cytokine profile resembles a Th1 response, both in acute and 
chronic TNBS-induced colitis 145,147,157,158. Remarkable, oral administration of TNBS 
simultaneously with IR TNBS instillation completely prevents TNBS-induced colitis 159–161. 
Additionally, T cells from mice with TNBS colitis respond to own self-microflora which further 
strengthens the involvement of the loss of tolerance to the mucosal microflora in this model 
161,162. The administration of mucosal T cells from mice with TNBS-colitis to recipient mice 
induces colonic inflammation whereas simultaneous administration of anti-IL-12, a central 
cytokine in Th1 T cell differentiation, completely prevents colitis induction 161,163,164. Thus, 
the TNBS model with pre-sensitization is highly suitable to study T cell dependent immune 
mechanisms involved in IBD. 
The sensitivity to TNBS highly depends on the mouse strain. Literature describes the 
sensitive SJL/J and BALB/c mice whereas C57BL/6 and C57BL/10 mice seem to be more 
resistant 159,165. However, both successful as lethal TNBS experiments have been reported in 
C57BL/6 mice, which is in line with our own observation 157,166,167. Basically every individual 
setting requires the optimization of TNBS concentration to generate the desired disease 
activity in the chosen mouse strain, and this in fact also relates to DSS-induced colitis. The 
advantage of TNBS to DSS involves the possibility of exploring adaptive immune-mediated 
mechanism and the loss of oral tolerance, two important aspects in the pathogenesis of IBD.   
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III. Metallothioneins and intestinal inflammation 
 
1. Metallothioneins 
 
1.1. Structure 
Metallothioneins (MTs) are 6-7 kDa proteins, initially isolated from the horse renal cortex in 
1957 by Margoshes and Vallee 168. The mammalian protein is formed of 61 to 68 amino acids 
with 20 of them being cysteines. The position of the cysteines is highly conserved and 
arranged in specific motifs: Cys-X-Cys, Cys-Cys-X-Cys-Cys, Cys-Cys-X-Cys (Figure 3) 169–171.  
 
 Figure 3: Amino-acid sequence of MT1B 
from the equine kidney, copied from Kojima 
et al,. 1976  170. 
 
 
 
All cysteine residues are involved in metal ligation through thiolate binding, bridging each 
metal ion to another in a two cluster formation. The cluster to the N-terminal, the β domain, 
consists of nine cysteines and is able to bind 3 metals; the C-terminal α domain contains 11 
cysteines and binds 4 metal ions (Figure 4) 172–176. 
 
Figure 4: Spatial structure of human MT1A. Cysteine 
residues are shown as yellow sticks, ions are shown in 
red (Cd2+), green (Zn2+), and orange (Na+), copied 
from Laukens et al., 2009 177. 
 
 
 
Mammalian MTs are subdivided into 4 isoforms, MT1 to MT4. The genes are located on a 
single chromosomal locus on chromosome 16 for human MTs and chromosome 8 for murine 
Mts. The human MT1 isoform has several functional subforms (MT1A, MT1B, MT1E-H, 
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MT1M and MT1X) and different pseudogenes are reported as well. For human MT2 only 1 
isoform, MT2A, has been identified. Murine Mts are less divergent without subdivisions for 
any isoform (Mt1, Mt2, Mt3, Mt4) 177–183. Importantly, MT1 and MT2 are highly similar 
(Figure 5) whereas MT3 and MT4 are quite distinct and this is reflected in the similar tissue 
distribution and function of MT1/2 compared to MT3 and MT4. 
 
Mt1: mdpncscstg gsctctssca cknckctsck ksccsccpvg cskcaqgcvc kgaadkctcc 
Mt2: mdpncscasd gscscagack ckqckctsck ksccsccpvg cakcsqgcic keasdkcscc 
 
Figure 5: protein sequence of murine metallothionein (Mt) 1 (NCBI Reference Sequence: 
NP_038630.1) and Mt2 (NCBI Reference Sequence: NP_032656.1). Different amino acids are 
indicated in red.  
 
1.2. Expression 
The MT1 and MT2 isoforms are constitutively expressed in almost every tissue. However, 
expression levels vary according to the tissue, cell type and the species. The highest 
concentrations are found in the liver, kidney, gut and pancreas. In the intestine, MT1/2 are 
mainly expressed in intestinal epithelial cells, with a higher expression in the ileum 
compared to the colon (unpublished data, Figure 6).  
 
 
 
Figure 6: Immunohistochemical staining for MT1/2 on an ileum (A) and colon (B) section of a 
healthy subject. Scale bars: 100 µm. 
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Differences in MT1/2 concentrations among species have been reported for the liver. The 
human liver contains up to 400-700 µg/g liver whereas in rodents this is only 2-10 µg/g liver. 
The expression of MT1/2 is highly inducible upon different stimuli such as metals, pro-
inflammatory cytokines and other chemicals which induce a stress or inflammatory reaction. 
As such, MT1/2 are considered ‘acute stress proteins’ (see further) 183.  
Metallothionein 3 is considered as the brain-specific isoform and its function has mainly 
been investigated in neuronal disorders. However, mRNA levels of MT3 have been found in 
the heart, kidneys, reproductive organs and recently, we showed that MT3 is clearly 
expressed in mouse intestinal tissue albeit to a lesser extend than MT1 and MT2 
(unpublished data, see future perspectives). In contrast to MT1/2, MT3 is not induced by 
metals or pro-inflammatory stimuli 184–186. Metallothionein 4 is only expressed in stratified 
squamous epithelia and maternal deciduum and is, as for MT3, not induced by zinc or pro-
inflammatory stimuli 182,187.  
The ubiquitous nature of MT1 and MT2 and their conserved aspect suggest an important 
role for these proteins. Despite the fact that mice with a genetic deletion of Mt1 and Mt2 
have a normal growth and phenotype under physiologic conditions, in vivo experiments 
using MT mutant mice indicate that MT1 and MT2 are important in a broad range of 
stressful conditions, including immune-driven pathologies. We focused on MT1 and MT2 and 
further refer to these isoforms through this dissertation.  
 
1.3. Biological properties of MT1 and MT2  
1.3.1. Metallothioneins as metal binding proteins 
The best known characteristics of MT1 and MT2 came along with their identification as 
cadmium and zinc-containing proteins 168,169. Since then, MT’s metal binding capacity has 
been subject of many research. The fact that MT1/2 are able to exchange essential trace 
elements such as zinc and copper to other metalloproteins suggested a function as metal 
reservoir and preserver of metal homeostasis within the cell and through the body. The high 
inducibility of MT1/2 upon metal exposure in vitro as well as in vivo indicated a bi-partial 
metal binding function, namely also providing protection against heavy metal toxicity 188–190. 
The latter has extensively been explored following the development of mice lacking 
functional Mt1 and Mt2 genes 191,192 (further referred to as MT knockout mice, MT-KO mice) 
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and mice overexpressing Mt1 193 which initially revealed an increased sensitivity of MT-KO 
mice upon heavy metal exposure 194,195. Certainly, the development of these mutant mice 
opened the path to the exploitation of the role of MT1/2 under physio- and pathological 
condition in an in vivo biological model.  
 
1.3.2. Metallothioneins as anti-oxidantia 
Metallothioneins have a nucleophile character and can bind ROS through ion exchange 
196,197. A number of in vitro studies demonstrated anti-oxidant capacity of MT1/2 by 
oxidation of MT upon ROS or radical sequestering and Zn2+ release 198–202. In vivo, MT1/2 
protect in situations associated with ROS production whereas lacking functional Mt1 and 
Mt2 genes sensitized against oxidative stress. For example, Mt1 overexpressing mice were 
protected against ischemia-reperfusion induced myocardial injury 203,204 whereas cells 
isolated from MT-KO mice showed an increased sensitivity to oxidative stress 205. This 
property has further been explored in the light of cancer therapy where MT1/2 conferred 
protection against electrophilic antineoplastic agents 206.  
 
1.3.3. Metallothioneins as acute stress proteins 
The synthesis of MT1 and MT2 is rapidly induced by metals, cytokines, hormones, chemicals, 
stress and inflammation through metal responsive elements (MRE), anti-oxidant responsive 
elements (ARE) and in some MT genes, glucocorticoid responsive elements (GRE) (Figure 7). 
However, other responsive elements in the MT1 and MT2 promotor region have also been 
detected to respond to inflammatory mediators. Only two transcription factors have been 
shown to influence metal-induced MT1/2 transcription, MREBP (MRE binding protein that 
binds MRE of hMT2A) and MTF-1 (MRE binding transcription factor) 207–209. The transcription 
factor MTF-1 is thought to be essential for MT1 and MT2 expression since MTF-1 knockout 
cells show no MT1 and MT2 levels, neither at basal level nor after metal treatment 210. 
Interestingly, MTF-1 is also responsible for the regulation of other, vitally important, genes 
since MTF-1 knockout mice die in utero 211. Notable, human MT1 and MT2 transcription is 
regulated independently whereas mouse Mt1 and Mt2 are coordinately regulated 212,213. 
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Figure 7: Simplified representation of stimuli inducing metallothionein (MT) 1 and MT2 
expression. ARE: anti-oxidant responsive element; GRE: glucocorticoid responsive elements; 
MRE: metal responsive element, MTF-1: metal transcription factor-1; NO: nitric oxide; ROS: 
reactive oxygen species.  
 
The rapid induction of MT1 and MT2 upon stress and inflammation has designated these 
proteins as stress or acute phase proteins and this induction is, as for other acute phase 
proteins, regulated by stress hormones and inflammatory cytokines. Many groups have 
focused on elucidating the role of MT1 and MT2 in inflammatory diseases but unfortunately, 
reports do not always align. A key role for MT1/2 as (anti-)inflammatory mediators has 
frequently been proposed but has not been clarified to date. The most suitable example of 
this concept is the impact of MT1/2 on the LPS response. Following LPS injection in mice, 
MT1 and MT2 are induced in the liver and detectable in the plasma even before any other 
acute phase protein which justifies its nomination as acute phase or stress protein. However, 
while an increased responsiveness of MT-KO mice towards LPS is suggested, only one report 
effectively found increased liver damage following LPS in MT-KO mice 214–216. In addition, the 
intact acute phase response in MT-KO mice further contests its functional elementary role as 
acute phase protein in this inflammatory model.   
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1.3.4. Metallothioneins as immune modifiers 
The group of Lynes has focused on the immune-modulating properties of MT1/2 which 
clearly encompass both humoral and cellular immunity, as well as innate and adaptive 
immunological responses. They reported a suppressive effect of MT1/2 on humoral 
immunity. Mice immunized in the presence of exogenous MT developed a significant lower 
IgG response towards antigen provocation, which could be abolished by administration of 
MT1/2-specific monoclonal antibodies 217,218. Complementary, a significant higher anti-
ovalbumin response was observed in MT-KO mice 219.  
Metallothioneins’ effect on cellular immunity is more versatile. Recombinant MT1+2 induces 
the proliferation of cytotoxic lymphocytes 220,221, but suppresses the potential of 
macrophages to stimulate T-cell proliferation 222. Metallothioneins stimulate lymphocyte 
proliferation but have a mitigating impact on their differentiation to and activity of cytotoxic 
T-lymphocytes 223. On the other hand, MT1+2 induce the differentiation of naïve CD4+ T cells 
into IL-10 and transforming growth factor beta producing T cells and mice overexpressing 
Mt1 showed reduced susceptibility and enhanced IL-10 level in collagen-induced arthritis 224. 
Metallothionein 1 was recently found at the cell surface of DCs following ZnCl2 treatment 
and these DCs induced the proliferation of regulatory T cells. Anti-MT antibodies targeting 
MT1 and MT2 were able to counteract the tolerogenic effect of ZnCl2-treated DCs indicating 
that membrane-bound MT1 is essential for ZnCl2-treated DCs to induce regulatory T cell 
proliferation. However, MT1 was not transported to the cell surface and had no effect on 
tolerogenic DC function induced by other stimuli than ZnCl2 
225.  
The MT1 and MT2 genes cluster nearby chemokine genes, which is located near an 
important IBD locus 69,226, and MT1/2 also exhibit chemokine-properties: they have the 
ability to drive the migration of leukocytes in a chemotactic gradient 226. Chemokines are 
important regulators of leukocyte trafficking to damaged tissue, for example during 
inflammation. The appropriate influx of inflammatory cells results in efficient removal of 
tissue debris, necessary for rehabilitation. However, excessive infiltration of leukocytes 
during chronic immune stimulation may contribute to even more tissue damage and 
maintenance of inflammation. Metallothioneins are released upon stress and have been 
found at sites of inflammation 227–231. The involvement of MT1/2 in the process of leukocyte 
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attraction and immune cell activation during intestinal inflammation, was part of this 
project.  
 
2. Metallothioneins and inflammation 
 
2.1. Modulation of MT1 and MT2 in non-IBD inflammatory models 
The role of MT1/2 has been investigated in different inflammatory conditions using mice 
lacking functional Mt1 and Mt2 genes (MT-KO mice) or mice overexpressing Mt1. Most 
reports describe an increased sensitivity of MT-KO mice to experimental induced disease and 
a contribution of MT1/2 to protective mechanisms. For example, MT-KO mice are more 
susceptible to LPS-induced acute lung injury, to ovalbumin induced allergic airway 
inflammation, to oxidative lung injury and to LPS/D-GalN induced, oxidative and toxic acute 
liver injury 229,232–239. Most reports attribute the increased sensitivity of MT-KO mice to 
reduced anti-oxidative mechanisms or disturbance in zinc distribution. However, 
overexpression of Mt1 or zinc treatment does not always confer protection in the above 
mentioned conditions, indicating that other contributing factors may be important as well. 
Overexpression of Mt1 does protect in some conditions in which excessive ROS production is 
involved such as (hypoxia/reperfusion-induced) injury in pancreatic beta cells and 
cardiomyocytes 203,204,240–242. Contrarily, MT-KO mice were less affected during TNF-induced 
lethal shock and hyperoxic acute lung injury 243,244. Thus, deletion of Mt1 and Mt2 or 
overexpression of Mt1 yields different results in different conditions which are driven by 
distinct pathogenic mechanisms. Additionally, the (dis)advantage of MT1/2 might be time 
dependent in disease pathogenesis where different mechanisms dominate onset, 
progression and recovery of disease. This is nicely demonstrated in a number of 
experimental models associated with inflammation and oxidative stress. For example, in a 
mouse model for Alzheimer’s disease, Mt1, Mt2 and Mt3 are detrimental at an early stage of 
disease but reduce detrimental effects at advanced age 245–247. The MT-KO mice show 
increased numbers of apoptotic cells in skin transplants following UV-radiation but showed 
less epidermal hyperplasia during the epithelial regeneration phase compared to wild type 
controls 248,249. Intriguingly, both MT-KO mice as well as mice overexpressing Mt1 showed 
improved host defence against Listeria monocytogeneses infection compared to wild type 
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controls and this effect disappeared 3 days post inoculation 250. The latter suggests that 
different mechanisms regulate disease progression in mice lacking and overexpressing Mt1 
and that the outcome most likely depends on balances of these regulating mechanisms.  
 
2.2. Modulation of MT1 and MT2 in IBD models 
The interest in MT1/2 as potential regulators of intestinal inflammation has two principal 
causes: (1) MT1/2 are considered as important anti-oxidantia and oxidative damage is 
involved in IBD pathogenesis and (2) MT1/2 function as zinc chaperones and zinc deficiencies 
are frequently observed during intestinal inflammation. Unfortunately, the results of reports 
exploring the role of MT1/2 in intestinal inflammation are inconsistent. There are two 
different MT-KO strains and both strains have been tested in DSS-induced colitis 191,192. The 
two strains are generated by two different groups using a different targeted vector. As a 
result, the mice from Palmiter’s lab still generate both MT1 and MT2 mRNA, but premature 
stop codons result in a 12 amino acid original MT2 sequence and a 10 amino acid MT1 
sequence. In contrast, the mice from Choo’s lab express only MT1 mRNA, which results in a 
10 amino acid MT1 protein; MT2 is not transcribed due to interference in the transcription 
start site (Table 2). 
 
Table 2. The mRNA and protein expression in MT-KO mice from Palmiter’s and Choo’s lab 
 Palmiter Choo 
 MT1 MT2 MT1 MT2 
mRNA yes yes yes no 
protein 10 AA 15 AA (12 MT 
specific) 
10 AA 0 AA 
Neo cassette between MT1 and MT2 in MT2 
 
Additionally, both groups introduced the targeting vector into different mice strains. 
Palmiter’s lab incorporated the construct into AB1 embryonic stem cells, positive clones 
were injected into C57BL/6 blastocytes and transplanted into females. Chimeric animals 
were crossed with 129/SvCPJ mice to obtain heterozygous mice (which were further mated 
to generate mice homozygous for Mt1 and Mt2 disruption). The mice originally produced by 
Palmiter’s lab are commercially available at The Jackson Laboratory (Bar Harbor, Maine 
04609 USA) and were used in the experiments described in chapter 2 and 3 of this thesis. 
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Choo’s lab introduced the vector into the E14 embryonic stem cell line and positive clones 
were injected into blastocytes to create chimeric animals. Chimerics were mated to 
C57BL/6J mice to produce heterozygous animals. Thus, both strains are generated and 
maintained on a different background. Moreover, they have been backcrossed to other 
strains by several research groups which might additionally account for the differences in 
experimental outcome among groups.  
Oz and colleagues used the MT-KO mice, produced by Masters et al., on the OLA129/SvCPJ 
background and reported no difference in DSS susceptibility between MT-KO mice, mice 
overexpressing Mt1 nor wild type mice 251. However, the mice overexpressing Mt1 were on 
the C57BL/6J background and results of different groups can only be compared when they 
share the same genetic background. Tran and co-workers used the other MT-KO strain, 
produced by Michalska and Choo, on the OLA129/C57BL6/J background and backcrossed to 
C57BL/6J. Additional to the susceptibility of MT-KO mice to DSS-induced colitis, they also 
assessed the influence of zinc supplementation in this experimental setting. The MT-KO mice 
showed less myeloperoxidase activity, which is a measure for neutrophil infiltration, with a 
tendency towards a lower disease activity. Zinc supplementation during DSS colitis was able 
to lower the disease activity in wild type mice, no effect was observed in the MT-KO group 
252. The latest report exploiting MT knockout mice in colitis was published by Tsuji and 
colleagues who used the same strain as Tran. Contrarily, they reported an exacerbation of 
acute DSS-colitis in MT-KO mice 253. Differences in outcome of experimental groups may be 
attributed to mouse strain, background, origin and designation, microbial environment and 
other experimental settings, which is further discussed in chapter 2 of this thesis. 
Recently, MT1/2 were identified as critical factor for enhanced bacterial killing upon chronic 
PRR stimulation in human intestinal and mouse monocyte-derived macrophages. 
Metallothioneins were up-regulated in chronic NOD2-stimulated macrophages, which was 
regulated by NF-κB and caspase-1, and induced zinc-mediated autophagy 254. The enhanced 
bacterial clearance upon chronic PRR stimulation is associated with decreased pro-
inflammatory cytokine secretion and is assumed to be a protective mechanism to suppress 
tissue damage. The involvement of MT1/2 in this process might implicate important 
therapeutic potential since CD patients with NOD2 variants do not show enhanced  bacterial 
killing nor reduced cytokine production following chronic NOD2 stimulation 66,255–258. 
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2.3. Expression of MT1 and MT2 in human intestinal inflammation 
Different groups have reported on the expression of MT1/2 in IBD samples, however without 
uniformity. Lawrance and co-workers performed a microarray analysis to target differential 
mRNA expression in inflamed colonic specimens of UC and CD patients and found that MT1G 
and MT1H isoforms were decreased only in UC samples. Dooley et al. also performed a 
microarray analysis and found an up-regulation of MT1F, MT1G, MT1H in CD samples. 
Groups that addressed MT1/2 protein levels also reported conflicting results. The first 
studies used radio-immunoassay and silver-heme saturation on tissue homogenates and 
reported a decrease in total MT content 259,260. Ioachim and Kruideniers showed a decreased 
epithelial MT immunoreactivity on immunohistochemical stained colonic tissue of IBD 
patients. Both studies did however not report on MT expression in the inflammatory 
infiltrate 261,262. Contrarily, Bruwer et al. described an increased MT immunoreactivity, which 
was observed both in the intestinal epithelium and the infiltrate of IBD patients 263. 
Differences in patient characteristics, sample handling and the detection methods that were 
used, may account for the discrepant results reported in literature. Our group has tried to 
clarify MT1/2 expression in IBD patients by comparing MT1/2 immunoreactivity in biopsies 
of IBD, infectious colitis and healthy control patients, which is discussed in chapter 2 of this 
thesis. 
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AIMS – Elucidating the role of metallothioneins in IBD 
 
The general aim of this work was to clarify the role of MT1/2 in intestinal inflammation and 
to explore the therapeutic potential of exploiting MT1/2 as treatment strategy for IBD 
patients. This thesis is divided in three chapters, each describing a particular subject of how 
MT1/2 might be integrated in the intestinal inflammatory response. 
 
I. The relation between metallothioneins and the hypoxic adaptive response 
Hypoxia is one of the main factors involved in the pathogenesis of IBD. A positive correlation 
between MT1/2 and hypoxia has been described for other inflammatory diseases. In chapter 
1, we investigated whether  MTs and HIF-1α, the key-player in the hypoxic pathway, are also 
interrelated in intestinal epithelial cells and in a mouse model for IBD. 
 
II. The role of metallothioneins in the pathogenesis of murine colitis 
To investigate the role of MT1/2 in intestinal inflammation, we used mice with the genetic 
deletion of Mt1 and Mt2 and a monoclonal anti-MT1/2 antibody in different mouse models 
for colitis. This work is described in chapter 2. 
 
III. Impact of metallothioneins on macrophage phenotype and polarization 
In chapter 2, we found that colitis is characterized by an infiltration of MT1/2 positive 
inflammatory cells, including macrophages. Macrophages are key players in the onset, 
progression and restoration of intestinal inflammation. We therefore explored the effect of 
MT1/2 on macrophage phenotype and polarization by using bone-marrow derived 
macrophages from wild type and MT1/2 knockout mice. This work is described in chapter 3.  
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Chapter 1 
 
 
Metallothioneins and the 
Hypoxic Adaptive Response 
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Abstract 
 
A positive-feedback mechanism between hypoxia-inducible factor 1 alpha (HIF-1α) and 
metallothioneins (MTs) has been identified in different diseases. Both proteins have been 
independently proposed in the pathogenesis of inflammatory bowel disease (IBD); however, 
their relation has never been studied in the gut. In this study, we investigated the interaction 
between HIF-1α and MTs in colonic epithelial cells and during experimental colitis. 
Dimethyloxalylglycine (DMOG) was used to subject colonocytes to hydroxylase inhibition 
and HIF-1α stabilization in three experimental models (in vitro, in vivo and ex vivo). Small 
interfering RNA targeting HIF-1α (siRNA-HIF) and MT (siRNA-MT)  together with zinc-
mediated MT induction were used to study the interaction between HIF-1α and MT in HT29 
cells. Acute colitis was induced in C57BL/6 mice using dextran suphate sodium. MT 
expression and HIF-1α protein levels were measured using quantitative real-time PCR and 
ELISA respectively. Vascular endothelial growth factor (VEGF) expression was quantified as 
an indirect measure of HIF-1 transcriptional activity. DMOG down-regulated MT expression 
in HT29 cells, in freshly isolated human colonocytes and in colonocytes isolated from mice 
treated with DMOG (p < 0.05). SiRNA-HIF-treated cells displayed significant higher basal MT 
levels (p < 0.05) and an attenuated MT down-regulation after DMOG treatment. In turn, HIF-
1α stabilization was significantly lower in zinc-treated control cells, displaying high MT levels, 
compared to siRNA-MT cells treated with DMOG (p < 0.05). In the course of experimental 
colitis, MT and VEGF mRNA expression were inversely related. MTs were induced in the 
acute phase and down-regulated during recovery. Opposing results were observed for VEGF 
expression levels (p < 0.05). The present study underscores the inverse relation between 
HIF-1α and MT expression in colonocytes and during experimental colitis. The manipulation 
of MTs may represent a novel therapeutic strategy for patients suffering from IBD. 
 
 
Keywords: dimethyloxalylglycine; experimental colitis; hypoxia-inducible factor; hypoxic 
response, inflammatory bowel disease; metallothionein  
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1. Introduction 
 
Metallothioneins (MTs) are low-molecular-weight, cysteine-rich proteins with pluripotent 
capacities in a variety of processes, including immunoregulation and apoptosis. More than 
18 MT isoforms have been identified in mammalian cells, and they have been subdivided 
into the groups MT1 through MT4. While MT3 and MT4 are constitutively expressed, MT1 
and MT2 are highly inducible. Their expression patterns and potential contributions to 
pathogenesis have been investigated in a broad range of pathological conditions [1,2]. 
Despite the established role of MTs in different pathological disorders, their regulation 
remains unclear and appears to be tissue-dependent.  
Recently, a role for MTs in the adaptive hypoxic response has been proposed. An up-
regulation of MTs under low oxygen tension was first observed in cancer cells [3]. Hypoxia-
induced MT expression has been suggested to play a protective role in various tissues [4-8]. 
Additionally, MT over-expression or treatment with purified MT has been shown to protect 
against hypoxic damage in different cell types [8-13].  
A direct interaction between MT and hypoxia-inducible factor 1 alpha (HIF-1α) has been 
demonstrated. Under normoxic conditions, prolyl hydroxylases (PHDs) hydroxylate HIF-1α, 
which leads to its degradation. However, PHDs are inhibited under low oxygen tension, 
which results in stabilization of HIF-1α. The stabilization of functional HIF-1α leads to 
transactivation of different target genes, such as vascular endothelial growth factor (VEGF), 
and is considered to be a cellular rescue mechanism from stress [14]. An increased HIF-1α 
transcriptional activity by MT over-expression in cardiomyocytes under hypoxic conditions 
has been reported [15] and MTs have been implicated in the protection of the kidney against 
chronic hypoxia through HIF-1α stabilization [8]. Taken together, these reports have 
revealed the up-regulation of MTs during hypoxia, which protects against hypoxic damage 
through oxygen radical scavenging and/or HIF-1α stabilization.  
The expression and role of both MTs and HIF-1α have been independently investigated in 
inflammatory bowel diseases (IBD), comprising Crohn’s disease (CD) and ulcerative colitis 
(UC). An aberrant MT expression pattern has been found in IBD. We and other investigators 
have observed the down-regulation of MTs in gut epithelium where HIF-1α appears to be 
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over-expressed in IBD patients and displays protective properties in murine models of 
intestinal inflammation [2, 16-18].  
In this study, we examined whether a cooperative interaction between MTs and the hypoxic 
response could explain the observed MT down-regulation in IBD patients. The gut epithelium 
is located within a specific oxygen gradient and exists in a steady state of “physiological” 
hypoxia [19]. During inflammation, oxygen supply is insufficient, which is partly due to 
vasculitis and increased oxygen consumption by the inflammatory infiltrate. This low oxygen 
tension results in HIF-1α stabilization and activation of the hypoxic adaptive response. To 
investigate whether HIF-1α is able to control the transcriptional activation of MT isoforms in 
intestinal epithelial cells, colonocytes were treated with the hypoxia-mimicking pan-PHD 
inhibitor dimethyloxalylglycine (DMOG) to induce hydroxylase inhibition and HIF-1α 
stabilization in three experimental models. We revealed a HIF-1α-mediated inhibition of MT 
expression and investigated whether MTs are able to alter HIF-1α stabilization which may 
reinforce the effect of the hypoxic adaptive response, profoundly present during intestinal 
inflammation. Finally, we extrapolated our results to a model resembling ulcerative colitis. 
 
2. Materials and methods 
 
2.1. Cell culture  
 
HT29 cells (HTB-38, ATCC Cell Biology Collection, Virginia, USA) were cultured in McCoy’s5A 
medium supplemented with 10% foetal bovine serum and penicillin/streptomycin 
(Invitrogen, Merelbeke, Belgium).  
 
2.2. Induction of hypoxia 
 
HT29 cells were seeded at a density of 25 x 104 cells/well in a 24-well plate and exposed to 
atmospheric or 1% oxygen (O2) in a hypoxic chamber (Oxoid, Hampshire, UK) the next day. 
After overnight incubation, cells were lysed in either RNeasy Lysis Buffer for RNA extraction 
or in radioimmunoprecipitation assay buffer for protein assessment.  
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2.3. DMOG treatment of colonic epithelial cells 
 
In vitro treatment  
HT29 cells were seeded at a density of 25 x 104 cells/well in a 24-well plate and treated with 
1 mM DMOG (Bio-Connect, Huissen, the Netherlands) or vehicle (PBS) the next day. After 20 
hours, cells were lysed for RNA extraction or protein assessment.  
 
Ex vivo treatment  
Eight human colonic biopsies from a healthy individual were collected during a colonoscopy 
and placed in RPMI medium containing a high dose of antibiotics (200 μg/ml gentamycin and 
penicillin/streptomycin from Invitrogen) supplemented with 10% foetal bovine serum. The 
biopsies were rinsed 3 times and incubated for 2 hours in medium at 37°C. Next, the biopsies 
were incubated overnight in RPMI medium containing 100 μg/ml gentamycin and 1 mM 
DMOG or PBS. Colonocytes were isolated the next day by incubating the biopsies 2 times for 
30 minutes in medium containing 1 mM EDTA. After incubation, the biopsies were shaken 
gently to separate the epithelium. The remaining fragments were removed, and the 
resulting cell suspension was centrifuged and washed 2 times in PBS. The epithelial cells 
were subsequently lysed and used for RNA extraction. This study was approved by the local 
ethics committee (EC2000/242), and the volunteers signed and dated an informed consent 
form. 
 
In vivo treatment  
Eight-week-old SV129 mice were treated twice on alternating days with 8 mg DMOG (8 mg 
in 0.5 ml of sterile, endotoxin-free PBS) or PBS, intraperitoneally; this method was previously 
demonstrated to be effective for HIF-1α stabilization in vivo [20]. The mice were sacrificed 
the day after the second treatment by cervical dislocation. Colonic epithelial cells were 
isolated using Cell Recovery Solution (BD Bioscience, Belford, MA) and lysed for RNA and 
protein extraction [21]. The mice were treated according to institutional animal health care 
guidelines, following study approval by the Institutional Review Board of the Faculty of 
Medicine and Health Science of Ghent University. 
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2.4. Small interfering RNA  
 
To knock down HIF-1α and MT levels, small interfering RNA (siRNA) was used 
(Supplementary materials and methods). 
 
2.5. In vitro zinc treatment 
 
The siRNA-MT and HT29 control cells were seeded at a density of 25 x 104 cells/well in a 24-
well plate and treated the following day with 200 μM zinc acetate (Sigma Aldrich, Missouri, 
USA). Six hours after zinc treatment, 1 mM DMOG or an equivalent volume of PBS was 
added to the medium. Cells were lysed the next day for RNA and protein isolation. 
 
2.6. In vitro treatment with N,N,N’,N’-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN) 
 
HT29 cells were seeded at a density of 25 x 104 cells/well in a 24-well plate and were treated 
the next day with 2.5 μM TPEN (Sigma Aldrich). Two hours after TPEN treatment, the cells 
were treated with 1 mM DMOG and were lysed 6 hours post TPEN treatment. 
 
2.7. Experimental colitis 
 
Thirty 8- to 10-week-old C57BL/6 mice received 4% dextran sulphate sodium (DSS, MP 
Biomedicals, Illkirch, France) in their drinking water for 7 days followed by 7 days of normal 
drinking water. The mice were matched for initial body weight prior to the start of the 
experiment, and their body weight was measured daily. Five animals from each group were 
anaesthetized with isoflurane in oxygen for blood sampling and were sacrificed by cervical 
dislocation at day (D) 0, D3, D7, D10 and D15. Serum samples were stored at -80°C. Colonic 
epithelial cells were isolated using the Cell Recovery Solution (BD), as previously described 
and were lysed for RNA and protein extraction [21]. Mice were treated according to 
institutional animal health care guidelines, following study approval by the Institutional 
Review Board of the Faculty of Medicine and Health Science of Ghent University (ECD 
10/11). 
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2.8. RNA extraction  
 
Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen Benelux, Venlo, the 
Netherlands) with on-column DNase treatment. Needle homogenisation was performed for 
epithelial cells isolated from mice and biopsies. The concentration and purity of the total 
RNA were determined using a spectrophotometer (WPA Biowave II, Isogen Life Science, the 
Netherlands).  
 
2.9. quantitative real-time PCR  
 
The sequences and qPCR efficiencies of all primer sets are listed in Supplementary Table 1.S. 
Quantitative real-time PCR protocol can be found in the Supplementary materials and 
methods. 
 
2.10. HIF-1α ELISA  
 
The HIF-1α protein content was measured by ELISA according to the manufacturer’s protocol 
(human/mouse total HIF-1alpha DuoSet IC ELISA). The results were corrected for total 
protein content (Biorad Protein assay, California, USA). 
 
2.11. Statistical analysis  
 
Statistical analyses and figures were performed using GraphPad Prism® software (GraphPad 
Software, Inc., California, USA). Data are represented as the mean ± SEM. Differences 
between groups were compared using an unpaired t-test for normally distributed data and 
the Mann-Whitney U test for data that were not normally distributed. Correlations were 
analyzed using the Spearman’s Rho test, and two-tailed probabilities were calculated. 
Results with p values < 0.05 were considered statistically significant. 
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3. Results 
 
3.1. MTs are down-regulated in colonocytes after DMOG treatment  
 
In an initial experiment using DMOG, we investigated the effect of hydroxylase inhibition on 
cultured colonic epithelial cells (HT29), on freshly isolated human colonocytes and on 
colonocytes isolated from in vivo-treated mice. The effectiveness of DMOG treatment was 
shown by HIF-1α protein stabilization in cultured colonocytes and transcriptional induction 
of VEGF in human and mouse colonocytes (p < 0.05; Supplementary Fig. 1.S.) [20].  
All tested MT1 isoforms and MT2A were significantly under-expressed in DMOG-treated 
cultured cells (p < 0.05, Fig. 1A). Additionally, HT29 cells were exposed to 1% O2 to 
complement the effect of DMOG, a chemical hypoxia mimicker, by overnight incubation in a 
hypoxic chamber. Twelve hours of exposure to 1% O2 sufficiently down-regulated MTs 
expression in cultured colonocytes (p < 0.05; Fig. 1B).  
Consistent with our in vitro results, primary colonocytes isolated from colonic biopsies 
treated with 1 mM DMOG showed a reduced expression of all tested MT1 isoforms and 
MT2A compared to colonocytes from PBS treated biopsies (Fig. 1C). 
When analyzing the mRNA levels of the two Mt1 and Mt2 mouse isoforms, similar results 
were observed. The expression of Mt1 and Mt2 was significantly lower in colonocytes from 
in vivo DMOG-treated mice compared with vehicle-treated mice (p < 0.05; Fig. 1D).  
 
3.2. MT down-regulation in colonic epithelial cells is mediated by HIF-1α  
 
To determine whether the observed MT down-regulation after DMOG treatment is 
mediated by HIF-1α, HT29 cells were treated with siRNA-HIF before DMOG addition. HIF-1α 
was successfully down-regulated in siRNA-HIF-treated cells 48 hours post-transfection 
compared with siRNA-control-treated cells (p < 0.001, Supplementary Fig. 2.S.). The siRNA-
HIF-treated cells displayed a significantly higher basal MT mRNA level compared with the 
siRNA-control cells (p < 0.05; Fig. 2A). MT down-regulation after DMOG treatment was 
attenuated in siRNA-HIF cells compared with control cells for the MT1A, MT1E, MT1F and 
MT2A isoforms (Fig. 2B).  
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Because zinc is essential to form functional HIF-1α, we confirmed HIF-regulated MT 
inhibition by pre-treating cultured HT29 cells with 2.5 μM TPEN, a known intracellular zinc 
chelator. We observed no change in VEGF mRNA induction after DMOG treatment in TPEN-
treated cells (Fig. 2C). Moreover, no MT down-regulation could be observed in the TPEN-
treated cells, confirming MT inhibition through functional HIF-1α (data shown for MT2A, p < 
0.05;  Fig. 2D). Noticeable, less MT2A down-regulation was observed after 4 hours of DMOG 
treatment in control cells (Fig. 2D) compared to cells subjected to 20 hours of DMOG (Fig. 
1A). 
 
3.3. MTs are able to suppress HIF-1α  stabilization  
 
Based on previous results demonstrating that MTs are able to stabilize HIF-1α in the kidney, 
we also investigated the role of MTs in HIF-1α stabilization in colonic epithelial cells [8]. We 
used siRNA to create HT29 cells that were deficient in MT expression (siRNA-MT). The siRNA-
MT and control cells were first treated with zinc to induce MT synthesis to amplifying the 
effect. Subsequently, both groups were subjected to treatment with 1 mM DMOG. 
Significantly less MT up-regulation after zinc treatment was confirmed in the siRNA-MT 
group for MT1B (p < 0.01), MT1G (p < 0.05), MT1K (p < 0.05) and MT1X (p < 0.01) (Fig. 3A). 
Zinc-treated control cells, which displayed significantly higher MT levels, showed 6.4-fold 
less HIF-1α stabilization and significantly lower VEGF mRNA levels compared with siRNA-MT 
cells after DMOG treatment (p < 0.05, Fig. 3B and 3C).  
 
3.4. MT and VEGF expression are inversely correlated in the course of colitis 
 
In a final experiment, our aim was to extrapolate the previous results and elucidate the 
expression of MT and VEGF at different time points during acute colitis and recovery. Mouse 
colonocytes were isolated at different points, lysed and assessed for Mt1 and VEGF mRNA 
expression. The results demonstrated a negative correlation between both genes with an 
induction of Mt1 in the acute phase and a decrease in the recovery phase, while the 
opposite was true for VEGF (Fig. 4). A significant induction in Mt1 and a decrease in VEGF 
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expression were present at D7 and D10 (p < 0.01). Furthermore, Mt1 and VEGF showed an 
inverse correlation in each mouse during colitis (R = -0.474, p < 0.05).  
 
4. Discussion 
 
A role for MTs as mediators of inflammation has been implied in different inflammatory 
diseases. MTs are considered to be acute phase proteins because they are rapidly up-
regulated during inflammatory processes and are able to attract leucocytes to the site of 
inflammation [23]. Their expression patterns and roles have been investigated in different 
pathological disorders and protective properties have been associated with high MT 
expression in models of inflammation [24]. Many groups have focused on the contribution of 
MTs in IBD; however, their regulation and role in intestinal inflammation remain unclear. We 
and other investigators have proposed that MTs are down-regulated during active IBD [2]. 
The intestinal epithelial lining forms a specific barrier in the gut and is in a steady state of 
‘’physiological’’ hypoxia. Adaptive mechanisms have evolved in the form of oxygen sensors 
which enable epithelial cells to respond to the limited oxygen supply [25]. Nevertheless, the 
intestinal epithelium displays a certain susceptibility to further decreases in oxygen supply, 
for example during inflammation. The sensitivity of intestinal epithelial cells to low oxygen 
tension and recent reports that have identified MT as hypoxia-inducible gene have led to the 
assumption of a correlation between MT and the hypoxic adaptive response in the intestinal 
epithelium and during intestinal inflammation. 
In contrast to previous reports describing a positive-feedback mechanism between HIF-1α 
and MTs, we provide evidence for MT down-regulation through HIF-1α stabilization in three 
experimental models of colonic epithelial cells. The zinc chelator TPEN was used to confirm 
our results: no decrease in MT expression was observed without functional HIF-1α. 
Conversely, the attenuation of HIF-1α stabilization was observed in cells expressing high 
levels of MTs. While zinc chelation by TPEN treatment is able to inhibit the formation of 
functional HIF-1α, it is possible that the observed attenuation of VEGF induction is mediated 
by the capacity of MTs for zinc capitation and deprivation, which protects the cell from 
excessive metal toxicity [2,22]. This property could lead to less available zinc and, 
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subsequently, less functional HIF-1α stabilization after DMOG treatment in cells expressing 
high levels of MT.  
This observed reciprocity between HIF-1α and MT was further explored during intestinal 
inflammation. MTs, which are considered acute phase proteins, were up-regulated during 
active inflammation and decreased during recovery in DSS-induced colitis. Additionally, the 
low VEGF expression in the acute phase and its up-regulation in the subacute and recovery 
phases are consistent with the manifestation of hypoxia during ongoing mucosal 
inflammation and the need for activation of the protective pathway to restore barrier 
function. Both findings are consistent with a reduced expression of MTs and up-regulation of 
HIF-1α in the gut epithelium of IBD patients suffering from chronic intestinal inflammation 
[2,16]. While HIF-1α protein levels have protective properties in murine models of intestinal 
inflammation [17,18,20,26], no beneficial or detrimental effects could be demonstrated for 
MT levels in two independent murine colitis models [27,28]. Both latter studies have 
described MT up-regulation using a DSS-induced model of colitis. However, these reports did 
not examine MT expression during the course of colitis. The regulation and role of MTs may 
be critically time-dependent during intestinal inflammation. Furthermore, in vivo models are 
required to evaluate whether the observed acute induction of MT or its decrease during 
recovery demonstrates an essential adaptive mechanism. While the over-expression of MTs 
leads to HIF-1α stabilization in kidney tubular cells and cardiomyocytes, our results 
distinguish the intestinal epithelium from other cell types by revealing an inverse correlation 
between both [8,15]. 
In conclusion, we demonstrated the HIF-1α-mediated down-regulation of MTs in colonic 
epithelial cells. MTs were able to attenuate HIF-1α stabilization possibly through zinc 
deprivation in HT29 colonic epithelial cells. The negative-feedback regulation of colonic 
epithelial MT expression by HIF-1α could suggest an intestinal rescue mechanism during the 
acute phase of inflammation as demonstrated by the time-dependent expression of both 
during experimental colitis. The previously observed low MT profile in IBD patients may 
point to a hypoxia-driven adaptive response during the course of gut inflammation to 
restore the intestinal epithelial barrier and reduce further damage by pro-inflammation-
dependent mechanisms. Agents that target MTs and enhance the protective effects of HIF-
1α may represent future therapeutic opportunities for IBD patients.  
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Figure and table legends 
 
Figure 1 Fold reduction in metallothionein (MT) mRNA expression in colonocytes after 
dimethyloxalylglycine (DMOG) treatment 
(A) The mRNA expression of different MT isoforms was down-regulated in HT29 cells after 20 
hours of DMOG treatment and (B) after overnight incubation in a hypoxic chamber under 1% 
O2. The solid line represents a 4-fold (A) and a 1.5-fold (B) down-regulation (n = 4). (C) The 
mRNA expression of different MT isoforms was down-regulated in colonocytes isolated from 
DMOG-treated biopsies. The solid line represents a 2-fold down-regulation (n = 1, pool of 4 
biopsies). (D) Mt mRNA expression is down-regulated in mouse colonocytes after in vivo 
DMOG treatment. The solid line represents a 2.5-fold down-regulation (n = 4). Fold 
reductions are shown. * p < 0.05; ** p < 0.01. 
 
Figure 2 Hypoxia-inducible factor 1 alpha (HIF-1α) down-regulates metallothionein (MT) 
expression  
Small interfering RNA (siRNA) targeting HIF-1α was used to evaluate the effect of HIF-1α on 
MT expression in HT29 cells. Cells were transfected with siRNA-HIF or siRNA-control and 
treated 48 hours post-transfection with 1 mM DMOG. Additionally, the zinc chelator TPEN 
was used to confirm the necessity of functional HIF-1α to down-regulate MTs. (A) Basal MT 
mRNA expression was significantly higher in siRNA-HIF-treated cells compared with siRNA-
control-treated cells. Fold inductions are shown (n = 4). (B) MT down-regulation was 
attenuated in siRNA-HIF cells after DMOG treatment compared with control cells for MT2A, 
MT1A, MT1E, MT1F and MT1G. Fold reductions are shown (n =  3). (C) TPEN successfully 
inhibited the formation of functional HIF-1α as shown by attenuated vascular endothelial 
growth factor (VEGF) induction (n = 4). (D) No MT2A down-regulation after DMOG-
treatment was observed in TPEN-treated HT29 cells compared with control cells (n = 4).  * p 
< 0.05; *** p < 0.001. 
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Figure 3 Metallothioneins (MTs) are able to attenuate hypoxia-inducible factor 1 alpha 
(HIF-1α) stabilization 
The siRNA-mediated silencing of MTs was used to evaluate the effect of MTs on HIF-1α 
stabilization in HT29 cells. Zinc was used to induce MT synthesis in siRNA-MT cells and 
control cells. Both zinc-treated, siRNA-MT and control cells were treated with 1 mM DMOG 
to evaluate HIF-1α stabilization and vascular endothelial growth factor (VEGF) induction in 
both groups. (A) The MT induction by zinc was attenuated in siRNA-MT cells for MT1B, 
MT1G, MT1K and MT1X, confirming the efficacy of siRNA-MT. Transcripts were normalized 
against the MT levels in siRNA-MT cells (n = 3). (B) The HIF-1α protein (n = 2)  and (C) the 
VEGF mRNA levels (n = 3) were significantly less increased after DMOG treatment in zinc-
stimulated HT29 cells compared with the stimulated siRNA-MT cells.  * p < 0.05; ** p < 0.01. 
 
Figure 4 Negative correlation between mouse metallothionein 1 (Mt1) and vascular 
endothelial growth factor (VEGF) expression in the course of colitis  
Mice were treated with 4% dextran sulphate sodium (DSS) for 7 days followed by 7 days of 
normal drinking water. Colonocytes were isolated when mice were sacrificed at different 
time points (day (D) 0, D3, D7, D10 and D15) and the mRNA expression of Mt1 and VEGF was 
quantified using quantitative real time-PCR. The results were normalized to baseline levels 
(D0). A significant Mt1 induction and a decrease in VEGF expression were present at D7 and 
D10. Mt1 and VEGF were inversely correlated in each mouse during colitis (R = -0.474, p < 
0.05). The data are presented as the mean ± SEM (n = 5 per group). ** p < 0.01. 
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Figure 3 
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Supplementary data 
 
1. Supplementary Materials and methods 
 
1.1. Small interfering RNA  
 
To knock down the HIF-1α levels, HT29 cells were seeded at a density of 25 x 104 cells/well in 
a 24-well plate and were transfected the next day with either small interfering RNA (siRNA) 
duplexes targeting human HIF-1α or control siRNA (Biolegio, Nijmegen, The Netherlands) 
using 5 μl of lipofectamine (Invitrogen) in 500 μl of RPMI medium [18]. The siRNA sequences 
for HIF-1α and the scrambled control sequence used for duplex formation were AGU UAG 
UUC AAA CUG AGU UAA UCC C and CAA GAC CCG CGC CGA GGU GAA TT, respectively. Forty-
eight hours after transfection, cells were treated with either 1 mM DMOG or an equivalent 
volume of PBS and were lysed the next day. 
To knock down MT levels, a stable MT siRNA expressing cell line was created (siRNA-MT). A 
short hairpin RNA fused to the H1 promoter was synthesized by PCR and placed in the 
pSUPER vector (Tronolab, Lausanne, Switzerland) using the primers 5’-CAA TCT CTT GAA TTG 
CAC TTG CAG GAG CCG GGG GGA TCT GTG GTC TCA TAC AGA ACT TAT AA-3’ and 5’-CCA TCG 
ATT TCC AAA AAC CGG CTC CTG CAA GTG CAA TCT CTT GAA TTG C-3’ (scrambled control). 
The sequence in bold is a 19-mer that specifically targets MT and is present in MT1B, MT1E, 
MT1H, MT1J and MT1M. A siRNA control cell line was created with the primers 5’-CAA TCT 
CTT GAA TTG CAC TCT TTG CAC TTG CGG GGA TCT GTG GTC TCA TAC AGA ACT TAT AA-3’ and 
5’-CCA TCG ATT TCC AAA AAG CAA GTG CAA AGA GTG CAA TCT CTT GAA TTG C-3’. The PCR 
fragment was cloned into the pLVTH-siGFP vector (Tronolab). To produce virus for short 
hairpin RNA delivery, HEK293T cells (ATCC CRL1573) were transfected using the calcium 
phosphate method with 3 μg of pCMV-d8.91 (Tronolab), 1.5 μg of PMDG2 (Tronolab) and 1.5 
μg of the shRNA construct. After 48 hours, the supernatant containing the viral particles was 
harvested and passed through a 0.45 μm filter. One day before viral transduction, HT29 cells 
were seeded at a density of 50 x 103 cells/well in a 24-well plate. The cells were overlaid with 
viral supernatant and were centrifuged for 1 hour at 32°C. This procedure also was repeated 
with the 72-hour viral supernatant. Cells expressing high levels of GFP were subsequently 
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sorted with an EPICS Altra cell sorter (Beckman Coulter, Woerden, The Netherlands). 
 
1.2. quantitative real-time PCR  
 
One microgram of total RNA was converted to single strand complementary DNA (cDNA) by 
reverse transcription (Superscript, Invitrogen) with oligo(dT) priming. The cDNA was diluted 
1/8 and was used in real-time quantification with SYBR Green (Roche, Vilvoorde, Belgium) 
and 250 mM of each primer. A two-step program was run on a LightCycler® 480 (Roche). 
Cycling conditions were 95°C for 10 minutes and 45 cycles of 95°C for 10 seconds and 60°C 
for 1 minute. A melting curve analysis confirmed primer specificity. All reactions were 
performed in duplicate and normalised to glyceraldehyde phosphate dehydrogenase 
(GAPDH) and succinate dehydrogenase complex subunit A (SDHA) (for cultured HT29 cells 
and human biopsies) or to hydroxymethylbilane synthase (HMBS) (for mouse epithelial 
cells). The PCR efficiency of each primer pair was calculated using a standard curve from 
reference cDNA. The amplification efficiency was determined using the formula 10-1/slope. 
 
2. Supplementary Figure legends 
 
Figure 1.S. Dimethyloxalylglycine (DMOG) induces hypoxia-inducible factor 1 alpha (HIF-
1α) protein stabilization and vascular endothelial growth factor (VEGF) RNA levels 
HIF-1α protein levels and RNA VEGF levels are significant increased after DMOG treatment in 
HT29 cells (A). RNA VEGF levels are significant increased in mice colonocytes after in vivo 
DMOG treatment (B). RNA VEGF levels are increased in human colonocytes after biopsy 
treatment with DMOG (C). * p < 0.05. 
 
Figure 2.S. SiRNA targeting HIF was successful 48 hours post transfection 
HIF-1α protein levels were significantly lower in siRNA-HIF-treated cells compared to siRNA-
control-treated cells (n = 2) (A). HIF-1α protein stabilization (n = 2) (B) and vascular 
endothelial growth factor (VEGF) mRNA induction (n = 4) (C) were attenuated in siRNA-HIF 
cells compared with siRNA-control cells after DMOG treatment, confirming the siRNA 
efficacy.***p<0.001.
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Table 1.S. Sequences and qPCR efficiencies of the primer sets used for quantitative real time-PCR in this study 
Gene symbol Reference sequence Forward primer Reverse primer Efficiency R2 
Human           
GAPDH NM_002046 TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 91 0.9936 
SDHA NM_004168 TGG GAA CAA GAG GGC ATC TG CCA CCA CTG CAT CAA ATT CAT G 92 0.9947 
VEGF NM_001025366 TCGGGAACCAGATCTCTCAC TCTGTCGATGGTGATGGTGT 105 0.9508 
MT1A NM_005946 GCA AAG GGG CAT CAG AGA AGT G AAA TAC AGT AAA TGG GTC AGG GTT G 92 0.9768 
MT1B NM_005947 AAG TGC TGC TGC TCT TGC TG TGG TTG CTC TAT TTA TGT CTG GGA G 98 0.989 
MT1E NM_175617 TCA GGT TGG GAG GGA ACT CAA GAA AGC CTG GAG AGG GAA TGA 99 0.9974 
MT1F NM_005949 GCG ACT GAT GCC AGG ACA AC  CAC AGG AAA AGG AAT GTA GCA AAT G 95 0.9953 
MT1G NM_005950 ACAGCCCTGCTCCCAAGTA GGAATGTAGCAAAGGGGTCA 103 0.9798 
MT1K NM_176870 CTG CAA AGG GAC GTT GGA GAA C CAG CAA ATG GCT CAG TAT CGT ATT 92 0.9896 
MT1X NM_005952 GCAAATGCAAAGAGTGCAAA GCACTTGTCTGACGTCCCTT 94 0.9991 
MT2A NM_005953 AAA GGG GCG TCG GAC AAG TG GAA TAT AGC AAA CGG TCA CGG TCA G 95 0.9745 
Mouse           
HMBS NM_013551 AAG GGC TTT TCT GAG GCA CC AGT TGC CCA TCT TTC ATC ACT G 95 0.9944 
VEGF NM_001025250 ACTCGGATGCCGACACGGGA CCTGGCCTTGCTTGCTCCCC 98 0.998 
Mt1 NM_013602 GCTGCTCCTGCTGTCCCGTG GGTGGCAGCGCTGTTCGTCA 92 0,9988 
Mt2 NM_008630 CAGCCCTGGGAGCACTTCGC TCGCCATGGACCCCAACTGC 100 0,9996 
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Corrigendum to references 
Reference 21 “B. Rana, D. Mischoulon, Y. Xie, N.L. Bucher, S.R. Farmer, Cell-extracellular 
matrix interactions can regulate the switch between growth and differentiation in rat 
hepatocytes: reciprocal expression of C/EBP alpha and immediate-early growth response 
transcription factors, Mol. Cell. Biol. (1994) 5858-5869” should be replaced by the reference 
“N. Perreault and J. Beaulieu, Primary Cultures of Fully Differentiated and Pure Human 
Intestinal Epithelial Cells, Exp. Cell. Res. (1998) 34-42”. 
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Abstract 
Inflammatory bowel diseases (IBD) are recurrent intestinal pathologies characterized by a 
compromised epithelial barrier and exaggerated immune activation. Mediators that 
influence this chronic process of immune cell infiltration may represent new therapeutic 
opportunities. Metallothioneins (MTs) are stress-responsive proteins with immune-
modulating functions. Metallothioneins have been linked to IBD, but their role in intestinal 
inflammation is inconclusive. We investigated MT immunoreactivity in colonic biopsies from 
IBD and acute infectious colitis patients and healthy controls and evaluated MT’s role in 
experimental colitis using MT knockout mice and anti-MT antibodies. Antibody potential to 
target extracellular MT and its mechanism was tested in vitro. Biopsies of patients with 
active colitis showed infiltration of MT positive cells, in a pattern that correlated with the 
grade of inflammation. MT knockout mice displayed less severe acute dextran sulfate 
sodium (DSS)-induced colitis compared to congenic wild type mice based on survival, weight 
loss, colon length, histologic inflammation and leukocyte infiltration. Chronic DSS-colitis 
confirmed that Mt1 and Mt2 gene disruption enhances clinical outcome. Blockade of 
extracellular MT with antibodies reduced F4/80 positive macrophage infiltration in DSS- and 
trinitrobenzene sulfonic acid-colitis with a tendency towards a better outcome. Whole-body 
single-photon emission computer tomography of mice injected with radioactive anti-MT 
antibodies showed antibody accumulation in the colon during colitis and clearance during 
recovery. Necrotic and not apoptotic cell death resulted in western blot MT detection in 
HT29 cell supernatant. In a Boyden chamber migration assay, leukocyte attraction towards 
necrotic cell supernatant could be abolished with anti-MT antibody, indicating chemotactic 
potential of endogenous released MT. Our results show that human colitis is associated with 
infiltration of MT positive inflammatory cells. Since antibody blockade of extracellular MT 
can reduce colitis in mice, MT may act as a danger signal and may represent a novel target 
for reducing leukocyte infiltration and inflammation in IBD patients. 
 
Keywords: danger signal, inflammatory bowel diseases, metallothioneins, murine colitis 
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Introduction 
 
Inflammatory bowel diseases (IBD) are chronic intestinal inflammatory diseases that can 
affect the entire gastrointestinal tract (Crohn’s disease, CD) or remain restricted to the colon 
(ulcerative colitis, UC). A combination of genetic predisposition, gut microbiota and 
environmental factors are thought to contribute to excessive immune activation and 
disruption of the intestinal layer in IBD, however the exact etiology is still unclear. As a 
consequence, therapeutic options for IBD patients are limited [1-3]. 
 Metallothioneins (MTs) are stress-responsive proteins that are induced by a variety 
of stimuli including infection and inflammation and may harbour anti-inflammatory 
properties by for example scavenging reactive oxygen species [4]. Metallothioneins have 
also been found in extracellular compartments at sites of inflammation and can modify a 
number of immune activities [5-7]. Metallothioneins have been implicated in the 
pathogenesis of several inflammatory diseases, including IBD. Attempts to characterize MT 
expression in human IBD have yielded contradictory results that may be the result of 
differences in sampling, processing, and detection methods [8]. Similarly, murine models 
that explored MT’s role in intestinal inflammation have produced inconclusive results that 
may reflect differences in experimental design [9-11]. We, and others, have previously 
showed that MTs are up-regulated during murine colitis [11,12]. In this work, our aim is to 
clarify the consequence of MT expression in IBD, to focus on MT-mediated leukocyte 
trafficking and inflammation and to unravel MT’s role in colitis using validated mouse 
models.  
 
Materials and methods 
 
Human samples 
Colonic biopsies of 37 CD, 20 UC, 16 acute infectious colitis patients and 15 healthy controls 
were formalin fixed, paraffin embedded and evaluated for severity of colitis and MT 
immunoreactivity (see Table 1 for patients characteristics). Patients were diagnosed based 
on clinical, endoscopic and histologic criteria. Control biopsies were obtained from patients 
who underwent colonoscopy for follow up of polyp detection or colorectal carcinoma 
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screening. Colitis was histologically scored in blinded samples by two independent 
pathologists on hematoxylin and eosin (H&E)-stained sections using a modification of the 
grading scale described by Geboes et al [13]. Sections were classified as mild (1 or 2 crypt 
abscesses, small number of infiltrated granulocytes), moderate (multiple crypt abscesses, 
moderate infiltration of granulocytes) or severe (ulcers, large granulocytic infiltrate) (Table 
1). MT staining was carried out with the NexES IHC automated staining system (Ventana 
Medical Systems, Tucson, AZ) using mouse monoclonal anti-MT clone E9 (Zymed 
Laboratories, San Francisco, CA). An isotype-specific irrelevant antibody (mouse IgG1, Dako, 
Glostrup, Denmark) was used in a matched concentration to control for non-specific binding 
of the primary antibody. Sections were analysed by two independent observers using a semi-
quantitative grading system: 0: no MT-positive cells; 1: single MT-positive cells or foci (1 to 
5%); 2: moderate number of foci of MT-positive cells (6 to 40%); 3: large number of MT-
positive cells (40 to 70%); 4: majority of cells are MT-positive (>70%) and mean scoring 
values of the two observers were plotted against the severity of colitis. This study was 
approved by the local ethics committee of University Hospital Ghent (EC UZG 2000/242, 
2004/242 and 2006/362) and involves Caucasian participants.  
 
Mice   
DSS-induced colitis was evaluated in wild type (WT) and MT knockout (MT-KO) congenic 
mouse strains sharing the C57BL/6J background. The mice were bred at the University of 
Connecticut from strains produced as previously described [14,15]. In studies to evaluate 
monoclonal anti-MT antibody therapy, WT C57BL/6 mice were purchased from Harlan 
(Boxmeer, The Netherlands). Animals were reared and housed in the laboratory animal 
facility at University Hospital Ghent according to the institutional animal healthcare 
guidelines. Mice from different experimental groups were co-housed during the experiment 
in order to homogenize gut microbiota between groups. This study was approved by the 
Institutional Review Board of the Faculty of Medicine and Health Science of Ghent University 
(ECD 10/11).  
 
Colitis induction in WT and MT-KO mice 
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Acute colitis: Thirty 10-week-old mice per group received 4% dextran sulphate sodium (DSS, 
MW 36000-50000; MP Biomedicals, CA, US) in drinking water for 7 days followed by 7 days 
of normal drinking water. The mice were matched for body weight prior to start of the 
experiment. Five animals per group were sacrificed by cervical dislocation on day 10; the 
remainder of the animals were clinically monitored until day 15. Colon lengths were 
measured and distal colon samples were flash-frozen for assessment of myeloperoxidase 
(MPO) activity as previously described [16] and fixed in formalin for H&E and F4/80 
immunostaining.  
Chronic colitis: Sixteen 12-week-old mice per group received 3 cycles of 5 days of 4% DSS in 
drinking water, followed by 7 days of normal drinking water. The mice were analysed for 
survival and body weight loss and sacrificed at the end of the final cycle [17]. 
 
Antibody treatment during acute colitis  
DSS-induced colitis: Twenty-four 10-week-old WT C57BL/6 mice received 4% DSS through 
drinking water for 7 days and were followed up for weight loss and survival until day 10. Day 
10 was chosen as end point based on the previous DSS experiment showing maximum 
weight loss at this day. The mice were randomized on day 4 and treated intraperitoneally 
(i.p.) with 4 mg/kg monoclonal anti-MT antibody (clone UC1MT) or an equivalent dose of an 
irrelevant IgG (control) on days 4, 6 and 8 [6]. Colon samples were harvested as described in 
the previous section. 
Trinitrobenzene sulfonic acid (TNBS)-induced colitis: Fifteen 10-week-old WT C57BL/6 mice 
were treated intrarectally with 100 μl of 2.5% TNBS in ethanol (EtOH) on day 0 [18]. Mice 
received daily i.p. injections of 4 mg/kg UC1MT antibody or IgG control. Four mice only 
received EtOH intrarectally as control for the TNBS/EtOH treatment. Samples were collected 
at day 3, as described for the DSS experiment. 
 
Evaluation of murine colitis 
Colon sections were H&E stained and blindly scored for inflammation by two observers using 
a validated scoring system [19].  
 
Immunohistochemistry for F4/80 
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Paraffin-embedded mouse colon sections were rehydrated by serial immersion in xylene and 
ethanol and pre-treated with Antigen Retrieval solution (Dako, Glostrup, Denmark). After 
blocking with 3% peroxidase (in methanol) and rabbit serum (Dako), the primary antibody 
(1/200 rat anti-F4/80, Serotec, Dusseldorf, Germany) was applied overnight.  Rabbit anti-rat 
Ig (in rabbit serum) was applied for 45 min, followed by the Vectastain Elite ABC Kit (Vector 
Laboratories, Inc., Burlingame, USA) and the chromogen 3,3'-diaminobenzidine (DAB) 
(Dako). Counterstaining was performed with hematoxylin. Computerized semi-quantitative 
analyses were performed using Cell D software (Olympus Imaging Solutions, Münster, 
Germany). 
 
Small animal imaging of mice injected with anti-MT antibodies  
Indium (111-In) labelling of anti-MT antibodies (clone UC1MT): antibody conjugation was 
performed under strict metal-free conditions using the bifunctional chelator p-SCN-Bz-DOTA  
(Macrocyclics, Dallas, TX). Antibodies were transferred in metal-free 0,1M NaHCO3 (pH 8.5) 
via Centricon YM-30 (Cenfrigual Filter Device, Millipore, Darmstadt, Germany) at 3 mg/ml. 
Chelator conjugation to the antibody was performed at a 20:1 concentration overnight (4°C). 
Buffer exchange into 0.1 M ammonium acetate (pH 6.5) and removal of unbound chelator 
was performed by Centricon YM-30 ultrafiltration. The pH was adjusted to 6.0 with metal-
free ammonium acetate. Typically, labelling reactions were performed using 1 mg of 
antibody and 185 MBq of 111InCl3 (in 0.05M HCl) (Covidien, Mansfield, MA). DOTA conjugates 
were incubated for 60 min at 37°C.  The reaction was quenched by adding a 100-fold excess 
of Na2EDTA. Removal of free 111In was performed by Centricon YM-30 ultrafiltration. 
Labelling yields and radiochemical purities were higher than 95%. 
Imaging acquisitions: WT C57BL/6 mice received 4% DSS in drinking water, followed by 7 
days of normal drinking water to induce acute colitis. On day 0 (control), 7 (acute colitis) and 
14 (recovery) of DSS-colitis, mice (n = 4-6) received 35.0 ± 2.6 MBq 111In-labeled UC1MT 
intravenously. Two days after tracer injection (ensuring proper blood clearance of the 
antibody through the liver and kidneys), 0.5 ml gastrografin was administered rectally 
followed by computed tomography (CT, at 50 kV and 612 µA) and whole-body single-photon 
emission CT (SPECT) using the pre-clinical U-SPECT-II/CT system (MILabs, Utrecht, the 
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Netherlands). The mice were anesthetized with isoflurane in oxygen and body temperature 
was maintained using a heated bed.  
Data Analysis: SPECT acquisitions were iteratively reconstructed using ordered-subset 
expectation maximization [20]; 3 iterations were used in combination with 16 subsets and  
images were filtered using a Gaussian filter with a 1 mm full-width half-maximum. CT images 
were analytically reconstructed using the Feldkamp algorithm [21]. Volumes of interest 
(VOIs), determined on sagittal, coronal and transversal reconstructed CT slices, were drawn 
over the colon and entire mouse body using AMIDE [22]. Based on the global counts 
measured in the VOIs on the SPECT images, the percentage of injected dose per gram tissue 
(%ID/g) in the colon was calculated. 
Autoradiography: colon sections from SPECT-analysed animals were rinsed, immersed in 
embedding matrix (Cryocompound, Klinipath, Olen, Belgium), cut into 20 µM slices on a 
cryostat, and mounted on glass slides. The sections were exposed to a detector screen in an 
autoradiography cassette (FBCS 810, Fisher Scientific, Aalst, Belgium). After 15 min, screens 
were imaged by the Cyclone Plus Storage Phosphor System (PerkingElmer, Zaventem, 
Belgium). Consecutive sections were stained with H&E and analysed for inflammation [19]. 
 
Cell culture 
HT29 cells (HTB-38, ATCC Cell Biology Collection, Virginia, USA) were cultured in McCoy’s 5A 
medium (Invitrogen, San Diego, CA, USA), supplemented with 10% FBS. Cells were seeded at 
2.5 × 105 cells/well in 24-well plates and exposed for 6 and 24 h to 50 ng/ml tumor necrosis 
factor (TNF)-α (Invitrogen) + 300 ng/ml interferon (IFN), to 2 μM and 10 μM  staurosporine 
(Sigma) + 300 ng/ml IFN and to 300 ng/ml IFN alone. IFN was added to these treatments 
since IFN co-signalling is required for TNF-induced cell death and enhances staurosporine-
induced apoptosis in HT29 cells [23-25]. Nonspecific necrosis was induced by freeze/thaw 
cycles in liquid nitrogen-room temperature. All conditions were preceded by 250 μM zinc 
acetate (Sigma) treatment to up-regulate intracellular MT expression and amplify the effect. 
Cell supernatants were collected for MT detection by Western blot and lactate 
dehydrogenase (LDH) activity measurement (using an LDH Activity Assay Kit from Sigma). 
The activity of caspase-3/7 in cultured cells was analysed using the Caspase-Glo® 3/7 Glo 
Assay Kit (Promega, Leiden, the Netherlands) according to manufacturer’s instructions.  
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Western blot analysis for MT  
Twenty µl sample was mixed with 1:4 loading buffer (Invitrogen) and 1:10 reducing agent 
(Invitrogen). Samples were denatured, separated on 4–12% Bis-Tris SDS-PAGE gels 
(Invitrogen) and transferred to nitrocellulose membranes (GE Healthcare, Waukesha, 
Wisconsin, USA). Blotted membranes were incubated with 2.5% glutaraldehyde in distilled 
water for 1 h and in 50 mM monoethanolamine/PBS for 5 min. After blocking with 10% milk 
powder in PBS with 0.1% Triton-X100 (block buffer), blots were incubated with anti-MT 
antibody (1:100; clone E9, Zymed, Invitrogen) overnight. The next day, membranes were 
incubated with 1:10.000 horseradish peroxidase-HRP-conjugated secondary antibody (Santa 
Cruz, California, USA) in block buffer for 1 h (room temperature). Bound antibodies were 
visualized using BM Chemiluminesence Blotting Substrate POD (Roche, Brussels, Belgium) 
enhanced chemiluminesence detection kit, according to manufacturer’s instructions. The 
membranes were exposed to X-ray films.  
 
Boyden chamber chemotaxis assay  
Supernatants from necrotic cells containing detectable MT on western blot were subjected 
to 0.5 × 106 leukocytes (isolated from a healthy volunteer using Ficoll-PaqueTM Plus [GE 
Healthcare Bioscience AB, Uppsala, Sweden]) in a Boyden trans-well assay with and without 
100 μg/ml UC1MT anti-MT antibody (ThinCertTM 3µM pore size, TC Insert system, Greiner 
bio-one, Germany) [6]. Leukocytes migration through the membrane was counted in a 
Coulter chamber after 6 hours. 
 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism® software (GraphPad Software, 
Inc., California, USA) or SPSS, version 21 for Windows (SPSS Inc., Illinois, USA). Data are 
presented as mean ± SEM. Differences between groups were calculated using an unpaired t-
test or F test to compare variances in cases of normality or the Mann-Whitney test if the 
data were not normally distributed. Continuous data (body weight changes) were evaluated 
using linear mixed models. Kaplan-Meier survival curves were analysed using the log-rank 
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test (censored data). Correlations were calculated with the Spearman’s rho test. A value of p 
< 0.05 was considered statistically significant.  
 
Results  
 
Colonic MT immunoreactivity correlates with the severity of human colitis 
Colonic biopsies of IBD and acute infectious colitis patients were categorized based on 
histologic inflammation score and stained for MT. In biopsies of healthy subjects, MT was 
moderately to highly expressed in the epithelium, whereas a few immunopositive cells were 
observed in the lamina propria (Figure 1A). In contrast, biopsies from active colonic CD, UC 
and acute infectious colitis patients were characterized by an infiltration of MT positive 
inflammatory cells which correlated with the severity of colitis (r = 0.643 for colonic CD, r = 
0.328 for UC and r = 0.823 for infectious colitis, Figure 1A and 1B). Epithelial MT expression 
was absent or decreased in highly necrotic regions in biopsies of acute infectious colitis and 
IBD patients, and there was no correlation between epithelial MT expression and the level of 
inflammation. 
 
Metallothionein knockout mice are favoured in acute and chronic colitis 
To investigate the role of MT in colitis, we compared the course of DSS-induced colitis in WT 
and MT-KO mice. Strikingly, only 10% of MT-KO mice died during acute colitis in contrast to 
38% of the WT mice (cumulative percentage, Figure 2A). The higher survival rate in MT-KO 
mice was associated with less severe colonic inflammation, as demonstrated by a significant 
reduction of body weight loss, histological inflammation and colon shortening (Figure 2B-D). 
There was also less neutrophil infiltration in MT-KO compared to WT mice (based on 
reduced MPO activity levels without differences in infiltrating F4/80 positive macrophages) 
(Figure 2E and 2F).  
 Additionally, we investigated whether MT-KO mice were also favoured during chronic 
DSS-induced colitis. In accordance with results of the acute DSS model, we observed 
consistently higher body weights over time for MT-KO mice compared to WT mice (Figure 
3A). No differences were found in survival rates (2 mice died in each group) or histological 
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inflammation, but the preserved colon lengths in MT-KO mice suggest a better defence 
against structural damage and remodelling in these animals (Figure 3B).   
 
Anti-MT antibody treatment reduces signs of acute colitis  
To transfer our findings to a clinically relevant model, we tested the therapeutic potential of 
the UC1MT anti-MT antibody in two acute colitis models. Reflecting the results of MT-KO 
mice, anti-MT treated mice tended to exhibit a higher survival rate and less body weight loss 
in DSS-colitis compared to placebo-treated mice (Figure 4A). Histological analyses of H&E-
stained colon sections showed significantly less cell infiltration in UC1MT-treated mice 
compared to IgG-treated mice (Figure 4B). Differences were attributable to reduced 
macrophage infiltration, as demonstrated by lower F4/80 positive infiltrating cells in MT-KO 
mice (Figure 4C) without differences in MPO activity compared to control mice.  
 Finally, we evaluated the UC1MT treatment in TNBS-induced colitis. The UC1MT-
treated mice showed again a trend of reduced weight loss compared to IgG-treated mice 
(Figure 5A). The UC1MT-treated mice again showed a significantly lower influx of F4/80 
positive macrophages during active colitis compared to placebo-treated mice (Figure 5B and 
5C). These results indicate that anti-MT antibody treatment reduces leukocyte infiltration in 
experimental colitis. 
 
Anti-MT antibodies target the inflamed colon during colitis  
To ensure that the therapeutic antibody is present at the colon, we used non-invasive in vivo 
small animal imaging to follow antibody distribution during DSS-colitis in mice injected with 
radio-active anti-MT antibody. Significantly more radioactivity was observed in colons of 
mice during active colitis. Colonic activity decreased during recovery; however, it still 
remained above baseline levels compared with colonic activity of control mice (mice injected 
on day 0) (Figure 6A and 5B). Additionally, autoradiography of proximal, mid and distal colon 
sections correlated with these results and showed radioactivity over the entire colon length 
(Figure 6C). These data demonstrate colonic accumulation of the UC1MT antibody after 
systemic administration during active colitis and clearance of the antibody during healing. 
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Extracellular endogenous released MT attracts leukocytes 
Finally, we tested whether MTs can be released from a human colorectal cell line following 
different types of cell death. TNF induces receptor-dependent apoptosis, confirmed by 
increased caspase-3 activity after 6 and 24 hours. At 24 hours of TNF exposure, there was 
also increased LDH activity in cell supernatants, suggesting secondary necrosis following 
apoptosis [26], and this condition was associated with detectable MT in cell supernatants. 
Staurosporine, a receptor-independent apoptosis trigger, produced increased caspase-3 
after 6 and 24 hours without LDH release and did not result in MT release. Repeated 
freeze/thawing induced a significant increased LDH activity, which was associated with an 
abundance of MT in cell supernatants (Figure 7A-C). In conclusion, MT release coincided with 
LDH release, suggesting that MTs are released from HT-29 cells upon necrosis. 
 Others have shown that supernatant from necrotic cells attracts leukocytes [27]. To 
investigate whether MT contributes to this leukocyte attraction, supernatants from necrotic 
cells were used in a chemotaxis assay, with and without anti-MT antibody. Significant 
leukocyte migration toward necrotic cell supernatant was observed, and the addition of 
UC1MT abolished this chemo-attraction. These results support the idea that endogenous 
released MT can act as a potent chemokine (Figure 7D). 
 
Discussion 
 
This study identifies a positive relationship between MT immunoreactivity and inflammation 
in human colitis. Moreover, MT inhibition improved experimental murine colitis. MT 
knockout mice were favoured in terms of survival and inflammation in both acute and 
chronic colitis. At the applied dose, anti-MT antibodies accumulate at the colon during colitis 
and are able to reduce macrophage infiltration with a trend towards an enhanced clinical 
outcome.  
 Our results show predominant MT immunoreactivity in epithelial cells and in the 
infiltrating cells during active colitis, whereas epithelial MT is absent in highly necrotic 
regions. Given the similar results observed in samples from IBD and acute infectious colitis 
patients, inflammation-mediated increase of MT positive inflammatory cells is not IBD-
specific. The study of Bruwer et al aligns with our finding of increased MT immunoreactive 
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infiltrate during colitis, although they described a positive correlation between epithelial MT 
expression and inflammation [28]. Two other reports using immunohistochemistry on 
human colonic tissue describe decreased epithelial MT immunoreactivity in IBD patients 
compared to controls without MT detection in the lamina propria in IBD patients or controls 
[29,30]. The differences between the staining protocols described in the reported studies 
and ours relate to antigen retrieval [28,29] and primary antibody [30], factors that may 
influence MT immunoreactivity. Medication intake does not influence MT immunoreactivity, 
as previously reported [28]. Except for Ioachim and co-workers, who additionally included 
biopsies, the reported studies included surgical specimens whereas we exclusively used 
colonic biopsies. We can only speculate that tissue heterogeneity may be a factor 
contributing to the reported differences. Taken together, it can be concluded that MTs are 
predominantly expressed in the colonic epithelium and in inflammatory cells during active 
colitis. 
 The beneficial effect of genetic Mt1 and Mt2 deletion on survival and disease 
progression in our colitis model has previously been reported in an Alzheimer’s disease 
model, in the TNF-induced lethal shock model and in hyperoxic acute lung injury [31,32,33]. 
Though, pro-survival properties for MTs have also been described. MT-KO mice were more 
sensitive to LPS/GalN-induced lethality and cardiac overexpression of MTs prolonged the 
mice life span [34,35]. It is not surprising that a protein with as many housekeeping roles to 
play will have different effects in different circumstances. Unfortunately, there are also 
conflicting results reported by others using MT-KO mice in DSS-induced colitis. Tran and co-
workers saw less MPO activity and a tendency towards a lower disease activity in MT-KO 
mice compared to WT mice, which aligns our results [9]. In contrast, Oz and colleagues did 
not report a protective effect in MT-KO mice. Notably, in this study, the MT-KO was on a 
129/Sv genetic background whereas MT overexpressing mice and wild type mice were from 
the C57BL/6J background [10]. Differences in susceptibility to experimental colitis among 
mouse strains has been reported. Comparisons are most readily interpreted if groups share 
the same genetic background [36]. Moreover, in the Oz study, mice were sacrificed after 1 
week of DSS whereas we discovered a significant advantage at a later stage of disease (day 
10). Recently, Tsuiji and colleagues reported an exacerbation of acute DSS-colitis in MT-KO 
mice [11]. These opposing results may be due to various factors. We used MT-KO mice 
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derived from a genetic construct originally produced by Palmiter’s group [14] and used 
congenic WT mice sharing the same background as control. Tsuiji and co-workers used MT-
KO mice produced in Choo’s lab [37] and used WT mice originating from a different supplier. 
Although results reported by us and Tsuiji et al are both derived from C57BL/6 mice, reports 
in literature emphasize the impact of mice substrain and vendor on experimental outcome 
[36,38-40]. Besides the differences in genetic background between mice from different 
suppliers, microbial composition is also influenced by the environment and thus by the origin 
of the mice. Both factors, genetic background and gut microbiota, highly determine DSS-
susceptibility and therefore, experimental groups should be sufficiently backcrossed and co-
housed in order to minimize genomic and microbial heterogeneity among groups [36,38-44].
  Consistently higher body weights in MT-KO mice during chronic DSS-induced colitis, 
confirmed the clinical benefit observed during acute colitis and resulted in a protection 
against structural damage and remodelling. We expanded our observation by using 
antibody-mediated MT inhibition in two models of acute colitis and found a significant 
reduction in the inflammatory infiltrate, predominantly affecting macrophages, with a 
tendency towards a beneficial effect on survival and weight loss. To localize the antibody 
during colitis, we subjected our mice to medical imaging after injection with radioactive 
UC1MT. The increased colonic radio-activity observed during active inflammation followed 
by a decrease at the time of mucosal healing, indicates a specific but reversible binding at 
the moment of epithelial damage and leukocyte infiltration and suggests the opportunity for 
its therapeutic application in human IBD. 
 Since therapeutic antibodies act on the extracellular pool of MT and excessive cell 
death is a hallmark of IBD, we investigated the release of MTs from apoptotic and necrotic 
HT29 cells. We could only detect MT in cell supernatant following necrosis, associated with 
plasma membrane damage and LDH release. Both forms of cell death, apoptosis and 
necrosis, have been implicated in IBD pathogenesis [2,44,45-51]. Apoptosis is referred to as 
a physiologically controlled process of cell death characterized by containment of cellular 
proteins within membranes and the silent removal of apoptotic bodies by phagocytosis 
which does not evoke inflammation. However, when the apoptotic rate exceeds phagocyte 
capacity, the unprocessed cells undergo secondary necrosis [3,27,52]. Necrosis, in contrast 
to apoptosis, results in plasma membrane rupture and the release of signals, recognized as 
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danger signals or alarmins, which are able to attract, activate and/or alert nearby immune 
cells of ‘danger’ to the host resulting in an inflammatory response [51,52]. Lynes et al 
previously described chemokine properties for exogenous MTs [6,7]. Our in vitro results 
support these observations. We identified endogenous released MT as a danger signal, 
attracting leukocytes towards necrotic cells and potentially damaging bystander cells to 
release more MT. Targeting extracellular MTs in IBD could dampen this vicious cycle. Indeed, 
as also shown for other danger signals such as high mobility group box 1 (HMGB1), blocking 
danger signals can result in partial suppression of the immune response and disease 
amelioration in murine IBD models [53]. By using MT knockout mice, we found that MTs are, 
as extracellular danger signals, not essential for initiation of the inflammation but that 
absence of MT dramatically reduced the severity of colitis. 
 Although MTs have well-known anti-oxidant properties [54], we here report the 
rather unexpected finding that inhibition of MTs is a strategy to dampen gut inflammation in 
murine colitis. However, since MTs are released upon intestinal epithelial cell damage and 
act as potent chemokines, this observation may not be too surprising [7,55-57]. Apparently, 
during colitis, the antioxidant properties of MTs are overruled by their detrimental role as 
danger signals. Therefore, we believe that inhibition of MT’s bio-availability may be 
therapeutically valuable in immune-regulated pathologies that are associated with increased 
cell death.  
In conclusion, preventive and therapeutic inhibition of the chemotactic function of 
MTs as danger signals comprises an effective strategy to reduce leukocyte infiltration and 
inflammation in murine colitis. 
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Table 1. Patients characteristics 
 
    
Control Colonic CD UC Acute infectious colitis 
Histological inflammation No colitis 15 0 0 0 
 
Mild colitis 0 16 7 11 
 
Moderate colitis 0 10 5 5 
 
Severe colitis 0 11 8 0 
            
Age in years (mean, range) 
 
39 (24-63) 30 (11-57) 37 (13-68) 52 (15-82) 
      Gender Female/male 5/10 25/12 10/10 6/10 
      Medication No 15 18 3 15 
 
Immunosuppresives 0 2 1 0 
 
Corticosteroids 0 3 0 0 
 
Biologicals 0 1 0 0 
 
5-aminosalicylates 0 9 6 0 
 
Combination 0 4 8 0 
  Missing 0 0 2 0 
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Figure legends 
Figure 1. Active colitis is associated with metallothionein (MT) positive infiltrating cells in 
human colitis. (A) MT immunoreactivity in the colon of a healthy subject, an active colonic 
Crohn’s disease (CD) and an active ulcerative colitis (UC) patient. Original magnification x 
100. (B) Immunohistochemical scoring for lamina propria MT expression plotted against the 
degree of inflammation in colonic CD, UC and infectious colitis patients. Sections were 
scored for colitis and MT immunoreactivity by two independent observers and mean values 
are represented. 
 
Figure 2. Suppression of DSS-induced acute colitis in metallothionein knockout (MT-KO) 
mice. (A) Kaplan-Meier survival and (B) weight curve of wild type (WT) and MT-KO mice 
treated with 4% DSS for 7 days, followed by 7 days of normal drinking water; n = 25. (C) 
Histological inflammation score, (D) colon length, (E) mucosal cell infiltration score and (F) 
myeloperoxidase activity of WT and MT-KO mice on day 10 of acute DSS-induced colitis; n = 
5. Data are presented as the means ± SEM.  
 
Figure 3. Enhanced outcome for metallothionein knockout (MT-KO) mice in chronic DSS-
induced colitis. (A) Weight evolution and (B) colon length of wild type (WT) and MT-KO mice 
treated with 3 cycles of DSS/normal drinking water to induce chronic colitis; n = 14. Data are 
presented as the means ± SEM.  
 
Figure 4. Anti-MT antibody (clone UC1MT) treatment in acute DSS-induced colitis. (A) 
Kaplan-Meier survival curve of IgG control and UC1MT-treated mice. (B) Histological scores 
of mucosal cell infiltrate and representative pictures of H&E-stained colon sections of IgG 
control and UC1MT-treated mice at day 10 of DSS-colitis. (C) Histological scores for mucosal 
F4/80 macrophage infiltration and representative pictures of F4/80-stained colon sections of 
IgG control and UC1MT-treated mice at day 10 of DSS-colitis. Data are presented as mean ± 
SEM; n = 9-11. Original magnification x 200. 
 
Figure 5. Anti-MT antibody (clone UC1MT) treatment in acute TNBS-induced colitis. Mice 
treated with ethanol (EtOH) intrarectally served as controls for the TNBS/EtOH treatment. 
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(A) Weight evolution of IgG control and UC1MT-treated mice during TNBS-colitis. (B) 
Histological scores of mucosal cell infiltrate and representative pictures of H&E-stained colon 
sections of IgG control and UC1MT-treated mice at day 3 of TNBS-colitis. (C) Histological 
scores for mucosal F4/80 macrophage infiltration and representative pictures of F4/80 
stained colon sections of IgG control and UC1MT treated mice during TNBS-colitis. Data are 
presented as mean ± SEM; n = 4-8. Original magnification x 200.  
 
Figure 6. Anti-MT antibodies bind the colon during acute DSS-colitis. Antibody distribution 
was evaluated by injecting mice with radioactive UC1MT antibodies on days 0 (control, no 
colitis), day 7 (acute colitis), and day 14 (recovery) of DSS-induced colitis and subjecting 
them to a whole-body µSPECT/CT scan two days later. (A) Representative images of 
reconstructive SPECT/CT scans at the indicated time points. High activity in the kidneys and 
liver (interrupted arrows) represents blood clearance of the antibody. Full arrows indicate 
colonic binding. (B) Statistical analysis of the percentage injected dose per gram tissue 
(%ID/g) in the colon. The counts measured in the colon were normalized against the entire 
mouse body counts. Values are means ± SEM; n = 4-6 (C) Illustrative pictures of 
autoradiographic analyses of proximal, mid, and distal colon section at the indicated time 
points. 
 
Figure 7. Metallothioneins (MTs) are released from necrotic HT29 cells and act as potent 
chemokines upon release. Fold increases as compared to untreated controls of (A) caspase-
3/7 activity (luminescence) and (B) LDH activity of HT29 cell supernatant after 6 and 24 
hours of treatment with TNF, staurosporine (Stauro), IFN (as control) and three freeze/thaw 
cycles. All conditions were preceded by 3 hours of zinc acetate treatment to increase 
endogenous MT levels and amplify the signal. Mean fold induction ± SEM values are shown; 
n = 3; *p<0.05; **p<0.01; ***p<0.0001 compared with 6 and 24 h in untreated cells. (C) MT 
(6 kDa) Western blot analyses of HT29 cell supernatant after the respective treatments. (D) 
Leukocyte attraction toward the MT-containing supernatant of necrotic HT29 cells was 
tested in a Boyden chamber assay with and without the addition of anti-MT antibody 
(UC1MT). Values are mean ± SEM; n = 3. 
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Addendum to materials and methods 
 
(1) Regarding the MT-KO and WT mice used in DSS-induced colitis: 
Wild type (129S1/SvImJ) and MT-KO (129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J) mice were 
originally purchased from The Jackson Laboratory by the group of Prof. Lynes (University of 
Connecticut) and backcrossed to C57BL/6J background for more than 10 generation. The 
wild type mice and MT-KO mice on the C57BL/6J background were provided by Prof. Lynes 
and further housed and reared at the laboratory animal facility at University Hospital Ghent. 
In order to avoid genetic drift, we routinely backcross MT-KO to wild type C57BL/6J, so we 
are confident that the wild type and MT-KO mice used in our experiments do not represent 
two substrains. 
 
(2) Regarding the anti-MT antibodies used in the DSS- and TNBS-induced colitis and in in 
vitro experiments: 
Clone UC1MT are monoclonal anti-MT antibodies, originally produced by the group of Prof. 
Lynes, which cross react with the isoforms MT1 and MT2. They are commercially available at 
Abcam (Cambridge, UK). 
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ABSTRACT 
 
Macrophages can roughly be divided into two functional groups, the classically activated M1 
macrophages which respond to Toll like receptor (TLRs) ligands and the alternatively 
activated regulatory M2 macrophages which arise through interleukin-4 receptor alpha (IL-
4Rα) signalling. During inflammation, pro-inflammatory M1 macrophages are responsible for 
the initial immune response, whereas M2 macrophages dampen excessive M1 activation and 
initiate tissue restoration. Metallothionein (MT) 1 and MT2 are immune-modulating 
proteins, which worsen the susceptibility to experimental colitis. Interestingly, intestinal 
inflammation is characterized by an infiltration of macrophages that express high amounts 
of MT1/2 and MT1/2 deletion decreases pro-inflammatory cytokine production following 
lipopolysaccharide (LPS) treatment in murine macrophages. The present study was set up to 
investigate whether the expression of MT1/2 influences M1/M2 signal transducers. 
Significantly lower mRNA expression of TLR4, Interferon regulatory factor 5 (IRF5) and IRF3 
was found in untreated MT1/2 knockout (MT-KO) macrophages as compared to wild type 
(MT-WT) macrophages. Immunofluorescent staining confirmed low TLR4 levels in untreated 
and LPS-treated MT-KO macrophages and this phenotype was associated with an impaired 
M1 polarization following LPS. Conversely, only Krüppel-like factor 4 (KLF4), which facilitates 
M2 polarization, was significantly more expressed at mRNA level in MT-KO compared to MT-
WT macrophages. Immunofluorescent staining additionally revealed higher levels of IL-4R in 
MT-KO macrophages, both basal and after IL-4 stimulation. Consequently, macrophages 
from MT-KO mice showed an enhanced IL-4 response compared to MT-WT macrophages. In 
conclusion, this study demonstrates that MTs influence M1/M2 signalling in murine 
macrophages by regulating the levels of M1/M2 signal transducers. 
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INTRODUCTION 
 
Macrophages arise from the bone marrow as myelomonocytic precursor cells which 
differentiate to monocytes under interleukin-3 (IL-3), granulocyte macrophage-colony 
stimulating factor (GM-CSF) and  M-CSF stimulation. Monocytes are released into the blood 
stream, migrate into tissue, differentiate and become tissue specific resident macrophages. 
Upon inflammation, macrophages are activated and new inflammatory cells are recruited. 
Inflammatory macrophages secrete pro-inflammatory cytokines and chemokines as well as 
reactive oxygen species, which is essential for proper defence and propagates the initial 
inflammatory reaction. However, these effector mechanisms may cause bystander damage 
and are therefore controlled by anti-inflammatory macrophages which promote wound 
healing and protect tissue integrity (Valledor et al. 1998; Murray & Wynn 2011). Both types 
of macrophages, the pro-inflammatory M1 type and the regulatory M2 type, comprise a 
large group of functional macrophages and their distinction is based on gene expression and 
cytokine/chemokine secretion after stimulation. The classically activated M1 macrophages 
respond to Toll-like receptor (TLR) ligands and interferon-gamma (IFN-γ) and secrete pro-
inflammatory cytokines and chemokines such as IL-6, G-CSF and keratinocyte 
chemoattractant (KC) (Vellenga et al. 1988; Schaafsma et al. 1989; Larmonier et al. 2011; 
Murray & Wynn 2011; Tugal et al. 2013). Toll-like receptors are expressed by innate immune 
cells and function as sensors for pathogen-associated molecular patterns (known as PAMPs) 
and endogenous pathogenic signals (Janeway & Medzhitov 2002; Takeuchi & Akira 2010). 
Lipopolysaccharide (LPS) is a well-known stimulator of M1 macrophage polarization and 
LPS/TLR4 ligation results in MyD88-dependent and MyD88-independent pathway activation. 
The MyD88-dependent pathway activates the downstream transcription factor IFN 
regulatory factor 5 (IRF5) and nuclear factor-κB (NF-κB) which results in transcription of pro-
inflammatory genes. The MyD88-independent pathway also activates NF-κB, however, 
together with IRF3 leading to the activation of Type I INFs and this further optimizes M1 
polarization through the IFN feedback-loop (Figure 1) (Takaoka et al. 2005; Moynagh 2005; 
Honda & Taniguchi 2006; Lu et al. 2008; Tugal et al. 2013). The alternatively activated M2 
macrophages are activated by IL-4 and IL-13, which both bind IL-4 receptor alpha (IL-4Rα) 
complex and signal through signal transducer and activator of transcription 6 (STAT6). After 
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phosphorylation and homodimerization of STAT6, IRF4 is recruited and induces the zinc-
finger transcription factor Krüppel-like factor 4 (KLF4). The cooperation of STAT6 and KLF4 
further promotes M2-associated gene transcription, such as arginase-1 (Arg-1) and chitinase-
3 like 3 (Chi3l3 or Ym-1) (Figure 1) (Keegan et al. 1995; Kelly-Welch et al. 2003; El Chartouni 
et al. n.d.; Lawrence & Natoli 2011; Liao et al. 2011; Murray & Wynn 2011; Tugal et al. 2013).  
The intestine covers the largest bulk of resident macrophages. Yet, during intestinal 
inflammation, monocytes are still recruited from the blood stream through a chemotactic 
gradient which is established by the production of chemokines from pro-inflammatory 
activated macrophages. We recently reported that these infiltrating inflammatory cells 
express high amounts of metallothionein (MT) 1 and MT2 , which are acute stress proteins, 
and that MT1/2 on itself are able to attract inflammatory cells (Yin et al. 2005; Devisscher et 
al. 2014). Metallothioneins are zinc binding proteins that were initially known for their 
protective function as heavy metal and radical scavenger. However to date, focus has set on 
the potential of MT1/2 to modulate immune cell function and immune responses (Borghesi 
& Lynes 1996; Lynes et al. 2014). The activation of pattern recognition receptors (PRRs) up-
regulates MT1/2, which is essential for bacterial clearance, whereas MT1/2 deletion reduces 
bactericidal activity and pro-inflammatory cytokine production following LPS stimulation in 
murine macrophages (Youn et al. 1995; Kanekiyo et al. 2002; Sugiura et al. 2004; Itoh et al. 
2005; Lahiri & Abraham 2014). In order to explore how intrinsic MT1/2 levels influence the 
functional outcome of macrophages, we assessed the levels of key M1/M2 transducers and 
their corresponding downstream signallers in bone-marrow derived macrophages of wild 
type (MT-WT) mice and mice with a targeted disruption of MT1 and MT2 (MT-KO).  
 
MATERIAL AND METHODS 
 
Mice 
Wild type (129S1/SvImJ) and MT-KO (129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J) mice were 
purchased from The Jackson Laboratory (Bar Harbor, Maine, USA) and housed and reared in 
the laboratory animal facility of Ghent University Hospital according to the institutional 
animal healthcare guidelines. Wild type and MT-KO mice were mated to produce 
heterozygotes which are mated inter se to produce wild type and MT-KO mice of the same 
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background. This study was approved by the Institutional Review Board of the Faculty of 
Medicine and Health Science of Ghent University (ECD 14/55).  
 
Cells 
Femora and tibia bone-marrow canals of MT-WT and MT-KO mice were flushed with cold 
sterile phosphate buffer saline to obtain bone-marrow derived macrophages. Cells were 
cultured in 10x15 mm petri-dishes in DMEM+Glutamax (Invitrogen, Merelbeke, Belgium) 
supplemented with 10% foetal calf serum, penicillin/streptomycin (Invitrogen) and 
recombinant murine macrophage colony stimulating factor (M-CSF, PeproTech, London, UK). 
Medium was changed every other day and cells were seeded for experiments on day 7. Cells 
were stimulated with 100 ng/ml LPS (Ultrapure LPS from E. coli K, Invivogen, San Diego, 
California, USA), 20 ng/ml murine recombinant IL-4 (PeproTech) or were left untreated for 
24 hours. Cells were lysed for RNA extraction and supernatant was collected for 
cytokine/chemokine analyses. 
 
Quantitative real-time PCR 
Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen Benelux, Venlo, the 
Netherlands) with on-column DNase treatment. The concentration and purity of the total 
RNA were determined using a spectrophotometer (WPA Biowave II, Isogen Life Science, the 
Netherlands). One microgram of total RNA was converted to single strand complementary 
DNA by reverse transcription (Superscript, Invitrogen) with oligo(dT) priming. The cDNA was 
diluted 1/8 and was used in real-time quantification with SYBR Green (Roche, Vilvoorde, 
Belgium) and 250 mM of each primer. A two-step program was run on a LightCycler® 480 
(Roche, Vilvoorde, Belgium). Cycling conditions were 95°C for 10 minutes and 45 cycles of 
95°C for 10 seconds and 60°C for 1 minute. A melting curve analysis confirmed primer 
specificity. All reactions were performed in duplicate and normalised to glyceraldehyde 
phosphate dehydrogenase (GAPDH) and succinate dehydrogenase complex subunit A 
(SDHA). The PCR efficiency of each primer pair was calculated using a standard curve from 
reference cDNA. The amplification efficiency was determined using the formula 10-1/slope. 
The primer pairs used are listed in table 1.  
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Cytokine measurements 
Cytokines were measured in cell supernatant using the Bio-Plex MAGPIX multiplex reader 
(Bio-Rad, Hercules, California, USA) with a multiplex bead-based immunoassay kit for mouse 
IL-6, G-CSF, KC and IL-4. Samples were processed using the Bio-Plex ProTM Reagent Kit and 
analyzed with Bio-Plex ManagerTM Software.  
 
Immunofluorescent staining 
MT-WT and MT-KO macrophages were seeded at 105 cells/cm2 in culture slides (BD 
Bioscience, Erembodegem, Belgium) and were treated with LPS, IL-4 or left untreated for 24 
hours. Cells were fixed in 4% formaldehyde, permeabilized with 0,1% Triton X-100 (Sigma,  
Diegem, Belgium) and blocked in 1% bovine serum albumine (MP Biomedicals, Illkirch, 
France) for 10 minutes. Primary antibodies were applied overnight at 4°C (1/100 mouse 
monoclonal anti-TLR4, Abcam and 1/400 rabbit polyclonal anti-IL-4,antibodies online, 
Aachen, Germany). Alexa Fluor® 555 goat anti-mouse or Alexa Fluor® 488 goat anti-rabbit 
1/200 (Life technologies Europe BV, Ghent, Belgium) was used as secondary antibody. 
Fluorescent signals were visualized and photographed using a Nikon TE300 epifluorescence 
microscope equipped with a 40 x oil-immersion objective (Plan APO, NA 0.45; Nikon) and a 
Nikon DS-Ri1 camera (Nikon Belux, Zaventem, Belgium).  
 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism® software (GraphPad Software, 
Inc., California, USA). Data are represented as the mean ± SEM. Differences between groups 
were compared using an unpaired t-test for normally distributed data and the Mann-
Whitney U test for data that were not normally distributed. Results with p values < 0.05 
were considered statistically significant. 
 
RESULTS 
 
Metallothionein deletion dampens pro-inflammatory signaling in murine macrophages 
Since previous reports describe an impaired LPS response in MT-KO macrophages compared 
to wild type macrophages (Kanekiyo et al. 2002; Sugiura et al. 2004), we first addressed the 
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intrinsic expression of TLR4 and the respective MyD88-dependent and independent 
downstream transcription factors, IFR5 and IRF3 in bone-marrow derived macrophages  
from MT-WT and MT-KO mice. Untreated macrophages from MT-KO mice express 
significantly lower mRNA TLR4, IRF5 and IRF3 compared to MT- WT macrophages (Figure 
2A). Immunofluorescent staining confirmed lower TLR4 levels in MT-KO macrophages and 
this observation sustained following LPS stimulation (Figure 2B).  
We additionally investigated if the observed low TLR4, IRF5 and IRF3 expression of MT-KO 
macrophages  results in impaired M1 polarization. The secretion of the pro-inflammatory IL-
6, G-CSF and KC was significantly induced following LPS treatment and this induction was 
significantly less pronounced in macrophages from MT-KO mice (Figure 3A-3B).   
 
Metallothionein deletion facilitates M2 macrophage polarization 
Next we investigated the effect of MT deletion on M2 macrophages phenotype. The basal 
expression of IL-4Rα and the downstream transcription factors IRF4 and KLF4 were analysed 
in MT-WT and MT-KO macrophages cultured overnight. KLF4 mRNA was significantly higher 
expressed in MT-KO macrophages compared to wild type macrophages (Figure 4A), but not 
IL-4R and IRF4. However, immunofluorescent staining showed higher IL-4R levels in MT 
knockout compared to MT-WT macrophages, both in untreated and IL-4 treated 
macrophages (Figure 4B).  
We additionally assessed M2 polarization in MT-WT and MT-KO macrophages. IL-4 
stimulation resulted in the induction of Chi3l3 expression and this induction was significantly 
more pronounced in MT-KO macrophages compared to wild type macrophages. Notably, IL-
4 treatment evidently resulted in an increase of IL-4 cytokine in supernatant of both MT-WT 
and MT-KO macrophages, however, IL-4 concentrations were significantly more increased in 
supernatant of MT-KO macrophages which suggests an enhanced secretion compared to 
wild type macrophages (Figure 5).  
 
DISCUSSION 
 
The present study denotes the pro-inflammatory effect of MT1/2 on macrophage phenotype 
and their activation potential. MT1/2 deletion is associated with reduced TLR4 levels in 
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murine macrophages, resulting in an abrogation of downstream pro-inflammatory signalling. 
Vice versa, MT knockout macrophages display an M2 macrophage phenotype and an 
enhanced M2 response upon stimulation.  
Previous research  in murine derived MT knockout macrophages  investigated  the 
effect of MT1/2 on macrophage pro-inflammatory-associated functionality. Kanekiyo and 
colleagues report a reduction of NF-κB activity and TNF secretion following LPS treatment in 
MT-KO macrophages and additionally reported reduced bactericidal activity and nitric oxide 
production in MT knockout macrophages (Kanekiyo et al. 2002; Itoh et al. 2005). Sugiura and 
co-workers describe a defective phagocytic and antigen presenting activity and reduced pro-
inflammatory cytokine production in MT-KO macrophages (Sugiura et al. 2004). MT down-
regulation using an antisense MT mRNA vector resulted in the same reduction of LPS-
triggered monocyte activation (Leibbrandt et al. 1994). Recent discoveries even reported 
MT1/2 up-regulation as a critical factor for enhanced bacterial clearance upon PRR 
overstimulation in macrophages (Lahiri & Abraham 2014). Our results align with these 
observations. We show an impaired induction of pro-inflammatory markers upon LPS 
stimulation and extend the knowledge on how intracellular MT1/2 exert their effect on 
macrophage signature. MT1/2 deletion results in reduced TLR4 and increased IL-4Rα levels. 
Both signal transducers dominate LPS and IL-4 signalling pathways, and alterations in these 
receptors may readily affect downstream transcription factors and effector signals. Indeed, 
IRF5 and IRF3 were expressed at significantly lower levels in MT-KO macrophages and MT-
KO macrophages encompass a reduced sensitivity to MyD88-dependent and independent 
pathway activation (Figure 1). Indeed, IRF5 has been denoted as M1/M2 regulator since 
overexpression induces M1 and supresses M2 gene transcription (Krausgruber et al. 2011). 
Conversely, KLF4 was significantly higher expressed in MT-KO macrophages and 
overexpression of KLF4 facilitates M2 conversion (Liao et al. 2011). If MT1/2 directly 
influence transcriptional regulation of TLR4/IL-4R and affect downstream factors secondarily 
or if they exert their effect through transcription factors that in turn regulate receptor 
transcription remains to be investigated. It has been shown that NF-κB controls 
transcriptional activation and posttranscriptional stabilization of TLR4 and that MTs induce 
NF-κB activity (Abdel-Mageed & Agrawal 1998; Kanekiyo et al. 2001). The absence of tonic 
MT stimulation on NF-κB activity in MT knockout macrophages could therefore account for 
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the reduced TLR4 levels (Yan 2006). Furthermore, LPS induces MT1/2 expression which may 
further enhance NF-κB transcriptional activity, pro-inflammatory cytokine production and 
TLR4 expression (Leibbrandt & Koropatnick 1994).  
Importantly, the present results add further knowledge on how MTs might be involved 
in propagating – intestinal – inflammation. We previously reported decreased susceptibility 
to colitis in mice with reduced MT1/2 levels (Devisscher et al. 2014). MT knockout mice 
showed an enhanced survival and reduced signs of colitis. TLR4 and MyD88 are essential for 
bacterial defence and control the oral tolerance (Araki et al. 2005; Fukata et al. 2005; Fukata 
et al. 2006). However, when epithelial integrity is damaged, microbial infiltration into the 
lamina propria results in an excessive TLR4 stimulation. The subsequent rise in pro-
inflammatory cytokine secretion results in substantial bystander damage during on-going 
inflammation. Regulatory macrophages are therefore necessary to dampen the initial 
reaction, to promote recovery and to restore tissue integrity. Macrophages from MT 
knockout mice with reduced TLR4/IRF5/3 and enhanced IL-4Rα/KLF4 levels might more 
efficiently turn on their regulatory program and accelerate recovery.  
Collectively, we show that intracellular MTs influence M1/M2 signalling in murine 
macrophages by regulating the levels of M1/M2 signal transducers. 
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FIGURE LEGENDS 
 
Figure 1. Schematic overview of M1/M2 signalling in murine macrophages.  
Arg-1, arginase-1; Chi3l3, chitinase-3 like 3; G-CSF, granulocyte colony-stimulating factor; 
IFN, interferon; IL, interleukin; IRF, INF regulatory factor; KC, keratinocyte chemo-attractant; 
KLF4, Krüppel-like factor 4; LPS, lipopolysaccharide; MyD88, myeloid differentiation primary 
response gene 88; NF-κB, nuclear factor-κB; STAT, signal transducer and activator of 
transcription; TLR4, Toll-like receptor 4; TNF, tumor necrosis factor; TRIF, Toll-interleukin-1 
receptor domain-containing adaptor inducing IFN-β.  
 
Figure 2. Metallothionein promotes the M1 phenotype in murine macrophages  
(A) Basal mRNA expression of Toll-like receptor 4 (TLR4), Interferon regulatory factor (IRF) 5 
and IRF3 in wild type (MT-WT) and MT knockout (MT-KO) bone-marrow derived 
macrophages cultured for 24 hours. Results are representatives of two independent 
experiments, each in triplicate. *P<0.05. (B) Representative images of TLR4 
immunofluorescent stainings in MT-WT and MT-KO macrophages cultured for 24 hours in 
control medium and medium supplemented with 100 ng/ml lipopolysaccharide (LPS). 
 
Figure 3. Metallothionein promotes M1 macrophage polarization 
(A) Interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF) and keratinocyte 
chemoattractant (KC) concentrations in supernatant of wild type bone-marrow derived 
macrophages treated with 100 ng/ml lipopolysaccharide (LPS) or 20 ng/ml interleukin-4 (IL-
4). (B) Fold inductions of IL-6, G-CSF and KC cytokine secretion in supernatant of wild type 
(MT-WT) and MT knockout (MT-KO) macrophages following LPS stimulation. Results are 
representatives of two independent experiments, each in triplicate. **P<0.01; ***P<0.001. 
 
Figure 4. Metallothionein deletion promotes the M2 phenotype in murine macrophages 
(A) Basal mRNA expression of interleukin-4 receptor alpha (IL-4Rα), Interferon regulatory 
factor 4 (IFR4) and Krüppel-like factor 4 (KLF4) in wild type (MT-WT) and MT knockout (MT-
KO) bone-marrow derived macrophages cultured for 24 hours. Results are representatives of 
two independent experiments, each in triplicate. *P<0.05. (B) Representative images of IL-4R 
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immunofluorescent stainings in MT-WT and MT-KO macrophages cultured for 24 hours in 
control medium and medium supplemented with 20 ng/ml IL-4.  
 
Figure 5. Metallothionein deletion promotes M2 macrophage polarization 
(A) mRNA expression of chitinase-3 like 3 (Chi3l3) and interleukin-4 (IL-4) concentration in 
supernatant of wild type bone-marrow derived macrophages treated with 100 ng/ml 
lipopolysaccharide (LPS) or 20 ng/ml interleukin-4 (IL-4). (B) Fold inductions of mRNA Chi3l3  
expression and IL-4 cytokine secretion in supernatant of wild type (MT-WT) and MT 
knockout (MT-KO) macrophages following IL-4 stimulation. Results are representatives of 
two independent experiments, each in triplicate. *P<0.05; **P<0.01; ***P<0.001. 
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Table 1. Sequences and qPCR efficiencies of the primer sets used for quantitative real time-PCR 
 
Gene 
symbol Forward primer Reverse primer 
Efficiency 
% R2 
Mouse 
    GAPDH CATGGCCTTCCGTGTTCCTA GCGGCACGTCAGATCCA 85 0,99 
SDHA CTTGAATGAGGCTGACTGTG ATCACATAAGCTGGTCCTGT 103 0,99 
TLR4 GCTTACACCACCTCTCAAACTT AACTTCCTGGGGAAAAACTCTG 97 0,99 
IL-4Rα TGGAAGTGCGGATGTAGTCAG TGGATCTGGGAGCATCAAGGT 97 0,99 
IRF5 AGAGACAGGGAAGTACACTGAAG TGGAAGTCACGGCTTTTGTTAAG 95 0,99 
IRF3 GAGAGCCGAACGAGGTTCAG CTTCCAGGTTGACACGTCCG 100 0,99 
IRF4 TCCGACAGTGGTTGATCGAC CCTCACGATTGTAGTCCTGCTT 107 0,99 
KLF4 GTGCCCCGACTAACCGTTG GTCGTTGAACTCCTCGGTCT 95 0,99 
Chi3l3 CAGGTCTGGCAATTCTTCTGAA GTCTTGCTCATGTGTGTAAGTGA 95 0,99 
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Discussion 
 
Metallothionein 1/2 are acute stress proteins with immune-modulating functions. They 
participate in the pathogenesis of different inflammatory conditions and a role for MT1/2 in 
intestinal inflammation had been proposed, however without conclusive results. This work 
aimed at elucidating the role of MT1/2 in experimental colitis and providing further evidence 
for these isoforms as immune-regulating proteins in intestinal inflammation. This discussion 
is based on actual data provided in chapter 1, 2 and 3. In the future perspectives we 
elaborate on the unresolved issues of the presented work and provide some preliminary 
data of future projects. 
 
I. Metallothioneins and the hypoxic adaptive response 
 
Inflammation-induced hypoxia is a characteristic feature of a number of inflammatory 
conditions and contributes to the perpetuation of the inflammatory reaction and delay in 
tissue recovery. This is partly mediated by the increased metabolism of infiltrating cells and 
vasculitis. In the intestine, a high oxygen gradient exists from the well-perfused and 
oxygenated sub-epithelial mucosae to the anoxic luminal part. Therefore, the intestinal 
epithelium encounters a lower oxygen tension compared to other tissue, rendering them in 
a state of ‘physiological hypoxia’,  and it is intelligible that these cells are the most prone to a 
further decrease in oxygen supply 1. Cells are equipped with a hypoxia-induced mechanism 
that enables them to respond and adapt to reduced oxygen supply. This pathway involves 
the stabilization of HIF-1α which induces the transactivation of pro-angiogenic genes, such as 
VEGF and EPO. Activation of this hypoxic response has proven to be beneficial in IBD mouse 
models 2,3. Human IBD is characterized by increased HIF-1 levels and MT1/2 are known for 
their protective intracellular properties. Initially we speculated that the positive correlation 
between HIF and MT1/2, described in other inflammatory diseases, would also be present 
and advantageous in intestinal inflammation. The potential to manipulate this HIF/MT 
relation in order to abrogate the on-going inflammation, formed initially the basis of this 
thesis.  
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In chapter 1, we investigated the relation between MT1/2 and HIF-1α in intestinal epithelial 
cells. Surprisingly, we found that HIF-1α stabilization after DMOG treatment resulted in a 
down-regulation of mRNA MT expression in the HT-29 celline, in mouse as well as in human 
isolated colonocytes. By using SiRNA targeting HIF and MT1/2, we demonstrated that HIF 
down-regulates MT1/2 expression and that MT1/2 are in turn able to suppress HIF-1α 
stabilization. Intracellular zinc chelation inhibited the formation of functional HIF-1α and 
prevented MT1/2 down-regulation following DMOG, demonstrating the role of zinc in HIF-
mediated MT1/2 down-regulation. Subsequently, SiRNA-MT treated cells have increased 
free zinc levels 4 which can be applied for HIF-1α stabilization in case of PHD inhibition. The 
latter might account for the increased HIF-1α stabilization observed in SiRNA-MT cells 
compared to cells with high MT1/2 levels. The inverse HIF/MT relation was also present 
during DSS-induced colitis. Metallothionein 1 increased during the peak of inflammation, 
which is consistent with their identification as acute phase protein. The observed decreased 
expression of VEGF might come from MT’s mitigating impact on HIF induction but could also 
indicate that neo-angiogenic mechanisms are not yet activated at this stage of intestinal 
inflammation. 
 
II. Metallothioneins and experimental colitis 
 
Since HIF-1α stabilisation is beneficial in IBD mouse models 2,3, the HIF/MT inverse 
correlation questioned the proposed protective role of MT1/2 in intestinal inflammation. 
Indeed, in chapter 2 we demonstrated the beneficial effects of reducing MT1/2 in the 
outcome of experimental colitis. Complete elimination of Mt1 and Mt2 resulted in reduced 
susceptibility to colitis in MT-KO mice, both in an acute and chronic setting. Partial 
neutralisation of released MT1/2 by the use of anti-MT antibodies targeting the isoforms 
MT1 and MT2, reduced signs of colitis in acute DSS and TNBS colitis. Importantly, 
systemically administrated radioactively labelled antibodies were detected at the inflamed 
colon on microSPECT/CT scans of mice and colonic radioactivity was less pronounced during 
mucosal healing. This strengthens the potential for therapeutic use of anti-MT1/2 antibodies 
in human colitis. Since anti-MT antibodies only act extracellular, we tested the release of 
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MT1/2 following apoptotic and necrotic triggers in vitro.  Extracellular MT1/2 could only be 
detected after necrotic cell death and was partly responsible for the chemotactic effect of 
necrotic cell supernatant, demonstrated by anti-MT1/2 antibodies. The release of MT1/2 
following necrosis, their chemotactic effect as extracellular proteins and the ability of anti-
MT1/2 antibody to suppress leukocyte infiltration in vitro and in vivo indicates that MT1/2 
might function as danger signals during colitis.  
 
In chapter 2, we focused on the release of MT1/2 following apoptosis and necrosis since 
these are the two major forms of cell death implemented in the pathogenesis of human and 
murine intestinal inflammation. An increased rate of apoptosis was found in IBD patients 
and in DSS-induced colitis 5–7 and apoptotic cells become secondary necrotic cells when 
insufficiently phagocytised 8. Epithelial necrosis has been described in experimental induced-
colitis, in IBD patients and has even been demonstrated in crypts of patients without IBD 9–
12. Danger signals are per definition secreted by activated immune cells or passively released 
from dying cells following plasma membrane rupture. Plasma membrane rupture occurs 
during uncontrolled primary or secondary necrosis and in case of necroptosis and pyroptosis, 
two forms of programmed cell death. Necroptosis is a caspase-independent mode of cell 
death regulated by receptor-interacting protein kinases (RIPK)-1 and RIPK-3 and has recently 
been implemented in IBD pathogenesis 13. Pyroptosis involves inflammasome and caspase-1 
or capsase-11 activation and also results in cell swelling and plasma membrane rupture 14. 
Inflammasomes are important mediators of intestinal inflammation and have genetically 
been linked to IBD 15. We confirmed the presence of dying cells with plasma membrane 
damage in DSS and TNBS colitis and human ulcerative colitis by measurement of LDH activity 
in serum and H&E staining of colon sections (unpublished data, Figure 8).  Of note, these 
techniques cannot distinguish between necrotic, necroptotic and pyroptotic cell death. 
Nevertheless, in our interest of DAMPs release, and thus potential MT release, they hold the 
same fate of plasma membrane rupture and cell lysis. 
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Figure 8: Colonic cell death is present during colitis. Lactate dehydrogenase activity (LDH) and 
representative images of H&E stained colon sections of mice during (A) DSS- and (B) TNBS-
induced colitis. Data are represented as means ± SEM; n = 5 mice per time point; P < 0.05 
compared to control (day 0). (C) Representative image of H&E stained colon section of a 
healthy control and ulcerative colitis patient. Arrays mark intact extracellular nuclei as 
residues of necrotic colonocytes. Original magnification x200.  
 
The concept of targeting danger signals as treatment strategy in IBD has raised interest with 
the identification of HMGB1 as novel biomarker and potential target for IBD patients 16,17. 
However, blocking one DAMP results in partial suppression of disease activity 8,16. A more 
effective strategy could be the use of a multi-ligand receptor inhibitor. Potential therapeutic 
targets are RAGE and TREM-1, two specific DAMP receptors which signal via NF-κB activation 
upon ligand binding 18. However, blocking RAGE or TREM induced signalisation also did not 
fully protect against experimental colitis 19–21.  Using multiple inhibitors of different ligands 
and receptors could be more effective but is challenged by finding a balance between the 
preservation of an essential immune response and the suppression of an excessive 
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inflammatory response. At the applied dose, anti-MT1/2 antibody therapy resulted in 
reduced leukocyte infiltration following DSS and TNBS treatment. If higher doses are able to 
enhance disease activity suppression while preserving effective immune responses will be 
tested in the future. Anti-MT1/2 antibody therapy might have some advantages compared 
to anti-TNF treatment, the most widely used antibody in the treatment of IBD. The biological 
function of MT1/2 is subtle (MT1/2 knockout mice have no adverse phenotype), whereas 
TNF is a central mediator of inflammation. Additionally, anti-MT1/2 antibodies might  
counteract the development of cancer since high MT1/2 levels have been identified as 
cancer risk factor in IBD patients 22. However, anti-TNF used to be linked with increased risk 
of cancerogenesis but has recently been proposed as protective treatment in the 
development of colitis-associated cancer 23,24 and might in this aspect thus act synergistically 
with anti-MT1/2 antibodies. Notable, 10-30% of IBD patients does not respond to anti-TNF 
and this number increases to 40% because of  loss of response over time. Thus, anti-MT1/2 
antibodies might be an attractive strategy for end-stage IBD patients.  
 
In chapter 2 we showed that MT1/2 are absent in highly necrotic intestinal epithelium of 
active IBD patients. We speculate that (1) MT1/2 are released from the damaged intestinal 
epithelial cells and/or (2) the MT1/2 down-regulation is part of the protective HIF-mediated 
response (results of chapter 1). In order to strengthen the latter, double 
immunohistochemical staining for MT1/2 and HIF should be performed on human IBD 
samples. Notwithstanding this epithelial MT1/2 down-regulation, active IBD is associated 
with an infiltration of MT1/2 positive inflammatory cells which could also be a source of 
(massive) extracellular MT1/2 that can be targeted by anti-MT1/2 antibodies (see future 
perspectives). Antibodies act outside the cell and current results indicate that cell leakage is 
the only source of extracellular MT1/2. In this context, anti-MT1/2 antibody therapy might 
be most effective in active IBD patients, characterized by excessive cell death, in order to 
dampen on-going inflammation and in patients in remission to prevent the effect of released 
MT1/2 in a potential upcoming flare-up. 
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III. Metallothioneins and macrophage plasticity  
 
Since the intestinal mucosa of IBD patients is infiltrated with MT1/2 positive macrophages 
and fibroblasts (unpublished data), we analysed the effect of MT1/2 on macrophage 
phenotype and polarisation in chapter 3. We report that MT1/2 deletion in murine bone-
marrow derived macrophages (BMDM) is associated with reduced levels of M1 ( 
TLR4/IRF5/IRF3 ) and increased levels of M2 (IL-4R/KLF4) signallers which resulted in a 
reduced pro-inflammatory response to LPS and an enhanced IL-4 response respectively. 
 
The functional characterisation of macrophages is based on gene expression profiles and 
secretion of specific cytokines and chemokines. The classically M1 and alternatively M2 
activated macrophages are involved in pro-inflammatory and immune suppressive 
mechanisms respectively 25. In order to circumvent extravagant bystander damage, 
regulatory macrophages dampen immune activation and promote tissue restoration. 
However, M2 macrophages are also involved in wound healing and fibrosis, ultimately 
resulting in a deleterious outcome if uncontrolled. In optimal conditions , a subset of M2 
macrophages seems to be involved in counteracting this process of fibrosis and promotes 
complete tissue recovery and homeostasis 26–29. Colitis is associated with an M1/M2 
imbalance and alternative M2 macrophages are associated with attenuated disease activity 
in experimental colitis 30,31. Weisser et al. showed that M2 macrophages confer protection 
against DSS-induced colitis by using genetically modified mice with a pronounced M2 
macrophage phenotype 30. Moreover, transfer of ex vivo derived M2 macrophages was able 
to reduce DSS-susceptibility, demonstrated by two independent groups 30,31.  Thus, the 
reduced disease activity of MT-KO mice in DSS-induced colitis might additionally be 
mediated by reduced TLR4 and enhanced IL-4R levels in the macrophages of these mice. In 
order to strengthen these data, M1/M2 macrophage levels need to be determined in colonic 
tissue of healthy MT-KO and WT mice and in these mice during colitis. 
 
Extrapolation of data derived from murine BMDM cannot simply be extrapolated to humans. 
Murine M1 and M2 macrophages can easily be distinguished based on gene expression 
profiles. Unfortunately , an unambiguous delineation for human macrophages is not present. 
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For example, the typical M2 polarization markers Arg-1, Chi3l3 (Ym-1) and Retnla (Fizz1) are 
not expressed by in vitro stimulated human macrophages. To circumvent this issue, we will 
further characterize the effect of MT1/2 on macrophage phenotype and function by using 
blood-isolated human monocytes. Previous research stated that there are two distinct 
macrophage populations in the gut, one derived from circulating mononuclear cells and the 
other comprised residing phagocytes 25,32. This hypothesis has recently been refuted and 
Bain and Mowat claim that intestinal macrophages require constant replenishment from 
blood monocytes and differentiate in situ depending on the environmental stimulus 33. In 
accordance with the latter paradigm, blood-isolated monocytes nicely represent the 
circulating pool of residing macrophages. The question remains however if these cells 
respond equally ex vivo as in vivo after entering the lamina propria.  
 
 
 
In summary, colitis is characterized by necrotic cell death, which is associated with the 
release of MT1/2. Released MT1/2 attract leukocytes, a process that can be abrogated by 
anti-MT1/2 antibodies. Anti-MT1/2 antibody therapy partly suppresses experimental colitis 
and complete ablation of MT1/2 results in an even greater reduction of disease activity in 
MT1/2 knockout mice. These MT1/2 knockout mice harbour M2-skewed macrophages which 
is associated with an impaired pro-inflammatory and enhanced regulatory response 
following stimulation ex vivo and this could additionally have contributed to the reduced 
susceptibility to DSS-induced colitis in these mice.  
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Future perspectives 
 
I. Metallothionein suppression in chronic IBD models 
 
In chapter 2 we showed that genetic deletion of Mt1 and Mt2 results in a significant reduced 
weight loss during DSS-colitis. Antibody-mediated MT1/2 inhibition reduces leukocyte 
infiltration with a marginal effect on weight preservation. The pronounced effect of genetic 
MT1/2 deletion compared to antibody treatment might result from the applied antibody 
dose and/or the additional effect of intracellular MT1/2 deletion on macrophage phenotype 
and function, described in chapter 3. To extrapolate anti-MT1/2 antibody therapy to clinical 
practice, additional experiments are necessary. Antibody dose effectiveness needs to be 
tested in acute and chronic colitis models which are more specific for the immune 
dysregulation in human IBD patients, such as the adoptive T cell transfer model. Secondly, 
safety and specificity of the anti-MT1/2 antibody should be determined. Systemically 
administered radioactively labelled anti-MT1/2 antibodies were detected at the inflamed 
colon on microSPECT/CT scans of mice at day 7 of DSS-induced colitis and colonic 
radioactivity was less pronounced in mice scanned during recovery. To be able to link 
SPECT/CT signals to colonic injury, every mouse was euthanized following scanning and the 
colon was removed for histological evaluation and auto-radiography. In order to evaluate 
anti-MT1/2 antibody accumulation and safety during colitis, mice should be injected at 
specific time points (extrapolated from pharmacokinetic studies), scanned through the 
course of colitis and euthanized when fully recovered. Additionally, colonic radio-activity 
following injection of radio-actively labelled anti-MT1/2 antibody during colitis should be 
compared to the activity observed after injection of radio-actively labelled IgG control 
antibodies. The observed enhanced colonic radioactivity following injection of radio-actively 
labelled anti-MT1/2 antibody could be specific and indicative for extracellular released 
MT1/2 in the colon but could also merely reflect increased intestinal vascularization during 
inflammation. Notably, irrespective of the latter outcome, the current results showed that 
the antibody at least reached the colon and could target MT1/2 during colitis.  
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Finally, our results implement the involvement of MT1/2 as pro-inflammatory mediators in 
the course of colitis. In order to comprise intestinal inflammation and IBD in general, the 
involvement of MT1/2 in ileitis needs to be determined. We already started a first pilot 
experiment by backcrossing Mt1/2-KO (Mt-/-) mice to TNFΔARE/WT mice (who have normal MT 
levels and are denoted as MtWT/WT,TNFΔARE/WT). The TNFΔARE/WT mice are genetically modified 
mice which lack the RNA stability and transcriptionally-regulatory TNF AU-rich elements in 
one allele, resulting in an overproduction of TNF. These mice establish two specific 
phenotypes at the age of 6 to 8 weeks: chronic inflammatory ileitis and arthritis 34. We 
followed up the first generation offspring of MtWT/WT,TNFΔARE/WT x MtWT/WT,TNFWT/WT and 
MtWT/WT,TNFΔARE/WT x Mt-/-,TNFWT/WT mice and saw that MtWT/WT,TNFΔARE/WT mice gained 
significantly less weight compared to their littermate controls MtWT/WT,TNFWT/WT; while the 
MtWT/-,TNFΔARE/WT mice showed the same weight evolution as their littermate controls MtWT/-
,TNFWT/WT (Figure 9A). This effect disappeared after 16 weeks, which was, based on clinical 
evaluation of the mice and previously reports, presumable the result of MT1/2 deletion-
associated obesity in the MtWT/- mice on a C57BL/6 background 35. Why MtWT/-,TNFΔARE/WT do 
not develop this phenotype will be further investigated. Regardless of the disappearance in 
weight evolution, serum analyses revealed that MtWT/WT,TNFΔARE/WT  mice showed a higher 
increase in KC levels than MtWT/-,TNFΔARE/WT compared to their respective littermate controls, 
whereas the opposite was observed for IL-4 levels (Figure 9B). These initial results are 
indicative for disease amelioration by partial MT1/2 deletion in TNFΔARE/WT mice. To prove 
this hypothesis, weight evolution and additional parameters for ileitis will be compared 
between MtWT/WT,TNFΔARE/WT and MtWT/-,TNFΔARE/WT littermates. Breeding pairs delivering the 
appropriate littermates have been set up for future experiments (MtWT/-,TNFWT/WT x  MtWT/-
,TNFΔARE/WT). If results of MT1/2 deletion are favourable, anti-MT1/2 antibodies will 
additionally be tested in TNFΔARE/WT mice.   
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Figure 9: (A) Body weight evolution (n=5-12) and (B) fold difference of serum cytokine levels 
(n=3) of the first generation offspring of indicated breeding pairs. Cytokine concentrations 
were determined using luminex bead-based immunoassay. 
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 II. Metallothionein suppression on macrophage function 
 
1. Intracellular MT1/2 deletion 
 
In chapter 3, we provide evidence for a differential expression in signal transducers and 
downstream effectors in WT and MT-KO macrophages. However, no conclusion can be 
drawn on the mechanism by which MT1/2 mediate this effect. Metallothioneins may directly 
regulate the transcription of TLR4/IL-4R and/or may exert its effect through downstream 
effectors that in turn control receptor levels.  
Different transcription factors, such as NF-κB and KLF4, depend on intracellular zinc 
donation and MTs function as zinc chaperones. It has been shown that overexpression of 
MT1/2 results in reduced bio-available zinc levels whereas MT1/2 silencing increases free 
intracellular zinc concentrations in cancer cell lines 4. While zinc signals are required for 
MyD88-dependent induction of pro-inflammatory cytokines 36, zinc negatively regulates 
TLR4 signalling through reduced IRF3 activation in macrophages 37. Furthermore, zinc 
chelation/depletion elevated the oxidative burst but reduced the production of pro-
inflammatory cytokines 38. Apparently, low concentrations of zinc seem to stimulate TLR 
signalling while higher concentrations result in an anti-inflammatory effect of zinc on LPS-
induced cytokine secretion 39. Thus, zinc might be readily available in MT1/2 knockout 
macrophages and might as such participate in establishing the regulatory effect on 
macrophage phenotype. If zinc chelation in MT-KO macrophages results in an abrogation of 
the enhanced M2 phenotype/polarization, zinc can be addressed as a contributing causative 
factor. It is further to be investigated to what extent MT1/2 may function as selective zinc 
donator and thereby promote the M1 regulatory phenotype in macrophages.  
The impact of MT1/2 deletion on macrophage phenotype and function may also participate 
in the reduced susceptibility of MT knockout mice to colitis. Bone-marrow derived 
macrophages from MT1/2 knockout mice display a regulatory phenotype and have a 
reduced LPS and an enhanced IL-4 response. TLR4 is essential for oral tolerance and bacterial 
defence 40,41. However, excessive microbial infiltration due to intestinal barrier disruption 
might induce exaggerated TLR4 stimulation resulting in bystander damage during on-going 
inflammation. In addition, colonic epithelial proliferations and wound healing depends on Il-
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4 and IL-13, cytokines associated with alternative macrophage activation 42. In order to 
investigate if reduced TLR4 and enhanced IL-4 signalling might have attributed to the 
reduced signs of colitis in DSS-treated MT knockout mice, macrophage signatures need to be 
determined in colonic tissue of WT and MT-KO mice, at baseline and during colitis.  
 
2. Extracellular MT1/2 suppression 
 
In chapter 2, we showed that MT1/2 are released from necrotic IECs and attract leukocytes 
upon release. During intestinal inflammation, there is a high infiltration of MT positive 
inflammatory cells. Since danger signals leak passively from necrotic cells or are actively 
released from activated immune cells, we also investigated if MT1/2 are released from 
macrophages. We evaluated MT1/2 expression following LPS and IL-4 treatment and their 
subsequent release from M1 and M2 BMDM respectively. As previously described 43, we 
found an up-regulation of MT1/2 following LPS and not IL-4 (Figure 10A). However, MT1/2 
could not be detected by western blotting in cell supernatant of BMDM following LPS nor IL-
4 (Figure 10B). Similar data have been reported for DCs 44 and thus to date, no evidence exist 
for an active secretion of MT1/2 from immune cells. If in active IBD patients, highly MT1/2 
positive macrophages undergo some form of cell death which results in cellular leakage of 
MT1/2 into the extracellular environment, they could serve as another source of 
extracellular MT1/2. Thus, other triggers which are known to release DAMPs from immune 
cells, such as inflammasome activation, should be tested for their ability to induce MT1/2 
release from macrophages. 
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Figure 10: Bone-marrow derived macrophages were stimulated with 100 ng/ml LPS or 20 
ng/ml IL-4 for 24 hours. The mRNA expression of Mt2 was analysed by qPCR; n=3 (A); 
supernatant was collected and analysed for MT by western blotting (B). Of note, MT 
secretion was tested using macrophage medium with and without foetal calf serum since this 
intrinsically contains high amounts of MT. 
 
 
Extracellular MT1/2 aids in perpetuating the inflammatory response by attracting leukocytes 
45,46. The group of Lynes showed that MT binds the plasma membrane of macrophages and 
increases macrophage killing capacity upon phagocytosis 47. We additionally investigated the 
effect of recombinant MT1/2 (Enzo Life Science, Antwerp, Belgium) on macrophage 
polarization. First results indicate that high doses of MT (10-30 µM) promote M1 
signalization whereas low concentrations (0,1-1 µM) induce IL-4 secretion from wild type 
BMDM (Figure 11A). Anti-MT1/2 antibodies were able to block pro-inflammatory cytokine 
secretion following MT stimulation in BMDM (Figure 11B).  
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Figure 11: (A) Cytokine secretion of BMDM following different concentrations of recombinant 
MT1/2. (B) Supernatant KC cytokine secretion from BMDM following 30µM MT with and 
without 100µM pertussis toxin (PTX) or anti-MT1/2 antibody (130µg/ml UC1MT); n=2-3. 
Cytokine concentrations were determined using luminex bead-based immunoassay. 
 
In future experiments, we will investigate how extracellular MT1/2 exert their action on 
macrophage polarization. A receptor for MTs has been identified on astrocytes using a 
fluoresceinated probe that binds all four MT isoforms 48. In renal tubular cells, MT1 is 
believed to be internalized through megalin, a receptor for small protein ligands, whereas 
MT2 promotes neurite growth through the same receptor 49–51. However, a specific MT1/2 
receptor on macrophages has yet to be discovered. Leukocyte migration is mediated 
through G protein-coupled receptors (GPCRs) present on immune cells and can be blocked 
by pertussis toxin (PTX) 52,53. The MT-mediated leukocyte migration could be inhibited by 
anti-MT1/2 antibodies and by PTX which may indicate that MT1/2 function through 
interaction with a GPCR 45. On itself, PTX induces pro-inflammatory cytokine secretion in 
macrophages  54–57. Additional treatment with PTX alone will have to reveal if the observed 
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marked increase in pro-inflammatory cytokine release following MT+PTX treatment results 
from an additive effect of MT1/2 and PTX on macrophage polarization (Figure 11B). 
Additionally, TLRs are typical PRRs recognizing PAMPs but some of them also recognize 
endogenous danger-associated molecules. For example, HSPs are, like MT1/2, acute stress 
proteins denoted as danger signals and partly exert their pro-inflammatory action through 
TLR4 interaction 58. If MTs also functions as TLR ligands and as such mediate M1 polarization 
is subject for further research. Future experiments employing specific inhibitors of M1/M2 
signal transducers and transcription factors will reveal the mechanism by which MT1/2 drive 
M1 macrophage activation. The ability of high doses of recombinant MT1/2 to induce pro-
inflammatory cytokine secretion further contributes to the denotation of MT1/2 as 
extracellular danger signals. Besides blocking chemo-attraction of inflammatory cells, anti-
MT1/2 antibodies might be able to supress the pro-inflammatory effect of MT1/2 on 
macrophages and thereby limit the inflammatory response. To strengthen the hypothesis of 
MT1/2 as M1 stimulator and the potential to abrogate this by anti-MT1/2 antibodies, 
macrophage signatures need to be determined in intestinal tissue of anti-MT1/2 antibody 
and control treated mice during inflammation. 
 
 
III. Metallothionein 3 as counterpart of MT1 and MT2? 
 
Through this dissertation, we focussed on the role of MT1 and MT2 in experimental colitis 
and macrophage functional activation. Since MT3 is considered to be a brain specific 
isoform, its function has merely been investigated in neuronal disorders. However, we 
recently examined Mt3 expression in IECs of mice during acute and chronic colitis and found 
that mRNA Mt3 expression is, in opposite to Mt1 and Mt2, decreased during acute DSS-
induced colitis and is induced during chronic DSS-colitis (Figure 12A). This indicates that MT3 
does not function as acute stress protein and presumably has a different, perhaps opposing, 
role in inflammation. In addition, MT3 expression was down-regulated following LPS 
stimulation whereas its expression was enhanced upon IL-4 treatment in murine BMDM 
(Figure 12B).  
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Figure 12: (A) Intestinal epithelial cells were isolated from wild type mice at day 7 of DSS-
induced colitis and from mice following three cycles of DSS/drinking water. The mRNA 
expression of Mt1, 2 and 3 was analysed by qPCR; n=5. (B) Bone-marrow derived 
macrophages were stimulated with 100 ng/ml LPS or 20 ng/ml IL-4 for 24 hours, the mRNA 
expression of Mt3 was analysed by qPCR; n=3. 
 
These results show that MT1/2 and MT3 are differentially expressed under inflammatory 
conditions and that MT3 associates with a regulatory macrophage phenotype.  
 
Our current results show that MT1 and MT2 function as pro-inflammatory mediators and 
that targeting these two isoforms, genetically or by antibody therapy, reduces colonic 
inflammation. The preliminary opposing results for MT3 warrant for further investigation of 
the differential role of MT3 in the pathogenesis of intestinal inflammation and its potential 
therapeutic application in IBD. 
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Closing note 
 
Inflammatory bowel diseases are characterized by a disruption of the intestinal epithelial 
barrier which is partly mediated by necrotic cell death. Necrosis results in the release of 
MT1/2 and other danger signals which attract and activate immune cells and further drive 
the inflammatory response (Figure 13). The use of anti-MT1/2 antibodies that specifically 
bind the inflamed colon represents an attractive strategy to suppress leukocyte infiltration 
and inflammation. Additionally, human colitis is characterized by an infiltration of MT1/2 
positive macrophages and MT1/2 have been associated with a pro-inflammatory 
macrophage signature. It remains to be investigated if these MT1/2 positive cells are M1 
macrophages and thus aid in perpetuating inflammation. Moreover, if extracellular MT1/2 is 
able to skew macrophages towards pro-inflammatory cells, the potential of anti-MT1/2 
antibodies to counteract this polarization would strengthen their therapeutic use. Future 
research needs to confirm if anti-MT1/2 antibody therapy is able to reduce leukocyte 
infiltration and thus inflammation and additionally may aid in the process of mucosal healing 
and recovery by shifting the balance towards regulatory M2 macrophages in human IBD 
patients. 
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The results of this dissertation led to the filing of a patent application: ‘Use of antagonists 
targeting metallothionein to treat intestinal inflammation’ (TTRM PR2011/083 – 
P2010/099; national filing 17/01/2014). Future studies comparing anti-MT1/2 antibodies 
to conventional anti-TNF treatment in chronic IBD mouse models are in the pipeline to 
bridge fundamental, pre-clinical research towards the use of anti-MT1/2 antibodies in 
human clinical trails. 
 
Figure 13: Overview of how metallothioneins (MTs) may drive intestinal inflammation.  
During intestinal inflammation, the epithelial barrier is compromised and pro-inflammatory 
cytokines and DAMPs, such as MT1/2, are released. Released MT1/2 attract leukocytes and 
polarize macrophages (M) towards a pro-inflammatory M1 phenotype. The latter contributes 
to more pro-inflammatory cytokine release and immune cell attraction which eventually 
results in bystander damage, further breakdown of the intestinal epithelium and 
maintenance of this viscous circle. IFN: interferon; IL: interleukin; MAMP: microbe-associated 
molecular pattern; NLR: NOD-like receptor; PAMP: pathogen-associated molecular pattern; 
TLR: Toll-like receptor; TNF: tumour necrosis factor. Adapted from Hindryckx and Laukens 59. 
 175 
 
References 
1.  Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med (Berl). 
2007;85(12):1295-300.  
2.  Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial 
hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 
2004;114(8):1098-106.  
3.  Hindryckx P, De Vos M, Jacques P, et al. Hydroxylase inhibition abrogates TNF-alpha-
induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent 
repression of FADD. J Immunol. 2010;185(10):6306-16.  
4.  Habel N, Hamidouche Z, Girault I, et al. Zinc chelation: a metallothionein 2A’s 
mechanism of action involved in osteosarcoma cell death and chemotherapy 
resistance. Cell Death Dis. 2013;4:e874.  
5.  Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial 
barrier by maintaining tight junction protein expression and preventing apoptosis in a 
murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296(5):G1140-9.  
6.  Chen L, Park S-M, Turner JR, Peter ME. Cell death in the colonic epithelium during 
inflammatory bowel diseases: CD95/Fas and beyond. Inflamm Bowel Dis. 
2010;16(6):1071-6.  
7.  Araki Y, Mukaisyo K, Sugihara H, Fujiyama Y, Hattori T. Increased apoptosis and 
decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis 
in mice. Oncol Rep. 2010;24(4):869-74.  
8.  Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev 
Immunol. 2008;8(4):279-289. 
9.  Dourmashkin RR, Davies H, Wells C, et al. Epithelial patchy necrosis in Crohn’s disease. 
Hum Pathol. 1983;14(7):643-8.  
10.  Barkla DH, Gibson PR. The fate of epithelial cells in the human large intestine. 
Pathology. 1999;31(3):230-8.  
11.  Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J 
Biomed Biotechnol. 2012;2012:718617.  
12.  Targan SR, Shanahan F KL. Inflammatory bowel disease, from bench to bedside, 
second edition. :89. 
 176 
 
13.  Pierdomenico M, Negroni A, Stronati L, et al. Necroptosis is active in children with 
inflammatory bowel disease and contributes to heighten intestinal inflammation. Am J 
Gastroenterol. 2014;109(2):279-87.  
14.  Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 
2014;157(5):1013-22.  
15.  Aguilera M, Darby T, Melgar S. The complex role of inflammasomes in the 
pathogenesis of Inflammatory Bowel Diseases - Lessons learned from experimental 
models. Cytokine Growth Factor Rev. 2014.  
16.  Davé SH, Tilstra JS, Matsuoka K, et al. Ethyl pyruvate decreases HMGB1 release and 
ameliorates murine colitis. J Leukoc Biol. 2009;86(3):633-43.  
17.  Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal 
mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 
2011;106(11):2029-40.  
18.  Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front 
Biosci (Landmark Ed. 2009;14:1403-13.  
19.  Srikrishna G, Turovskaya O, Shaikh R, et al. Carboxylated glycans mediate colitis 
through activation of NF-kappa B. J Immunol. 2005;175(8):5412-22.  
20.  Zen K, Chen CX-J, Chen Y-T, Wilton R, Liu Y. Receptor for advanced glycation 
endproducts mediates neutrophil migration across intestinal epithelium. J Immunol. 
2007;178(4):2483-90.  
21.  Mueller C. Danger-associated molecular patterns and inflammatory bowel disease: is 
there a connection? Dig Dis. 2012;30 Suppl 3:40-6.  
22.  Bruewer M, Schmid KW, Krieglstein CF, Senninger N, Schuermann G. Metallothionein: 
early marker in the carcinogenesis of ulcerative colitis-associated colorectal 
carcinoma. World J Surg. 2002;26(6):726-31.  
23.  Onizawa M, Nagaishi T, Kanai T, et al. Signaling pathway via TNF-alpha/NF-kappaB in 
intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. 
Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G850-9.  
24.  Grimm M, Lazariotou M, Kircher S, et al. Tumor necrosis factor-α is associated with 
positive lymph node status in patients with recurrence of colorectal cancer - 
indications for anti-TNF-α agents in cancer treatment. Anal Cell Pathol (Amst). 2010. 
25.  Murray PJ, Wynn T a. Protective and pathogenic functions of macrophage subsets. 
Nat Rev Immunol. 2011;11(11):723-737. 
 177 
 
26.  Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to 
inhibit cytokine production by Th1 cells. J Immunol. 1991;146(10):3444-51.  
27.  Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 
2004;4(8):583-94.  
28.  Savage NDL, de Boer T, Walburg K V, et al. Human anti-inflammatory macrophages 
induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound 
TGFbeta-1. J Immunol. 2008;181(3):2220-6.  
29.  Pesce JT, Ramalingam TR, Mentink-Kane MM, et al. Arginase-1-expressing 
macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 
2009;5(4):e1000371.  
30.  Weisser SB, Brugger HK, Voglmaier NS, McLarren KW, van Rooijen N, Sly LM. SHIP-
deficient, alternatively activated macrophages protect mice during DSS-induced 
colitis. J Leukoc Biol. 2011;90(3):483-92. 
31.  Zhu W, Yu J, Nie Y, et al. Disequilibrium of M1 and M2 Macrophages Correlates with 
the Development of Experimental Inflammatory Bowel Diseases. Immunol Invest. 
2014:1-15.  
32.  Bogunovic M, Mortha A, Muller PA, Merad M. Mononuclear phagocyte diversity in the 
intestine. Immunol Res. 2012;54(1-3):37-49.  
33.  Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. 
Immunol Rev. 2014;260(1):102-17. 
34.  Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off 
regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for 
joint and gut-associated immunopathologies. Immunity. 1999;10(3):387-98.  
35.  Beattie JH, Wood a M, Newman a M, et al. Obesity and hyperleptinemia in 
metallothionein (-I and -II) null mice. Proc Natl Acad Sci U S A. 1998;95(1):358-63. 
36.  Haase H, Ober-Blöbaum JL, Engelhardt G, et al. Zinc signals are essential for 
lipopolysaccharide-induced signal transduction in monocytes. J Immunol. 
2008;181(9):6491-502.  
37.  Brieger A, Rink L, Haase H. Differential regulation of TLR-dependent MyD88 and TRIF 
signaling pathways by free zinc ions. J Immunol. 2013;191(4):1808-17.  
38.  Mayer LS, Uciechowski P, Meyer S, Schwerdtle T, Rink L, Haase H. Differential impact 
of zinc deficiency on phagocytosis, oxidative burst, and production of pro-
inflammatory cytokines by human monocytes. Metallomics. 2014. 
 178 
 
39.  Haase H, Rink L. Signal transduction in monocytes: the role of zinc ions. Biometals. 
2007;20(3-4):579-85.  
40.  Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal 
response to epithelial injury and limiting bacterial translocation in a murine model of 
acute colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G1055-65.  
41.  Araki A, Kanai T, Ishikura T, et al. MyD88-deficient mice develop severe intestinal 
inflammation in dextran sodium sulfate colitis. J Gastroenterol. 2005;40(1):16-23. 
42.  Seno H, Miyoshi H, Brown SL, Geske MJ, Colonna M, Stappenbeck TS. Efficient colonic 
mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci U S A. 
2009;106(1):256-61.  
43.  Leibbrandt ME, Koropatnick J. Activation of human monocytes with 
lipopolysaccharide induces metallothionein expression and is diminished by zinc. 
Toxicol Appl Pharmacol. 1994;124(1):72-81.  
44.  Spiering R, Wagenaar-Hilbers J, Huijgen V, et al. Membrane-bound metallothionein 1 
of murine dendritic cells promotes the expansion of regulatory T cells in vitro. Toxicol 
Sci. 2014;138(1):69-75.  
45.  Yin X, Knecht DA, Lynes MA. Metallothionein mediates leukocyte chemotaxis. BMC 
Immunol. 2005;6:21.  
46.  Devisscher L, Hindryckx P, Lynes MA, et al. Role of metallothioneins as danger signals 
in the pathogenesis of colitis. J Pathol. 2014;233(1):89-100. 
47.  Youn J, Borghesi LA, Olson EA, Lynes MA. Immunomodulatory activities of 
extracellular metallothionein. II. Effects on macrophage functions. J Toxicol Environ 
Health. 1995;45(4):397-413.  
48.  El Refaey H, Ebadi M, Kuszynski CA, Sweeney J, Hamada FM, Hamed A. Identification 
of metallothionein receptors in human astrocytes. Neurosci Lett. 1997;231(3):131-4.  
 
49.  Klassen RB, Crenshaw K, Kozyraki R, et al. Megalin mediates renal uptake of heavy 
metal metallothionein complexes. Am J Physiol Renal Physiol. 2004;287(3):F393-403.  
50.  Wolff NA, Abouhamed M, Verroust PJ, Thévenod F. Megalin-dependent 
internalization of cadmium-metallothionein and cytotoxicity in cultured renal 
proximal tubule cells. J Pharmacol Exp Ther. 2006;318(2):782-91.  
51.  Fitzgerald M, Nairn P, Bartlett CA, Chung RS, West AK, Beazley LD. Metallothionein-IIA 
promotes neurite growth via the megalin receptor. Exp brain Res. 2007;183(2):171-80.  
 179 
 
52.  Andreasen C, Carbonetti NH. Pertussis toxin inhibits early chemokine production to 
delay neutrophil recruitment in response to Bordetella pertussis respiratory tract 
infection in mice. Infect Immun. 2008;76(11):5139-48.  
53.  Bestebroer J, De Haas CJC, Van Strijp JAG. How microorganisms avoid phagocyte 
attraction. FEMS Microbiol Rev. 2010;34(3):395-414.  
54.  Akira S. Toll-like receptor signaling. J Biol Chem. 2003;278(40):38105-8.  
55.  Locht C, Coutte L, Mielcarek N. The ins and outs of pertussis toxin. FEBS J. 
2011;278(23):4668-82.  
56.  Seow V, Lim J, Iyer A, et al. Inflammatory responses induced by lipopolysaccharide are 
amplified in primary human monocytes but suppressed in macrophages by 
complement protein C5a. J Immunol. 2013;191(8):4308-16.  
57.  Lipszyc PS, Cremaschi GA, Zorrilla-Zubilete M, et al. Niacin Modulates Pro-
inflammatory Cytokine Secretion. A Potential Mechanism Involved in its Anti-
atherosclerotic Effect. Open Cardiovasc Med J. 2013;7:90-8.  
58.  Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative 
endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164(2):558-
61.  
59.  Hindryckx P, Laukens D. Intestinal Barrier Dysfunction: The Primary Driver of IBD?, 
Inflammatory Bowel Disease - Advances in Pathogenesis and Management, Dr. Sami 
Karoui (Ed.),2012, ISBN: 978-953-307-891-5, InTech, DOI: 10.5772/26436.  
 
 
 
 
 
 
 
 
 
 
 180 
 
 
 
 
 
 
 
 
 181 
 
Curriculum Vitae  
 
Personal address Professional address 
 
Lindsey Devisscher Dpt. of gastroenterology and hepatology 
Vijverstraat 13     Ghent University,   
B-9860 Moortsele                                                           De Pintelaan 185, 3K12 
0477/84.85.51                                                                 B-9000 Ghent   
lindsey.devisscher@ugent.be                                       09 332 56 65  
                                                                                            lindsey.devisscher@ugent.be 
 
Personal information 
 
Birth place Ghent 
Birth date 07/06/1981 
Nationality Belgian 
Marital state Married 
 
Education 
 
2005-2006  Equine Internship, Faculty of Veterinary Medicine, Ghent University 
1999-2005 Veterinary Medicine (great distinction), Faculty of Veterinary 
Medicine, Ghent University 
  Thesis: Postoperative myopathy in horses (nominated), promotor: 
Dr. Schauvliege Stijn, co-promotor: Prof. Dr. Gasthuys Frank 
1993-1999 Science and mathematics, Sint-Pietersinstituut, Ghent 
 
 
 
 
 182 
 
Additional education 
 
2009-2014 Doctoral schools of Life Sciences and Medicine program, Ghent 
University 
  Felasa C, Laboratory Animal Sciences, Ghent 
  Advanced Academic  English, writing skills, Ghent 
  Fundamentals of Technology Transfer, Ghent 
  Authenthic Networking, Ghent 
  Economic evaluations of medical interventions, Ghent 
2009 Course in Communication Skills, MSOURCE, Kraainem 
 Time Management course, MSOURCE, Kraainem 
2008 Assertiviness course, MSOURCE, Kraainem 
 Clinical Research and ICH-GCP for junior monitors, MSOURCE, 
Kraainem 
2006 Post University Education, Faculty of Veterinary Medicine, Ghent 
University 
  New developments in diagnostic and treatment of tendinitis in 
horses 
  Echography of the tarsus and fetlock 
  Regional anaesthesia and punctures of the distal limb 
 9th Education at WVGP (Wetenschappelijke Vereniging voor de 
Gezondheid van het Paard), Faculty of Veterinary Medicine, Ghent 
University 
2005 Training in Identification of the Horse 
 Education at Belgian Equine Practioners Society, Brussels 
 
Professional experience 
 
2009-2014 (present) PhD Student at the Department of Gastroenterology, Internal 
Medicine, Faculty of Medicine and Health Sciences, Ghent University 
 Prof. Dr. De Vos Martine, co-promotor:  Laukens Debby, PhD 
 183 
 
Since 2014 Guest lecturer ‘Practica Laboratory Animals Sciences’, Bachelor Bio-
Medical Laboratory Technology, Hogeschool Vesalius, Ghent 
Since 2014 Member of the Animal Ethics Committee at the Faculty of Medicine 
and Health Sciences, Ghent University 
2008-2009 Clinical Research at MSOURCE, Kraainem  
2006-2008 Assistant at the Faculty of Veterinary Medicine, Department of 
Surgery and Anaesthesiology of Domestic Animals, Ghent University 
  
Publications 
 
A1-publications 
 
Van Acker A, Filtjens J, Van Welden S, Taveirne S, Van Ammel E, Vanhees M, Devisscher L, 
Kerre T, Taghon T, Vandekerckhove B, Plum J, Leclercq G. Ly49E Expression on CD8αα-
Expressing Intestinal Intraepithelial Lymphocytes Plays No Detectable Role in the 
Development and Progression of Experimentally Induced Inflammatory Bowel Diseases. PLoS 
One. 2014 Oct 13;9(10):e110015. 
 
Laukens D*, Devisscher L*, Van den Bossche L , Hindryckx P, Vandenbroucke R, 
Vandewynckel YP, Cuvelier C, Brinkman B, Libert C, Vandenabeele P, De Vos M. 
Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal 
epithelial cell death. Lab Invest 2014 Oct 13. *equal contribution 
 
Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, Devisscher L, 
Bogaerts E, Paridaens A, Verhelst X, Van Steenkiste C, Libbrecht L, Lambrecht BN, Janssens S, 
Van Vlierberghe H. Therapeutic effects of artesunate in hepatocellular carcinoma: 
repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 2014 Aug;26(8):861-
70. 
 
 184 
 
Devisscher L, Hindryckx P, Lynes MA, Waeytens A, Cuvelier C, Vos FD, Vanhove C, Vos MD, 
Laukens D. Role of metallothioneins as danger signals in the pathogenesis of colitis. J Pathol. 
2014 May;233(1):89-100. 
 
Lynes MA, Hidalgo J, Manso Y, Devisscher L, Laukens D, Lawrence DA. Metallothionein and 
stress combine to affect multiple organ systems. Cell Stress Chaperones. 2014 
Sep;19(5):605-11. 
 
Devisscher L, Hindryckx P, Olievier K, Peeters H, De Vos M, Laukens D. Inverse correlation 
between metallothioneins and hypoxia-inducible factor 1 alpha in colonocytes and 
experimental colitis. Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):307-12.  
 
Schauvliege S, Marcilla MG, Verryken K, Duchateau L, Devisscher L, Gasthuys F. Effects of a 
constant rate infusion of detomidine on cardiovascular function, isoflurane requirements 
and recovery quality in horses. Vet Anaesth Analg. 2011 Nov;38(6):544-54.  
 
Hindryckx P, Staelens S, Devisscher L, Deleye S, De Vos F, Delrue L, Peeters H, Laukens D, De 
Vos M. Longitudinal quantification of inflammation in the murine dextran sodium sulfate-
induced colitis model using μPET/CT. Inflamm Bowel Dis. 2011 Oct;17(10):2058-64.  
 
Hindryckx P, Devisscher L, Laukens D, Venken K, Peeters H, De Vos M. Intrarectal 
administration of oxygenated perfluorodecalin promotes healing of murine colitis by 
targeting inflammatory hypoxia. Lab Invest. 2011 Sep;91(9):1266-76.  
 
Devisscher L, Schauvliege S, Dewulf S, Gasthuys F. Romifidine in isoflurane anaesthetized 
horses: a clinical study. Vet Anaesth Analg. 2010 Sep;37(5):425-33.  
 
Vertenten G, Declercq J, Gasthuys F, Devisscher L, Torfs S, van Loon G, Martens A. Abomasal 
end-to-end anastomosis as treatment for abomasal fistulation and herniation. Vet Rec. 2009 
Jun 20;164(25):785-6.  
 
 185 
 
Schauvliege S, van Loon G, De Clercq D, Devisscher L, Deprez P, Gasthuys F. Cardiovascular 
responses to transvenous electrical cardioversion of atrial fibrillation in anaesthetized 
horses. Vet Anaesth Analg. 2009 Jul;36(4):341-51.  
 
Torfs S, Delesalle C, Dewulf J, Devisscher L, Deprez P. Risk factors for equine postoperative 
ileus and effectiveness of prophylactic lidocaine. J Vet Intern Med. 2009 May-Jun;23(3):606-
11.  
 
Schauvliege S, Bouchez S, Devisscher L, Reyns T, De Boever S, Gasthuys F. Influence of two 
different ventilation modes on the function of an anaesthetic conserving device in 
sevoflurane anaesthetized piglets Vet Anaesth Analg. 2009 May;36(3):230-8.  
 
Levet T, Martens A, Devisscher L, Duchateau, Bogaert L, Vlaminck L. Distal limb cast sores in 
horses: risk factors and early detection using thermography. Equine Vet J. 2009 Jan;41(1):18-
23.  
 
Abstracts from oral presentations 
 
Van Welden S, Laukens D, Devisscher L, Devlies H, Olievier K, Correale C, S. D Alessio S, 
Danese S, De Vos M, Hindryckx P. Silencing of prolyl hydroxylase 1 in intestinal microvascular 
endothelial cells prevents inflammation-induced endothelial dysfunction and dampens 
murine colitis. Digestive Disease Week Chicago 2014.  
 
Vandewynckel YP, Laukens D, Geerts A, Colle I, Bogaerts E, Paridaens A, Verhelst X, 
Devisscher L, Vansteenkiste C, Descamps B, Vanhove C, Libbrecht L, Lambrecht B, Janssens S, 
Van Vlierberghe H. Temporal dynamics and therapeutical potential of the unfolded protein 
response in HCC. Belgian week of Gastroenterlogy 2014. 
 
Devisscher L, Hindryckx P, Lynes M, Cuvelier C, De Vos F, Vanhove C, De Vos M, Laukens D. 
The role of metallothioneins as danger signals in mice models for inflammatory bowel 
 186 
 
diseases. Group for Research and Studies on Mediators of Inflammation: The 
underestimated role of epithelium in inflammation, Paris, 2013. 
 
Devisscher L, Hindryckx P, Lynes M, Cuvelier C, De Vos F, Vanhove C, De Vos M, Laukens D. 
Metallothioneins are danger signals and represent a novel target to dampen intestinal 
inflammation in mice. Cell Stress Society international, Stress proteins in biology and 
medicine, Sheffield, 2013. 
 
Devisscher L, Hindryckx P, Lynes M, Cuvelier C, De Vos F, Vanhove C, De Vos M, Laukens D. 
Metallothionein, an emerging danger signal during experimental colitis. Belgian week of 
Gastroenterlogy 2013. 
 
Devisscher L, Hindryckx P, Olievier K, Peeters H, Lynes M, Cuvelier C, De Vos M, Laukens D. 
Targeting metallothionein in DSS-colitis points to new therapeutic strategies for IBD patients. 
Belgian week of Gastroenterlogy 2012. 
 
Laukens D, Devisscher L, Hindryckx P, Peeters H, De Vos M. TUDCA alleviates DSS-induced 
colitis by forcing IRE1 activity and reducing colonocyte apoptosis. Belgian week of 
Gastroenterlogy 2012. 
 
Devisscher L, Hindryckx P, Peeters P, De Vos M, Laukens D. The hypoxia adaptive response 
regulates metallothionein expression in intestinal epithelial cells. Belgian week of 
Gastroenterlogy 2011. 
 
Declercq J, Vertenten G, Devisscher L, Barberet V, Gasthuys F, Verleyen P, Martens A. 
Bilateral Surgical Fracture Repair in an Alpaca. Jubilee World Buiactics Congress 2008. 
 
Schauvliege S, van Loon G, De Clercq D, Devisscher L, Deprez P, Gasthuys F. Cardiovascular 
function in anaesthetized horses during transvenous electrical cardioversion as therapy for 
atrial fibrillation. Association of Veterinary Anaesthetists Meeting 2008. 
 
 187 
 
Schauvliege S, Bouchez S, Devisscher L, Reyns T, De Boever S, Gasthuys F. Influence of two 
different ventilation modes on the function of an anaesthetic conserving device 
(AnaConDa®) in sevoflurane anaesthetized pigs. Association of Veterinary Anaesthetists 
Meeting 2007. 
 
Devisscher L, Delesalle C, Dewulf J, Deprez P, Torfs S, Schauvliege S, Martens A, Gasthuys F. 
Pre- and intraoperative parameters related to hypotension and hypoxaemia during 
anaesthesia in colic horses: a retrospective study. Association of Veterinary Anaesthetists 
Meeting 2007. 
 
Abstracts from poster presentations 
 
Kiekens F, Devisscher L, Blancquaert D, Van Der Straeten D, Lambert WE and Stove CP. 
Demonstration of bioaccessibility, bioavailability and biological activity of natural folates 
from metabolically engineered rice: a long-term study in rats. International Vitamin 
Conference 2014. 
 
Devisscher L, Hindryckx P, Lynes M, Cuvelier C, De Vos F, Vanhove C, De Vos M, Laukens D. 
Metallothioneins are danger signals and represent a novel target to dampen intestinal 
inflammation in mice. European Crohn's and Colitis Organization 2013. 
 
Devisscher L, Hindryckx P, Lynes M, Cuvelier C, De Vos F, Vanhove C, De Vos M, Laukens D. 
Metallothioneins are danger signals and represent a novel target to dampen intestinal 
inflammation in mice. Digestive Disease Week 2013. 
 
Devisscher L, Hindryckx P, Olievier K, Peeters H, Lynes M, Cuvelier C, De Vos M, Laukens D. 
Targeting metallothionein in DSS-colitis points to new therapeutic strategies for IBD patients. 
European Crohn's and Colitis Organization 2012. 
 
 188 
 
Laukens D, Devisscher L, Hindryckx P, Peeters H, De Vos M. Tauroursodeoxycholic acid forces 
epithelial IRE1 activation and alleviates DSS-induced colitis. European Crohn's and Colitis 
Organization 2012. 
 
Devisscher L, Hindryckx P, Peeters P, De Vos M, Laukens D. The hypoxia adaptive response 
regulates metallothionein expression in intestinal epithelial cells. European Crohn's and 
Colitis Organization 2011. 
 
Hindryckx P, Devisscher L, Laukens D, Venken K, Peeters H, De Vos M. Intrarectal 
administration of oxygenated perfluorodecalin promotes healing of murine colitis by 
targeting inflammatory hypoxia. European Crohn's and Colitis Organization 2011. 
 
Hindryckx P, Staelens S, Devisscher L, Deleye S, De Vos F, Delrue L, Peeters H, Laukens D, De 
Vos M. Longitudinal quantification of inflammation in the murine dextran sodium sulfate-
induced colitis model using μPET/CT. United European Gastroenterology Week 2010. 
 
Devisscher L, Hindryckx P, Peeters P, De Vos M, Laukens D. The hypoxia adaptive response 
regulates metallothionein expression in intestinal epithelial cells. HypoxiaNET EU COST 
Action Research Conference 2010, Dublin. 
 
Review activities 
 
Reviewer for Clinical and Experimental Gastroenterology (2013) 
 Pharmacological Research (2012) 
 
Patents 
 
‘Use of antagonists targeting metallothionein to treat intestinal inflammation’ (TTRM 
PR2011/083 – P2010/099; national filing 17/01/2014) 
 
 189 
 
Grands 
 
2010-2014 PhD fellowship of the Scientific Research Foundations of UGent - 
Bijzonder Onderzoeksfonds, BOF 
2011 Laureate of the yearly grant of the Flemish society for 
gastroenterology (Vlaamse vereniging voor gastro-enterologie, VVGE) 
 
Student supervision 
 
2013-2014  Lisa Crapé: Role of metallothioneines in experimental models for 
chronic intestinal inflamation, Master in Health Science and Medicine
 
2008  Rienske Mortier: Anaesthesia of the neonatal foal, Master in 
Veterinary Medicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 190 
 
You cannot change the direction of the wind,  
but you can adjust your sails to reach your destination.  
(Adapted from Jimmy Dean.) 
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Dankwoord 
 
Eindelijk, ik kan beginnen schrijven… en ik begin er toch maar mee: het dankwoord. 
Waarom? Misschien omdat dit het eerste is wat iedereen leest maar vooral, omdat jullie 
allemaal een bron van inspiratie zijn! 
 
Prof. De Vos, de gedrevenheid waarmee u zowel de kliniek als het onderzoek in goede banen 
tracht te leiden, kan anderen alleen maar inspireren. Uw constructieve opbouw heeft van 
mij een kritischer onderzoeker gemaakt en heeft mij steeds gemotiveerd door te gaan. Ik wil 
u dan ook enorm bedanken mij de kans te hebben gegeven om van uw groep deel uit te 
maken en steeds in mij te geloven. U staat voor uw mensen, iets wat wij allemaal zeer sterk 
appreciëren. Ik hoop dan ook hier verder iets te kunnen opbouwen en bedank u voor deze 
nieuwe start. 
 
Debby, wat een jaren! Vanaf dag 1 zag je dat het goed was, samen ging het lukken. En ja, je 
maakte van mij een ECHTE onderzoeker . Ik bedank je om mij deze kans te hebben geven 
dit ‘MT project’ tot een goed einde te brengen. Wel leuk te weten dat MTs als eerste werden 
ontdekt in de niercortex van het paard en ik van bij de paarden op jouw MT onderwerp 
terechtkwam ; het zal wel voorbestemd geweest zijn! Ik denk dat we wel mogen zeggen 
dat het iets moois geworden is en wie weet zitten we later naast ons zwembad te genieten 
van de verdienste van ‘Metallamab’? We kunnen er maar van dromen . Debby, ik denk dat 
hier te weining plaats is om alles te zeggen, we doen dit nog eens over een bubbeltje! 
Duizendmaal dank! 
 
Pieter, jij wijdde mij in in de wereld van de muisjes… ongelooflijk wat een imperium er toen 
van jou in het animalarium stond . En alhoewel het voor mij een enorme aanpassing leek 
om in plaats van de dieren te helpen met – meestal oorspronkelijk – uit de humane 
afkomstige producten, nu de dieren te gebruiken om pathologieën bij de mensen te 
onderzoeken, was de overgang vrij snel gemaakt. Jij mag hier zeker verdienste voor nemen, 
het gemak en de flow waarmee jij je onderzoek leek te voeren, heeft me de juiste aanzet 
gegeven bij mijn start! Ik denk dat we goed samenwerken en kijk dan ook uit naar de 
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toekomst! Onderweg naar de muizen is ook wat tijd om te babbelen waardoor we elkaar ook 
iets beter mochten leren kennen. Je bent een uniek persoon met een goed karakter. Als 
staflid een aanwinst voor de dienst en ik wens je dus veel succes met je verdere carriere! 
 
Harald, ook al ben je er niet meer, ik ben je nog niet vergeten. Bedankt voor de aangename 
start op het UZ! 
 
Prof. Van Vlierberghe, Prof. Geerts, Prof. Colle en Xavier, bedankt voor het vertrouwen dat 
jullie reeds in mij hebben en jullie steun bij het verder uitbouwen van de onderzoeksgroep! 
 
Prof. Cuvelier, bedankt voor de lessen histopathologie en de tijd die u nam om mijn coupes 
samen door te nemen. 
 
Prof. Michael Lynes, partly thanks to you we persisted in unravelling the MT story in IBD. You 
were of enourmous help when we were struggling. I am very pleased to have met you as a 
scientist and a person and I wish you all the best, in the lab and beyond!  
 
Leden van de examencommisie, bedankt voor het kritisch nalezen van dit werk. Members of 
the examination committee, thank you for your critical view on this dissertation. 
 
Labo-mensjes, één voor één unieke personen! Ik denk dat er geen grotere diversiteit aan 
persoonlijkheden bestaat als bij ons… maar gelukkig zijn er ook enkele ‘stabiele’ factoren die 
de rust ten gepaste tijde terugbrengen . 
Kimmie, ik begin met jou. Jij was er als eerste om mij te helpen met de muisjes en een groot 
deel van dit werk is ook jouw verdienste. Ik zie ons nog zitten bij Julien, wat waren we blij 
dat hij er was! Bedankt voor alle hulp en goede samenwerking! Ik vind het zeer jammer dat 
je het UZ achter jou laat maar ik hoop dat je gauw wat rust terugvindt en wat meer tijd vindt 
om te genieten van je drie mannen. 
Hilde, jij kwam iets later maar voor jou geldt hetzelfde. Je stond ook altijd klaar om te helpen 
en te blotten . Jouw maturiteit brengt rust in de groep en ik denk dat we er allemaal veel 
van kunnen leren! Bedankt! 
Elien, jij behoort zeker tot de stabiele factor van het labo. Gelukkig maar. Jij verzorgt de 
databank als de beste! Wat leuk dat we naast elkaar belandden en op tijd en stond de 
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kinderverhalen konden delen! We laten de kindjes binnenkort eens samenspelen in 
Pieternelleke! 
Anja en Petra, jullie zijn als laatste bijgekomen maar vervolledigen de mengelmoes aan 
karakters zeker! Anja, bedankt om een groot deel van het muizenwerk over te nemen en 
Petra, let op de cellen hé! Ik wens jullie veel succes zowel op werk- als privé-vlak en Anja, ik 
hoop ooit te weten wie ECHT de man van Anja wordt… . Griet, jij bent er pas bijgekomen 
maar je doet het prima! 
Evi, met jou startte ik samen. Alhoewel het in het begin niet leek te klikken werden we op 
termijn goeie maatjes! Hopelijk komen voor jou de artikels snel, dit zal ook jou zeker een 
factor rust bezorgen. Ik duim voor jou! Bedankt voor de vriendschap en de babbels! 
Sarah, de stiltste onder ons. Alhoewel, je kan er soms recht op zitten met je gevatte 
uitspraken! Ik bewonder je om desondanks je afkeer toch te blijven volhouden met de 
muisproeven en alhoewel het wat stroef lijkt te lopen, je komt er wel! Het heeft allemaal 
met die bacteriën te maken! 
Sophie, je bent een harde werkster en zet Pieter zijn werk dan ook gedreven verder. We zien 
elkaar wel nog bij de muisjes!  
Lien, ik denk dat we veel gelijkenissen hebben. We kunnen het dan ook goed met elkaar 
vinden en ik ben blij dat je erbij gekomen bent! Succes met het TUDCA-verhaal! 
Tom, gelukkig, een man erbij… jij weet de nodige rust in het labo te brengen en staat klaar 
voor ieders kwaaltje en klaagje. Alvast bedankt voor het opvolgen van ‘de bloeddruk’. Je 
bent een verstandig en rustig persoon en een grote meerwaarde voor de groep! Ik ben 
benieuwd naar het verloop van je onderzoek! 
Hugo, gelukkig was jij er nog om het vrouwelijk geweld wat te temperen over de middag. Ik 
denk dat het niet altijd even boeiend was voor jou maar dat je zelf ook veel bijgeleerd hebt 
over de vrouwelijke kwaaltjes. Binnenkort ga je op pensioen en ik wens je dan ook een 
prachtige tijd toe samen met Godelieve. Misschien zien we elkaar nog bij het uitwisselen van 
moestuingroenten! 
Iris, even though the cells were not always performing as you wished, you kept cheerful and 
trying. It was nice to have you in the lab and I wish you all the best with your two boys! 
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De hepato’s: Femke en Stephanie, jullie werk in Gent zit er reeds op maar ik ben jullie niet 
vergeten! Bedankt voor de tussen-de-muizen-door babbels en ik wens jullie beide veel 
succes in de toekomst! Julien, wat jammer dat je weg bent! Iemand zoals jij is onvervangbaar 
en ik wil je dan ook enorm bedanken voor je hulp bij mijn eerste proeven! Ik weet niet wat 
Kim en ik zonder jou gedaan zouden hebben…  
Christophe, ik denk dat jouw doctoraat het eerste was wat ik bijwoonde op het UZ en het 
werk zag er fantastisch uit! Je gaf me dan ook enorm veel zin hiervan deel uit te maken. We 
werken zeker nog samen in de toekomst!  
De ‘nieuwen’ van blok B: Eliene, Annelies, Sarah, Yves-Paul en Xavier; wat de één mist vult 
de ander zeker aan . Jullie aanwezigheid in K12 gaat zeker niet onopgemerkt voorbij! 
Bedankt voor jullie vertrouwen en ik kijk uit naar de toekomst! 
Natacha, jij hoort ook een beetje bij ‘Blok B’. Bedankt voor het gebruik van jullie propere 
lokaal tijdens de ratproeven. Het maakte het werk zeker aangenamer. Veel succes met je 
werk en je Johan! 
Anneleen, als enige bekende van de nefro… ik ken niet veel van jouw onderzoek, alleen dat 
het iets met ratten en nieren te maken heeft. Ik heb enorme bewondering voor jouw 
volharding en kracht door te gaan, zowel op persoonlijk als professioneel vlak! De verdienste 
is er, een doctoraat en een flinke dochter. Ik wens je een prachtige tijd samen, geniet er 
volop van! 
Elke Decrock, bedankt voor de hulp met de immunofluorescentie microscoop tijdens de 
laatste weken van het parktisch werk. 
 
Het animalarium: Ingrid, Marit, Lien, Evelyn, Chantal, Lut, Deborah en Johan: je moet het 
toch maar doen, dag in dag uit tussen de muizen… en steeds met een lach en een vriendelijk 
woord. Dank jullie wel om te waken over al onze muisjes! Ingrid, wij konden het als 
‘collega’s’ al gauw vinden en ik bedank je voor de samenwerking en de babbels! 
 
Het Infinity-lab: bij jullie was het altijd gezellig binnenkomen! Tussen de scans door konden 
we het even hebben over de onderzoeksperikelen, wat precies toch overal hetzelfde is . 
Bedankt voor het vlot scannen van mijn muisjes en jullie zien mij zeker nog in de toekomst 
terug! Prof. Filip De Vos, bedankt voor de antibody labeling. Sara, bedankt voor de hulp bij 
het IV inspuiten! 
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De oude collega’s van de diergeneeskunde. Alhoewel ik het werk (en ook jullie) wel mis, heb 
ik toch mijn plaatsje gevonden op het UZ. Het was een enorm moeilijke stap de paarden 
achter me te laten maar jullie zien, er is nog leven na de dienst Heelkunde . Ik had jullie 
beloofd iets te laten weten, bij deze… 
 
De vriendinnetjes, Lisa, Caroline, nog een Caroline, Katrien, Liat, Michele, Evelyn, wat leuk 
om allemaal in dezelfde periode kindjes te hebben! Ik geniet er enorm van hen samen te 
zien spelen. Bedankt aan jullie en jullie mannen voor de onstpannen weekends en de 
vriendschap! 
 
De schoonouders, meme en pepe Zwijnaarde: bedankt voor de man die jullie mij gaven en 
jullie zorg voor Warre. Het is leuk te zien hoe hij van jullie aandacht geniet! 
 
Mama, vandaag ben je om vis naar de markt voor mij… wat ben je toch een lieve mama. 
Altijd wil je goed doen en zorg dragen voor iedereen. Ik heb deze eigenschap van jou 
overgenomen (of meegekregen) en alhoewel dat soms heel vermoeiend en moeilijk kan zijn, 
ik ben er zeker van dat het op termijn altijd loont! Papa, jij bent de rots waar iedereen op 
bouwt. Ik heb jouw ambitieuze en jouw doorzetting. Er zijn voor jullie zeker hevige jaren 
geweest. Ik was niet de gemakkelijkste puber, ook mijn latere keuzes zullen voor jullie soms 
onbegrijpelijk geweest zijn maar jullie zien, ik ben er geraakt! Ik heb een prachtige man, een 
schat van een zoon en een doctoraat! Ik geniet er zo van jullie met Warretje te zien. 
‘Bedankt’ is te weining om jullie te bedanken… 
 
Purdey, mijn purdey, wij zijn gelijk en verschillend en zo ben je eigenlijk mijn tweede helft. Je 
zal altijd mijn ‘kleine’ zus blijven en ik zal altijd zorg voor je dragen. Er is gewoon wat tijd 
nodig geweest om elkaar goed te begrijpen, we zijn ook geen kinderen meer, we hebben er 
nu zelf! Af en toe denk ik nog terug aan onze tijd in Gent… gelukkig zit dit enkel in onze 
gedachten opgeslagen ! En we zijn blij dat die nu plaats gemaakt heeft voor ‘rustige’ 
zondagmiddagen waar de kindjes samenzijn en wij uiteraard een bubbeltje drinken! Bedankt 
om mijn zus te zijn en geniet van jullie wondertje, Enoa! Jelle, draag zorg voor je vrouwen en 
tot zondag! 
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Voor mijn 2 mannen,  
deze laatste pagina is aan jullie gericht… 
 
Bert, dat ik jou mocht tegenkomen in de Ginsdreef op de trap! Iedereen hield zijn hart vast 
. Ik heb het tegendeel bewezen, soms moet je niet zelf om de TV-aansluiting zoeken maar 
gewoon de plaatselijke elektricien roepen... Wij zijn er zeker van dat niet veel mensen 
samenzijn zoals wij. Wij zijn er altijd voor elkaar en begrijpen elkaar zoals niemand anders. Jij 
bent de man die mij alles gaf: mijn Warretje, onze schat, ons leven. Hij heeft ons hart 
veroverd, die kleine sloeber, dit hadden we nooit kunnen dromen. Jullie twee zijn mijn leven 
vandaag en in de toekomst, voor altijd.  
 
Warre, mijn lieve kleine man. Als je met je lief schattig snoetje lacht naar mij, weet je wel 
hoeveel ik van jou hou. Mijn hart breekt elke ochtend als je vraagt ‘mama, nie wejken?’… ik 
hoop dat je later, misschien als je dit boek leest, begrijpt waarom mama’s gaan werken… 
Warretje, ik zal je als mini-mensje missen later, als je groot bent, maar ik zal erover waken 
en ervoor zorgen dat jij, mijn klein groot wonder, opgroeit tot een flinke man. Dus, voor 
iedereen in de zaal die zegt dat wonderen niet bestaan, ze hebben niet goed gekeken want 
jij zat hier vandaag vooraan in mijn gedachten op de eerste rij! 
 
 
 
 
The best and most beautiful things in the world cannot be seen or even touched - they must be 
felt with the heart. 
The best and most beautiful things in the world cannot be seen or even touched 
they must be felt with the heart. 
(Helen Keller) 
 
